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Acute Myocardial Infarction (AMI) remains a leading cause of death 
worldwide. After AMI, clinical restauration of blood flow aggravates tissue 
damage (Ischemia/Reperfusion, I/R injury), critically decreasing the 
number of viable cardiomyocytes (CMs). Besides CMs, other myocardial 
cell populations such as cardiac stem/progenitor cells (CSCs) and 
cardiac fibroblasts (CFs) play key roles in tissue pathology and 
regeneration upon AMI. Several studies have demonstrated the relevant 
role of endogenous CSCs in myocardial repair after I/R injury, supported 
by the establishment of a paracrine cross talk between CSCs and the 
injured tissue. Due to their regenerative properties, human CSC (hCSC) 
transplantation has been arising as a promising therapy for AMI patients. 
Clinical trials using hCSC have demonstrated some physiological 
improvements, but the limited cell retention and engraftment in the heart 
still constitutes one of the main challenges that stand in the way of 
meeting hCSCs full clinical potential. The low cell engraftment efficiency 
further supports the hypothesis that the beneficial effects of hCSCs are 
mainly due to paracrine modulation. In fact, novel strategies for heart 
regeneration involve the direct protein and small-molecule based 
activation of endogenous CSCs populations. A better understanding of 
hCSC biology upon I/R in the context of allogeneic transplantation is 
therefore paramount, envisioning novel cell-based and cell-free therapies 
in order to fully avail and potentiate hCSC regenerative properties. 
Moreover, human CFs (hCFs) also have a central role in myocardium 
pathophysiology, namely in fibrosis, a process of tissue reorganization 
upon I/R injury and other ischemic heart conditions. The study of this cell 
population has been limited by the lack of standardized and reliable 
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molecular markers, since none of the antigens currently used for 
characterization and isolation is specific for hCFs. 
The main focus of this thesis is to characterize human cardiac cell 
populations in contexts of homeostasis and AMI, including hCSCs and 
hCFs, as well as to develop relevant I/R in vitro human cell models. In 
particular, advanced mass spectrometry (MS) tools were used to unveil 
hCSC mechanisms of action in a myocardial I/R context as well as to 
provide a comprehensive description of hCF membrane molecular 
landscape.  
Envisioning at studying hCSC response to an AMI situation, the 
development of a two-dimensional (2D) in vitro cell model of myocardial 
I/R injury was explored in Chapter II. Here, a heterotypic co-culture was 
used, with hCSCs and human induced pluripotent stem cell derived CMs 
(hiPSC-CMs) , in order to better mimic the complexity of the in vivo 
paracrine milieu. This model was able to recapitulate important hallmarks 
of I/R pathophysiology, including hiPSC-CM death, the protective effect 
of hCSCs on hiPSC-CM viability and hCSC proliferation activation. This 
model also allowed us to probe hCSCs biology in response to I/R injury 
with a whole-proteome approach, enabling us to propose novel pathways 
involved in the regenerative process activated by hCSCs, including cell 
cycle regulation, proliferation through EGF signaling, and reactive oxygen 
species detoxification. 
Following this work, another I/R injury in vitro model was established in 
Chapter III, taking advantage of three-dimensional (3D) hiPSC-CM 
spheroid cultures and stirred-tank bioreactor technology. 3D culture 
enables more extensive networks of cell-cell and cell-extracellular matrix 
(ECM) interactions, representing a step closer to the in vivo 




ensures the possibility to control/ monitor environmental parameters such 
as pH and dissolved oxygen, critical in the context of I/R physiology. 
Using this setup we were able to once again recapitulate hallmarks of 
AMI, including hiPSC-CM death, secretion of pro-inflammatory and 
angiogenic factors and changes at a cell ultra-structural level, including 
disruption of sarcomeres and mitochondria organization.  
In order to further investigate hCSC response to the factors secreted by 
injured hiPSC-CM, in Chapter IV, hCSCs were incubated with the 
conditioned medium from these bioreactor experiments, and their 
response was analyzed in terms of quantitative whole-proteome profiling. 
Besides investigating the paracrine cross-talk between hCSCs and 
hiPSC-CMs in an injury setup, in Chapter V we further explored the 
interaction of hCSCs with T-lymphocytes, aiming at better understanding 
the interactions of hCSCs with the host immune system in a allogeneic 
transplantation context. More specifically, the effect of hCSCs and hCSC 
conditioned media on T-lymphocyte proliferation were accessed, 
shedding new light on how hCSC immunomodulatory properties are not 
only depending on contact-dependent programmed death ligand 1 (PDL-
1) mechanisms but also on tryptophan metabolism. 
Chapter VI was focused on another myocardial cell population: hCFs. In 
this chapter, we examined hCF proteome profile with a focus on 
membrane proteins. In order to define a protein signature distinctive of 
this cell population, we further compared the membrane-enriched 
proteome of these cells with membrane-enriched fractions from another 
stem and cardiac cell populations, yielding a subset of 30 membrane 
proteins exclusively identified in hCFs, constituting a valuable source of 
information for further studies aiming at defining a membrane molecular 
signature of hCFs. 
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Overall, by developing and characterizing in vitro I/R cell models and 
applying advanced MS proteomic tools, this thesis contributed to 
generate novel and relevant knowledge on cell populations of the human 
heart with key roles in AMI pathology, regarding their molecular identity 
and mechanisms of action upon I/R injury. Moreover, we believe that the 
myocardial human I/R in vitro models established herein will constitute 
important tools for further studies, which will enable the development of 
novel therapies focused on activation, recruitment and improvement of 















O infarte agudo do miocárdio (IAM) constitui uma das principais causas 
de morte a nível mundial. Após o IAM, a restauração do fluxo sanguíneo 
na área afectada agrava o dano causado no miocárdio (lesão de 
Isquémia/Reperfusão, I/R), diminuindo criticamente o número de 
cardiomiócitos (CMs) viáveis. Além dos CMs, outras populações 
celulares tais como células estaminais cardíacas (CSCs) e fibroblastos 
cardíacos (CFs) desempenham papéis fundamentais na patologia e 
regeneração após o IAM. Diversos estudos demonstraram que as CSCs 
endógenas têm um papel relevante na regeneração do miocárdio após a 
lesão de I/R, baseada no estabelecimento de comunicação parácrina 
entre estas células e o tecido afectado. Devido ás suas propriedades 
regenerativas, o transplante de CSCs humanas (hCSCs) tem vindo a 
surgir como uma nova e promisora terapia para pacientes de IAM. Vários 
ensaios clínicos demonstraram algumas melhorias a nível funcional, mas 
a limitadaretenção e inclusão das células no tecido cardíaco impedem o 
total aproveitamento das capacidades regenerativas destas células.  
Além de hCSCs, os CFs humanos (hCFs) têm também um papel central 
na fisiopatologia do tecido cardíaco, nomeadamente na fibrose, um 
processo de reorganização do tecido que ocorre após a lesão de I/R e 
outras patologias de isquémia cardíaca. O estudo desta população 
celular tem sido restringido pela falta de marcadores moleculares 
uniformes e fidedignos, uma vez que nenhum dos antigénios utilizados 
actualmente para a caracterização e isolamento de hCFs é específico 
para os mesmos. 
Esta tese teve como principal objectivo a caracterização de populações 
de células cardíacas humanas em contextos de homeostase e IAM, 
incluido hCSCs e hCFs, bem como o desenvolvimento de modelos 
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celulares humanos in vitro de lesão de I/R. Nomeadamente, foram 
utilizadas ferramentas avançadas de espectrometria de massa (MS) 
para estudar os mecanismos de acção de hCSCs em contextos de lesão 
de I/R, bem como para uma caracterização abrangente das proteínas de 
membrana dos hCFs. 
Tendo como objectivo o estudo da resposta das hCSCs a uma situação 
de AMI, o Capítulo II explora o desenvolvimento de um modelo bi-
dimensional (2D) in vitro de lesão de I/R. Neste estudo foi utilizada uma 
co-cultura heterotípica com hCSCs e CMs derivados de células 
estaminais pluripotentes humanas (hiPSC-CMs), com o fim de mimetizar 
a complexa rede de interacções parácrinas do tecido cardíaco. Este 
modelo demonstrou capacidade para recapitular aspectos importantes 
da fisiopatologia de lesão de I/R, incluindo a perda de viabilidade dos 
hiPSC-CMs, o efeito protector das hCSCs nos hiPSC-CMs e a activação 
da proliferação das hCSCs. Através deste modelo foi também possível 
investigar a resposta das hCSCs à lesão de I/R, através de um estudo 
de proteoma global, desvendando assim novas vias moleculares 
envolvidas nas capacidades regenerativas destas células, incluindo 
regulação de ciclo celular, proliferação através de sinalização por EGF e 
detoxificação de espécies reactivas de oxigénio.  
Na sequência deste trabalho, no Capítulo III foi desenvolvido um modelo 
in vitro de lesão de I/R mais avançado, utilizando sistemas de cultura tri-
dimensionais (3D) e bioreactores de tanque agitado. A utilização de 
sistemas de cultura 3D permite a criação de redes complexas de 
interacção célula-célula e célula-matriz extracelular (ECM), 
representanto assim um microambiente mais próximo ao tecido in vivo. 
O uso de bioreactores de tanque agitado possibilita  a 
monitorização/controlo de vários parâmetros de cultura, tais como pH e 




esta estratégia, foi possível recapitular uma vez mais aspectos da 
fisiopatologia de IAM, incluindo a morte de hiPSC-CMs, a secreção de 
factores angiogénicos e disrupção da organização de sarcómeros e 
mitocôndrias. Com o intuito de investigar em mais detalhe a resposta 
das hCSCs aos factores parácrinos secretados pelos hiPSC-CMs após a 
lesão de I/R, no Capítulo IV, as hCSCs foram incubadas com o meio 
condicionado das experiências de bioreactores (Capítulo III). A resposta 
das hCSCs foi analizada quantitativamente em termos de proteoma total. 
Além do estudo da comunicação parácrina entre hCSCs e hiPSC-CMs, a 
interacção de hCSCs com linfócitos T foi explorada no Capítulo V, num 
contexto de transplante alogénico de hCSCs. Nomeadamente, foi 
analizado o efeito das hCSCs e de meio condicionado das mesmas na 
proliferação de linfócitos T, permitindo elucidar que os mecanismos 
imunomodulatórios das hCSCs não dependem apenas dos previamente 
descritos mecanismos de contacto directo através do receptor PDL-1, 
mas também através do metabolismo de triptofano extracelular. 
O Capítulo VI centra-se noutra população de células do miocárdio: CFs 
humanos (hCFs). Neste capítulo, o perfil proteómico destas células é 
analizado, com um foco em proteínas de membrana. Com o objectivo de 
definir uma assinatura molecular distintiva e específica de hCFs, foram 
comparados os perfis proteómicos destas células com outras 
populações de células cardíacas e estaminais, gerando um painel de 30 
proteínas de membrana exclusivamente identificadas em hCFs, 
constituindo assim uma valiosa fonte de informação para novos estudos 
envolvendo esta população cardíaca. 
Em suma, esta tese contribui para o estado da arte no campo de 
populações celulares cardíacas e na sua resposta em contextos de IAM, 
através do desenvolvimento de modelos in vitro de lesão de lesão de I/R 
e da aplicação de técnicas avançadas de proteómica. Os modelos 
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estabelecidos constituem ferramentas importantes para estudos 
posteriores que possibilitarão o desenvolvimento de novas terapias 
focadas em activação, recrutamento e melhoria das capacidades 























Sebastião, M.J., Pereira, R., Serra, M., Gomes-Alves, P., Alves, P.M. 
“Human Cardiac Fibroblast Membrane Proteome Characterization.” 
Proteomics e1700446, 2018. doi:10.1002/pmic.201700446. 
Sebastião, M.J., Pereira, R., Palacios, I., Serra, M., Gomes-Alves, P., 
Alves, P.M. “Myocardial ischemia/reperfusion injury human in vitro model 
to study human cardiac stem cells activation and regeneration 
mechanisms.” (submitted). 
Sebastião, M.J.*, Menta, R.*, Serra, M., Palacios, I., Alves, P.M., 
Lombardo E.†, Gomes-Alves†, P., “Study of immunomodulatory 
properties of human cardiac stem cells.” * These authors contributed 
equally. †Co-corresponding authors. Stem Cell Research and Therapy (in 
press). 
Sebastião, M.J., Reis I., Palacios, I., Serra, M., Gomes-Alves, P., Alves, 
P.M. “Merging bioreactor technology with 3D culture: a novel myocardial 
I/R in vitro model.” (manuscript in preparation). 
 
Book Chapters:  
Sebastião, M.J.*, Abecasis, B.*, Carrondo M. JT., Alves, P.M., Gomes-
Alves, P., Serra, M. (In press) 3D Strategies for expansion of human 
cardiac stem cells, Bioreactors For Stem Cell Expansion and 
Differentiation. CRC Press Taylor & Francis Group, Florida. * These 






Conference Proceedings:  
Sebastião, M.J., Gomes-Alves, P., Pereira, R., Palacios, I., Serra, M., & 
Alves, P. (2017). LB41 – Unveiling human cardiac stem cells 
regenerative potential in ischemia/reperfusion injury. Cytotherapy (Vol. 
19). 
Sebastião, M. J., Paiva, M., Reis, I., Palacios, I., Serra, M., Gomes-
Alves P., & Alves, P. (2018). P494 – Applying proteomic tools to disclose 
human cardiac stem cells regenerative potential in ischemia/ reperfusion 
injury. Cardiovascular Research (Vol. 114, Pages S120). 
Sebastião, M. J., Pereira, R., Serra, M., Gomes-Alves P., & Alves, P. 
(2018). P466 – A step closer to disclose human cardiac fibroblasts 




Torán, J.L., López, J.A.,Gomes-Alves, P., Aguilar, S., Torroja, C., 
Trevisán-Herranz, M., Moscoso, I. Sebastião, M.J., Serra, M., Brito, C., 
Sepúlveda, J.C. Martínez, F., Borlado, LR., Vázquez, J., Alves, P.M., 
Bernad, A. Definition of human cardiac progenitor cells core functions; 
genomic and proteomics comparative analysis with human mesenchymal 
stem cells. (submitted). 
Correia, C., Koshkin, A., Duarte, P., Hu, D., Carido, M., Sebastião, M.J., 
Gomes-Alves, P., Elliott, D.A., Domian, I., Teixeira, A.P., Alves, P.M., 
Serra, M. 3D aggregate culture improves metabolic maturation of human 
pluripotent stem cell derived cardiomyocytes. Biotechnology and 




Table of contents  
Chapter I…………………………………………………………………..…..1 
Chapter II – Modeling acute myocardial infarction in vitro: using a 2D 
co culture system to study human cardiac stem cells activation and 
regeneration mechanisms…….………………..…………………...……...51 
Chapter III – Merging bioreactor technology with 3D human 
cardiomyocytes culture: a novel myocardial I/R in vitro model…………97 
Chapter IV – A step closer to regeneration: using advanced quantitative 
proteomic tools to unveil hCSCs response to I/R injury paracrine 
factors………………………………………...……………………………..125 
Chapter V – Advancing the knowledge on immunomodulatory properties 
of human cardiac stem cells……..…………………………….………….151 
Chapter VI – Unveiling human cardiac fibroblast membrane 
proteome..............................................................................................173 









List of Abbreviations 
2D two-dimensional 
2DE two-dimensional gel electrophoresis 
3D three dimensional 
ACE angiotensin-converting-enzyme  
AMI acute myocardial infarction 
ASCs adipose-derived mesenchymal stem cells 
bFGF basic fibroblast growth factor  
CDCs cardiosphere-derived cells 
CFs cardiac fibroblasts 
CFSE carboxyfluorescein succinimidyl ester 
CHF chronic heart failure 
c-kit tyrosine kinase 
CMs cardiomyocytes 
CSCs cardiac stem/progenitor cells 
CTGF connective tissue growth factor 
CXCL6 granulocyte chemotactic protein 2 
DDA dependent data acquisition 
DDR2 tyrosine kinase discoidin domain receptor 
DIA data independent acquisition 
EB embryoid body 
ECGM2 Endothelial Cell Growth medium 2 
xxii 
 
ECM extracellular matrix 
ECs endothelial cells  
EGF epidermal growth factor 
ELISA enzyme-linked immunosorbent assay 
ERS endoplasmic reticulum stress 
ESCs embryonic stem cells  
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FDA fluorescein diacetate 
FDR false discovery rate 
FSG Fish Skin Gelatin 
G-CSF granulocyte colony-stimulating factor  
hASCs human adipose-derived mesenchymal stem cells 
hCFs human cardiac fibroblasts 
hCSCs human cardiac stem/progenitor cells 
hDFs human dermal fibroblasts 
HGF hepatocyte growth factor 
HIF-1α hypoxia-inducible factor 1 α 
hiPSC-CMs human induced pluripotent stem cell derived cardiomyocytes 
HLA human leukocyte antigen 
hMSCs human mesenchymal stem cells 




HPLC high performance liquid chromatography 
HUVECs human umbilical vein endothelial cells 
I/R Ischemia/ Reperfusion 
ICAT isotope-coded affinity tag  
iCSCs induced cardiac stem/progenitor cells 
IDA independent data acquisition 
IDO indoleamine 2,3-dioxygenase 
IFN-γ Interferon gamma 
IGF-1 insulin-like growth factor 1 
IHD ischemic heart disease 
IMS ischemic mimetic solution 
IPA ingenuity pathway analysis 
iPSCs induced pluripotent stem cells  
Isl-1 insulin gene enhancer protein  
Kyn kyurenine 
LAD left anterior descending  
LC liquid chromatography 
MACS magnetic –activated cell sorting 
MHC major histocompatibility complex 
MPTP mitochondrial permeability transition pore  
MS mass spectrometry  
PBMCs peripheral blood mononuclear cells 
xxiv 
 
PCI percutaneous coronary intervention 
PD-1 programmed cell death-1 
PDL-1 programmed death ligand 1 
Pen/Strep penicillin/streptomycin 
PFA paraformaldehyde 
PI propidium iodide 
PSCs pluripotent stem cells 
ROS reactive oxygen species 
Sca-1 stem cells antigen-1 
SCF stem cell factor 
SDF-1 stromal cell derived factor 1 
SILAC stable isotope labeling in cell culture 
SMA smooth muscle actin 
SMCs smooth muscle cells  
SWATH sequential window acquisition of all theoretical mass spectra 
T3 triiodothyronine 
TCR T-cell receptor 
TEM transmission electron microscopy 
TGF-β transforming growth factor β 
Trp tryptophan 
TW traswells 




VEGF vascular endothelial growth factor 












































This Chapter was adapted from: 
Sebastião, M.J.*, Abecasis, B.*, Carrondo M.J.T., Alves, P., Gomes-Alves, P., Serra, M., 3D strategies 
for expansion of human cardiac stem cells, Bioreactors for stem cell expansion and differentiation. CRC 







Introduction ......................................................................................................... 3 
1. Acute myocardial infarction: the unmet clinical need .......................... 3 
1.1. Pathophysiology of myocardial ischemia/reperfusion ................................ 4 
2. Current treatments for myocardial I/R injury ......................................... 6 
3. Novel therapeutic strategies for myocardial I/R injury ......................... 8 
3.1. Cell therapy ................................................................................................ 8 
3.1.1. Cardiac stem cells in cell therapy ............................................................... 9 
3.2. Cell-free approaches ................................................................................ 11 
4. The role of endogenous cardiac stem cells in cardiac repair ............ 14 
4.1. Identification and isolation of endogenous CSCs ..................................... 15 
4.1.1. C-kit+ CSCs ............................................................................................. 15 
4.1.2. Sca-1+ CSCs ........................................................................................... 15 
4.1.3. Isl-1+ CSCs .............................................................................................. 16 
4.1.4. CSC isolation methods ............................................................................. 16 
4.1.5. Derivation of cardiac stem cells from other cell sources .......................... 18 
4.2. Cardiac stem cells regenerative mechanisms .......................................... 20 
5. Cardiac Fibroblasts: key players in heart homeostasis and 
disease ............................................................................................................... 24 
5.1. Cardiac Fibroblasts molecular identity ..................................................... 25 
6. Modeling myocardial I/R injury ............................................................. 25 
6.1. In vitro models .......................................................................................... 27 
6.1.1. Cell sources.............................................................................................. 28 
6.1.2. Mimicking AMI physiology ........................................................................ 31 
6.1.3. 3D culture strategies ................................................................................ 31 
6.1.4. Bioreactors ............................................................................................... 32 
7. Proteomics as powerful tool for characterization of cardiac 
populations ........................................................................................................ 33 
8. Aims and scope of the thesis ................................................................ 36 







1. Acute myocardial infarction: the unmet clinical need 
Over the last decades, better medical care and living conditions have led 
to a gradual increase in average life expectancy, which reached a 
worldwide average of 71.4 years in 2015 (WHO). According to United 
Nations 2015 world population ageing report, the number of people aged 
60 years or over increased from 607 million in 2000 to 901 million in 
2015, with projections pointing to 1.2 billion in 2030 and 2.1 billion in 
2050. Such increase in life expectancy has led and will lead in the 
coming decades to a higher prevalence of age-related diseases including 
cancer, neurodegenerative disorders and cardiovascular diseases.  
Ischemic Heart Disease (IHD) is one of the most common types of 
cardiovascular disease, and a major cause of death worldwide (Benjamin 
et al., 2017). IHD consists in atherosclerosis (lipid plaque deposits) in 
heart arteries inner walls, narrowing and reducing blood flow to the heart, 
ultimately leading to an Acute Myocardial Infarction (AMI), commonly 
known as heart attack. AMI consists on the cessation of blood flow to an 
isolated region of the heart, causing oxygen and nutrient supply depletion 
(ischemia), leading to myocardial tissue damage with loss of 
cardiomyocytes (CMs), the main cell type in the heart. Since the extent of 
tissue damage and cell death is influenced by both the magnitude and 
duration of ischemia, the revascularization and restauration of blood flow 
as soon as possible remains the clinical intervention of choice for AMI 
patients (Anderson and Morrow, 2017). However, this process, also 
known as reperfusion, although necessary to reestablish the delivery of 
oxygen and nutrients to the affected area, causes increased tissue 
damage (Ischemia Reperfusion I/R Injury). The elevation of molecular 





final damaged tissue size (Hausenloy and Yellon, 2013) and contributing 
to almost one fourth of AMI mortality (Yellon and Hausenloy, 2007). 
Nevertheless, the current treatments are successful in reducing 
immediate mortality but the tissue damage is often too large (in average, 
about 1 billion CMs are lost during an AMI, Laflamme & Murry, 2011) to 
allow restauration of normal muscle function. Deposition of fibrous scar 
tissue leads to a decrease in myocardium tensile strength and 
progressive loss of cardiac output, often leading to Chronic Heart Failure 
(CHF), a highly fatal condition (survival rate of only 50% at 5 years, 
Cahill, Choudhury, & Riley, 2017) to which the only available clinical 
option is heart transplant. As it is known, this solution is not optimal in 
clinical practice due to the scarcity of available heart donors, high costs 
and need for immunosuppression (Lund et al., 2014). 
1.1. Pathophysiology of myocardial ischemia/reperfusion  
The two phases of I/R injury have distinctive physicochemical properties 
and therefore distinct pathophysiology mechanisms affecting 
myocardium tissue and CM death (figure 1.1). 
During ischemia, the deprivation of oxygen and nutrients results in a 
series of biochemical and metabolic cellular changes including decrease 
of ATP and pH levels, increase in intracellular lactate and accumulation 
of intracellular Ca2+. Without oxygen, CMs stop oxidative 
phosphorylation, leading to a decrease in ATP synthesis and an increase 
in anaerobic respiration by glycolysis and lactic acid fermentation with 
accumulation of intracellular lactate. While increased glycolysis helps to 
compensate for the lack of aerobic ATP, this pathway binds less ATP 
hydrolysis-generated H+, leading to lower pH. The intracellular 




of ATP during ischemia also causes CM contraction arrest and 
inactivation of 3Na+/2K+ exchanger ATPases, leading to intracellular Na+ 
accumulation. In response, the activation of the 2Na+/Ca2+ pump results 
in intracellular Ca2+ overload (Hausenloy and Yellon, 2013; Kalogeris et 
al., 2017) (figure 1.1) 
 
Figure 1.1. Schematic illustration of the main biochemical mechanisms underlying 
myocardial ischemia/reperfusion induced cardiomyocyte cell injury and death. 
During ischemia, metabolism is switched to anaerobic respiration, resulting in production 





. During reperfusion, the electron transport chain is 
reactivated, generating ROS that, together with higher Ca
2+
 accumulation, lead to MPTP 
opening and CM contracture. Neutrophils are recruited to the site of injury in response to 
the release of ROS and cytokines, contributing to tissue inflammation (Hausenloy and 
Yellon, 2013). 
Restauration of blood flow during reperfusion provides oxygen and 
metabolic substrates required for aerobic ATP generation. However, the 
reactivation of the mitochondrial electron transport chain leads to 
production of cytotoxic reactive oxygen species (ROS).  Acidosis is also 
corrected by the Na+/H+ exchanger which results in additional 
intracellular Na+ accumulation, resulting in the activation of 2Na+/Ca2+ 
exchanger. The release of extra Ca2+ from sarcoplasmic reticulum, 
adding to the ischemic Ca2+ accumulation culminates into a large 





(sarcomeres myofibrillar contraction) (Hausenloy and Yellon, 2013; 
Kalogeris et al., 2017). ROS synthesis, the increase in pH and the Ca2+ 
overload result in the opening of the mitochondrial permeability transition 
pore (MPTP), a non selective channel of the inner mitochondrial 
membrane. MPTP opening results in mitochondrial membrane 
depolarization and uncoupling of the electron transport chain, leading to 
ATP depletion, mitochondria swelling with mitochondria membrane 
rupture and release of apoptotic factors culminating in activation of 
apoptosis and cell death (figure 1.1) (Hausenloy and Yellon, 2013; 
Kalogeris et al., 2017).  
In response to the stress caused by reperfusion, CMs secrete several 
growth factors (including insulin-like growth factor 1 IGF-1, epidermal 
growth factor EGF, hepatocyte growth factor HGF, vascular endothelial 
growth factor VEGF), cytokines, chemokines and other pro-inflammatory 
molecules, which together with the released ROS recruit immune cells to 
the site of injury (figure 1.1). Neutrophils are key players in the post AMI 
inflammatory process: by secreting ROS, proteases, chemokines and 
other cytotoxic molecules, these cells further enhance inflammation and 
tissue damage (Frangogiannis, 2014). Phagocytic leukocytes also clear 
dead cells and matrix debris, setting the stage for fibrous collagen-based 
scar tissue deposition by activated cardiac fibroblasts (see section 5).  
 
2. Current treatments for myocardial I/R injury 
Duration of the ischemia phase is a major contributor to the extent of 
myocardial tissue damage. As so, the intervention of choice for a patient 
with AMI symptoms is the rapid reperfusion of the affected artery. The 




(percutaneous coronary intervention, PCI), by pharmacological anti-
platelet and fibrinolytic (anti-thrombotic) agents, or by a combination of 
both (e.g., drug eluting PCI stents). Another alternative to PCI is coronary 
bypass surgery, in which a healthy vessel is used to divert the blood flow 
around the blocked artery (Anderson and Morrow, 2017). In addition, 
angiotensin-converting-enzyme (ACE) inhibitors and β-blockers are 
commonly used in the clinic to downsize myocardial scar formation 
(Anderson and Morrow, 2017). A substantial decrease of in-hospital AMI-
related mortality rate of  7-18%  was registered over the last two decades 
(Cahill, Choudhury and Riley, 2017). Such improvement in AMI patients 
prognosis is a testament to advances in PCI and pharmacological 
therapies as well as implementation of preventative measures. While 
immediate unclogging of the affected artery remains the keystone for the 
treatment of AMI patients, several approaches focusing in reducing the 
damage caused by the reperfusion are being developed and tested in 
clinical trials.  
In contrast to classic unimpeded reperfusion, ischemic post-conditioning, 
also designated as slow reperfusion, consists in intermittent reperfusion, 
with brief repetitive interruptions of blood flow. This on/off reperfusion is 
thought to trigger a cascade of cell protection mechanisms that translate 
into a reduced myocardial injury size. Although promising results were 
registered in animal models, human clinical trials remain inconclusive 
(Giustino and Dangas, 2017). Another strategy showing more promising 
results in humans is remote ischemic per-conditioning, in which tissues 
other than the heart (usually limbs) are exposed to ischemia, resulting in 
the activation of systemic mechanisms of defense and myocardial 
protection (McLeod, Iansavichene and Cheskes, 2017).  
A multitude of pharmacological approaches have also been developed to 





being evaluated in clinical trials. One such example is cyclosporine A, an 
inhibitor of MPTP opening. However, a recent meta-analysis has shown 
that the use of this drug before PCI does not translate into a better 
clinical outcome (Rahman et al., 2018). 
Besides mechanical and pharmacological-based treatments, cell-based 
approaches have been emerging in the last years as a novel strategy to 
treat infarcted myocardium. 
 
3. Novel therapeutic strategies for myocardial I/R injury 
For many years, the adult mammalian heart has been considered an 
organ without regenerative potential. In 2003, Beltrami and colleagues 
identified cardiac stem/progenitor cells (CSCs) in the mouse heart for the 
first time (Beltrami et al., 2003), and in the following years CSCs were 
identified in other animals including humans (Bearzi et al., 2007). As 
most adult stem cells, CSCs have the ability to self-renew and to 
differentiate into tissue-specific lineages [CMs, vascular smooth muscle 
cells (SMCs) and endothelial cells (ECs)] (Beltrami et al., 2003). 
The discovery of CSCs is an hallmark in AMI-related research, as it 
challenges the previous paradigm in cardiovascular research, in which 
the heart was seen as a post-mitotic organ without endogenous 
regenerative capacity. This finding opened novel avenues in regenerative 
medicine strategies for recovery of infarcted myocardium, including cell 
therapy and protein-based stimulation of endogenous heart repair. 
3.1. Cell therapy 
In cell therapy-based approaches several cell types were already applied 




bone-marrow mononuclear cells (e.g., REPAIR-ACS- NCT00711542, 
BOOST-NCT00224536), bone marrow-derived mesenchymal 
stem/stromal cells (e.g. BOOST trial, NCT00224536), and adipose 
tissue-derived mesenchymal stem/stromal cells (e.g., APOLLO trial, 
NCT00442806).  
After “first generation” stem cell sources, more focus is now being 
devoted to therapies with purified and homogeneous “second generation” 
stem cell sources, such as CSCs. 
3.1.1. Cardiac stem cells in cell therapy 
CSCs are considered by several authors as the preferable candidate cell 
therapy for cardiac diseases, mainly due to their physiologic location and 
function in the heart, their potential to differentiate into myocardial 
lineages, and the promising regenerative effects of CSCs transplantation 
in myocardial infarction preclinical models. In a recent preclinical meta-
analysis, an estimated improvement of 10.7% of left ejection fraction was 
registered, with superior effects of CSCs compared with other cell types 
in mice (Zwetsloot et al., 2016). However, such trend seems to be lost 
when moving to large animal models (Zwetsloot et al., 2016). 
The first clinical trials using CSCs were based on autologous therapies 
(Chugh et al., 2012; Makkar et al., 2012; Ishigami et al., 2015) (table 1.1), 
which have the great advantage of not presenting immunogenicity risks 
to the patients. However, autologous cell therapy is associated with 
serious limitations that compromise widespread “off-the-shelf” clinical 
applications such as the difficult logistic, economic and time-constraints 
in patient specific tissue harvesting and expansion. Moreover, cell’s 
phenotype, regenerative potential, and quality will be highly variable and 





(Dimmeler and Leri, 2008; Wu et al., 2016; Sharma et al., 2017). To 
overcome such limitations, the field has been moving towards allogeneic 
clinical approaches, such as the clinical study ALLSTAR and more 
recently, the CAREMI trial (Sanz-Ruiz et al., 2017; Fernández-Avilés et 
al., 2018), which had success in demonstrating safety and lack of 
rejection of transplanted cells, as well as improvements in infarct size 
(table 1.1). Moreover, a cross-talk of transplanted allogeneic c-kit+ 
hCSCs  with innate natural killer cells has been shown to result in 
attenuation of myocardium inflammation and prevention of adverse scar 
tissue formation (Boukouaci et al., 2014). The same group has also 
identified programmed death ligand 1 (PDL-1) interaction with T 
regulatory cells as one of the mechanisms involved in this 
immunomodulatory capacity and suggested PDL-1 as a marker to 
identify and select low immunogenic risk allogeneic c-kit+ CSCs (Lauden 
et al., 2013). Another cell therapy approach being explored is the use of 
CSCs derived from pluripotent cell populations such as the ESCORT 
trial, in which CSCs derived from embryonic stem cells (ESC-CSCs)  
have been applied (table 1.1). 
For all different CSC subpopulations tested, clinical trials have 
demonstrated some physiological improvements, namely increase in 
viable tissue and in heart functional outcome (table 1.1), but very limited 
cell retention and engraftment in the heart was observed, regardless of 
the route of administration and cell dosage. Within 24 hours of delivery, 
less than 10% of injected cells remain at the targeted location, and most 
of the successfully retained cells die, probably due to the inflammatory 
environment in the infarct and infarct border zones of the myocardium 
(Hong and Bolli, 2014; Mathur et al., 2017). In order to further improve 
the physiologic benefit of cell transplantation, several strategies have 




to be transplanted, for example with an hypoxia cultivation priming phase 
(Hosoyama et al., 2015; Hernandez et al., 2018), preconditioning the 
target tissue (Assmus et al., 2013), repeated cell dosage (Tokita et al., 
2016), and biomaterial-based approaches (Hosseinkhani et al., 2010; 
Kryukov, Ruvinov and Cohen, 2014; Rajabi-Zeleti et al., 2014; Gaetani et 
al., 2015; Menasché, Vanneaux, Hagège, et al., 2015).  
3.2. Cell-free therapeutic approaches 
The low cell engraftment efficiency in preclinical and clinical studies 
strongly supports the hypothesis that the beneficial physiological effect of 
transplanted cells is due to paracrine modulation rather than to cells 
engraftment and differentiation (Madonna et al., 2016).  
In fact, novel strategies for heart regeneration involve the activation of 
endogenous CSCs populations directly with growth factors. Examples of 
growth factors investigated include IGF-1 and HGF (Urbanek et al., 2005; 
Ellison et al., 2011; Koudstaal et al., 2014; O’Neill et al., 2016; Blanco 
Blazquez et al., 2017), granulocyte colony-stimulating factor (G-CSF) 
(STEMMI-NCT00135928), erythropoietin (REVIVAL-3-NCT0039083), as 
well as VEGF (NORTHERN-NCT00143585). Such single growth factor 
therapies showed only little benefit in AMI patients, possibly due to the 
rapid diffusion and short half-lives of the injected molecules (Awada, 
Hwang and Wang, 2017). Other approaches try to overcome this by 
combining growth factor therapy with cell therapy, such as ALCADIA trial, 
in which a sustained release of basic fibroblast growth factor (bFGF) from 
a gelatin hydrogel sheet was used in order to augment the effect exerted 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Despite promising, several challenges still need to be addressed in order to 
reach the full clinical potential of CSCs. Further understanding of CSC 
biology is needed in order to discover and modulate molecular pathways 
involved in the regenerative potential of these cells. Novel findings will be 
pivotal for the development of improved clinical strategies, including 
enhanced activation of endogenous hCSCs, preconditioning of cells to be 
transplanted and protein-based therapies. New relevant human cell-based 
models of cardiac tissue damage should also be pursued to characterize 
CSC response to myocardial injury in vitro. 
International collaborative consortiums and multicenter studies such as 
Translational Alliance for Regenerative Therapies in Cardiovascular 
Syndromes (TACTIC) (Fernández-Avilés et al., 2017), Consortium for 
Preclinical Assessment of Cardioprotective Therapies (CAESAR) (Jones et 
al., 2015), and Cardio Repair European Multidisciplinary Initiative (CARE-
MI) (www.cordis.europa.eu) have been emerging as important platforms to 
bring basic researchers and clinicians together to discuss and define 
common goals and strategies, as well as to standardize protocols and 
analytical techniques in preclinical and clinical studies. 
 
4. The role of endogenous cardiac stem cells in cardiac repair 
Endogenous CSCs play important roles in cardiac homeostasis and in 
response to physiological stress and cardiac injury. The mammalian adult 
heart harbors a small percentage of endogenous CSCs (about one stem cell 
per 8000-20000 CMs (Anversa et al., 2006)), which are located in organized 
hypoxic niches within the myocardium, more abundant in lower 




niches, CSCs are typically clustered together with early committed cells and 
adult CMs (Leri et al., 2014). 
Since their discovery in 2003 (Beltrami et al., 2003), efforts have been made 
to isolate, cultivate, characterize and study the regenerative mechanisms of 
these cells. 
4.1. Identification and isolation of endogenous CSCs 
Several CSCs subpopulations have been described and isolated from the 
adult heart according to their phenotypic profile and differential expression 
of several surface molecular markers. These subpopulations include c-kit+, 
Sca1+, and Isl-1+ CSCs (reviewed in detail in Santini et al. 2016). 
4.1.1. C-kit+ CSCs 
C-kit+ cells were the first population of CSCs to be identified in the adult 
mouse heart in 2003 (Beltrami et al., 2003). These cells are characterized 
by expression of the stemmness marker c-kit, expression of cardiac lineage 
transcription factors such as GATA4, Nkx2.5, and Mef2C, and absence of 
hematopoietic lineage markers such as CD34 and CD45 (Santini et al., 
2016). c-kit+ CSCs are one of the most extensively studied CSCs 
subpopulations, already employed in several clinical trials such as SCIPIO, 
CAREMI, CONCERT and TAC-HFT-II (table 1.1) 
4.1.2. Sca-1+ CSCs 
Sca-1+ CSCs are characterized by the expression of the endothelial marker 
stem cells antigen-1 (Sca-1). These cells have been identified in mice and 
human adult heart and express the cardiac transcription factors GATA4, 





hematopoietic markers CD34 and CD45, and mature endothelial markers 
such as CD31 (Santini et al., 2016). 
4.1.3. Isl-1+ CSCs 
Another population of CSCs, characterized by the expression of the LIN-
homeodomain transcription factor insulin gene enhancer protein (Isl-1) has 
also been described in murine and human hearts. These cells do not 
express c-kit, Sca-1, or CD31 while expressing the cardiac transcription 
factors Nkx2.5 and GATA4. The expression of Isl-1 is closely associated 
with age: Isl-1+ cells can be found predominantly in fetal and neonatal 
myocardium, yet very low levels of this population could be found in adult 
hearts, which limits their clinical application (Weinberger et al., 2012). 
4.1.4. CSC isolation methods 
CSC subpopulations are usually isolated from the adult human heart tissue 
either from cadavers or from biopsies of patients undergoing heart surgery. 
Experimental approaches for the isolation of hCSCs from cardiac tissue can 
be separated into two categories: cardiosphere-based and 
immunoselection-based, taking advantage of the expression of specific 
molecular markers (figure 1.2).  
The first method to isolate CSCs from human heart biopsies was reported in 
2004 (Messina et al., 2004) (Patent number WO2005012510). Cardiac 
tissue explants were enzymatically digested and cultured as adherent 
explants. These explants gave rise to cellular outgrowths that 
spontaneously aggregate, generating three-dimensional (3D) structures, 
named cardiospheres, which are composed of mixed cell populations, with 
undifferentiated cells expressing stem cell markers in the core and 




endothelial and stromal commitment in the periphery (Davis et al., 2010). 
Cardiospheres are then collected, replated in fibronectin adherent culture 
dishes and further expanded as monolayers to yield cardiosphere-derived 
cells (CDCs) (Cheng et al., 2014; Kapelios, Nanas and Malliaras, 2016).  
Several preclinical studies using myocardial injury models (Kanazawa et al., 
2016) have demonstrated the beneficial effects of transplantation of CDCs 
in improving cardiac function and decreasing scar tissue size (for detailed 
reviews see Marbán 2014; Kapelios, Nanas, and Malliaras 2016). These 
studies have already been translated into several human clinical trials such 
as CADUCEUS and ALLSTAR (table 1.1, page 12). However, the cell 
population heterogeneity inherent to the cardiosphere isolation method has 
been pointed as a disadvantage in terms of obtaining robust and predictable 
clinical outcomes. 
Another method for isolating hCSCs from heart tissue is by using the 
enzymatic digestion of tissue explants followed by immune-selection for 
stem cell markers such as the surface receptors c-kit, Sca-1, Isl-1 and 
immunodepletion for hematopoietic and mesenchymal markers such as 
CD45 and Tryp, using magnetic-activated cell sorting (MACS) or 
fluorescence-activated cell sorting (FACS) (Barile et al., 2007; Lauden et al., 
2013; Goichberg et al., 2014). In particular, CSCs immunoselected for c-kit+ 
represent the most extensively characterized CSC population. Although 
controversy exists regarding the differentiation capability of c-kit+ CSCs 
(Ellison et al., 2013; Nadal-Ginard, Ellison and Torella, 2014; van Berlo et 
al., 2014) and the stability of c-kit marker expression during in vitro culture 
(Forte et al., 2011), numerous preclinical studies (for a more detailed review 
consult Nigro et al. 2015) and clinical trials (table 1.1, page 12) demonstrate 
that c-kit+ CSCs have relevant regenerative properties, since transplantation 
of this cell population results in improved cardiac tissue function and 





4.1.5. Derivation of cardiac stem cells from other cell sources 
Besides donated human hearts, other sources for CSC have emerged 
(figure 1.2). Pluripotent stem cells (PSCs), including induced pluripotent 
stem cells (iPSCs) and embryonic stem cells (ESCs), have unlimited self-
renewal capacity and the potential to differentiate in vitro, holding great 
promise for the clinical translation of cell therapies. In particular, hiPSCs 
hold the advantage of allowing for autologous therapies without invasive 
isolation procedures. In fact, as development of less invasive surgical 
interventions techniques is further explored, the availability of tissue for 
isolation of autologous and allogeneic hCSCs will be scarcer in a near 
future. Efforts have been made throughout the years to obtain CSCs from 
pluripotent stem cells (PSC-CSCs). 
The first study reporting PSC-CSCs (Isl-1+) was performed using murine 
ESCs, demonstrating the proliferative capacity of these derived CSCs on a 
feeder layer of mesenchymal cells (Moretti et al., 2006). Similarly, in 
following studies, human PSC (hPSC) were differentiated into CSCs either 
through an embryoid body (EB)-based spontaneous differentiation step 
originating  Isl-1+ hCSCs (Bu et al., 2009) or a bone morphogenic protein 2 
(BMP-2) directed differentiation originating stage specific embryonic 
antigen-1 (SSEA1+) hCSCs (Tomescot et al., 2007; Blin et al., 2010). Both 
types of hPSC-CSC have shown similar regenerative potential to the CSCs 
isolated from human fetal hearts in both rat and non-human primate models. 
More recently, these advances in the differentiation of hPCS-CSCs led to 
the translation from bench scale to a cell-based medicinal product 
(Menasché, Vanneaux, Fabreguettes, et al., 2015) culminating in the 
ongoing clinical trial with hESC-CSCs for patients with severe heart failure 
(ESCORT Trial, table 1.1 page 12). More recently, efforts have been made 




from hPSCs in a chemically defined medium under feeder- and serum-free 
culture conditions resulting in high purities of SSEA1+ mesoderm posterior 
protein 1 positive (MESP1+) cells (Cao et al., 2013). 
 
Figure 1.2. Sources currently available for obtaining cardiac stem/progenitor cells 
(CSCs). Abbreviations: Magnetic activated cell sorting (MACS); Fluorescence activated cell 
sorting (FACS); Cardiosphere derived cells (CDCs); Pluripotent stem cell derived cardiac 
stem cells (PSC-CSCs); induced cardiac stem cells (iCSCs). Examples from literature are 
included. Adapted from Sebastião et al 2018. 
Several questions still arise today on how these hPSC-CSCs compare to 
the CSCs isolated from the human heart. Within this context, several studies 
have been trying to bring light on the different cardiac progenitors generated 
during heart development, and which signaling pathways may be 
manipulated to obtain those (Birket et al., 2015). In a more recent study, 
global transcriptomic analysis of patient epicardium-derived CSCs and 
hPSC-CSCs was carried out showing that more than three thousand genes 
were differentially expressed between the two cell types, with hierarchical 





types of CSCs (Synnergren et al., 2016), confirming the phenotypic 
differences between these two populations. 
Other innovative strategies for the generation of CSCs have emerged 
through direct reprogramming of fibroblasts (induced CSCs, iCSCs) (figure 
1.2). These iCSCs have been described to i) express cardiac signature 
genes, ii) have extensive proliferative capacity, and iii) be able to 
differentiate into the three main cardiac lineages in vitro and in vivo after 
transplantation into infarcted mouse hearts (Lalit et al., 2016; Zhang et al., 
2016). Although these iCSCs have shown promising in vivo regeneration 
capacity, their direct comparison to isolated endogenous CSCs or hPSC-
CSCs is still lacking. In addition, these studies were performed using murine 
cells and further studies with human cells are still required (Chen and Wu, 
2016). 
4.2. Cardiac stem cells regenerative mechanisms 
Endogenous CSCs play important roles in cardiac tissue cell turnover, as 
well as in response to physiological stress, including I/R injury. Numerous 
studies suggest that these cells become activated after injury, having an 
immuno-supressive role, proliferating, differentiating into cardiomyogenic 
lineages, migrating to the site of injury, and secreting important paracrine 
factors involved in the modulation of cell proliferation, angiogenesis, 
vasculogenesis and pro-survival of CMs (figure 1.3). 
Although one of the hallmarks used to define CSCs is their ability to 
differentiate in vitro into the three major cells in the myocardium (CMs, 
SMCs and ECs), doubts and controversy still exist regarding the ability of 
endogenous and transplanted CSCs to differentiate in vivo upon injury. 
While some authors defend that endogenous CSCs can differentiate in vivo 




al., 2011, 2013; Vicinanza et al., 2017, 2018), others defend that CSCs 
differentiation to cardiac lineages occurs at a very low rate, making it 
unlikely to be the main mechanism for CSCs-induced tissue recovery(van 
Berlo et al., 2014, 2018). Additionally, the origin of new CMs during tissue 
homeostasis and upon injury is still a matter of debate, with different authors 
defending different origins, ranging from CSCs to division of pre-existing 
CMs (Senyo et al., 2013; Sereti et al., 2018), reviewed in more detail in 
(Cahill, Choudhury and Riley, 2017). 
Despite such doubts regarding the differentiation capacity of CSCs, there is 
a general consensus in the scientific community regarding CSCs-derived 
paracrine mechanisms. CSCs have been shown to exert potent paracrine 
regenerative effects both in vivo and in vitro (Li et al. 2012; Sharma et al. 
2016; Miyamoto et al. 2010; Torella et al. 2007). Upon injury, CMs activate 
the expression and secretion of a large number of growth factors and 
cytokines (e.g. IGF-1, HGF, stem cell factor SCF and stromal cell derived 
factor 1 SDF-1) (X. Li et al., 2014a) that bind to receptors expressed by 
CSCs (Gomes-Alves et al. 2015; Ellison et al. 2012; Li et al. 2014; Urbanek, 
Rota, et al. 2005). Consequently, an auto/paracrine cross-talk is established 
between CMs and CSCs, leading to a continued production of growth 
factors by CSCs, which have been shown to contribute to the modulation of 
angiogenesis, vasculogenesis, pro-survival of CMs and activation of CSCs 
proliferation and migration as well.  
Cardiac stem cell secretome studies have revealed that these cells secrete 
a large array of signaling molecules, including the growth factors IGF-1, 
EGF, VEGF, transforming growth factor beta (TGF-β), HGF and several 
interleukins and chemokines (Stastna et al., 2010; Albulescu et al., 2015; 
Sharma et al., 2015; Park et al., 2016; Torán et al., 2017). Several of these 
cytokines and growth factors have shown to induce CSCs proliferation in 





2014; Waring et al., 2014), EGF (Aghila Rani and Kartha, 2010), and 
connective tissue growth factor (CTGF) (Stastna and Van Eyk, 2012). CSCs 
are also proposed to exert potent cytoprotective effects in cardiomyocytes 
through factors such as IGF-1 (Linke et al., 2005; Kawaguchi et al., 2010; 
Miyamoto et al., 2010), HGF (Linke et al., 2005) and VEGF (Miyamoto et al., 
2010). Other factors secreted by CSCs have also been shown to promote 
neovascularization in infarcted hearts, including the pro-angiogenic factors 
VEGF (Miyamoto et al., 2010; Wang et al., 2014), TGF-β (Park et al. 2016; 
Ellison et al. 2012) as well as several interleukins (Valiente-Alandi et al., 
2016).  Exosomes have also emerged recently as a novel player in CSC 
paracrine regenerative properties, with observed cardiac functional 
improvement after administration of CSC-derived exosomes in mouse 
(Ibrahim, Cheng and Marbán, 2014), rat (Barile et al., 2014) and pig (Gallet 
et al., 2016; Nguyen et al., 2018) infarcted myocardium. Several micro-
RNAs have been described as having a role in this exosome-mediated 
protection, including miR-210, miR-132 and miR-146, miR-181 and miR-451 
(Chen et al., 2013; Barile et al., 2014, 2017; Mol, Goumans and Sluijter, 
2017). 
Upon AMI, CSCs also home and migrate to the site of injury, a process 
activated by ischemia through hypoxia-inducible factor 1α (HIF-1α) 
transcription factor and SDF-1 (Ceradini et al., 2004; Rota et al., 2008). 
During myocardial infarction, there is a sudden elevation of SDF-1 levels in 
the myocardium, which improves CSC homing to the site of injury (Penn et 
al., 2012). However, the repair potential of endogenous CSCs is thought to 
be restricted by the short half-life of SDF-1 in the myocardium due to its 
degradation by proteases such as DPP4. In mice, treatment with DPP4 
inhibitors has shown to improve cardiac function after myocardial injury 
(Zaruba and Franz, 2010). In addition to SDF-1, other molecules have 




chemotactic protein 2 (GCP-22/ CXCL6) (Torán et al., 2017), EGF and HGF 
(Urbanek et al., 2005; Boucek et al., 2015).   
Cardiac stem cell immunologic studies have also revealed that these cells 
have immunosuppressive effects, including the inhibition of T-lymphocyte 
proliferation (Lauden et al., 2013; van den Akker et al., 2018), by directing 
natural killer cells to secrete anti-inflammatory cytokines  (Boukouaci et al., 
2014), as well as by modulation of monocytes, macrophages and dendritic 
cells towards an anti-inflammatory phenotype (Dam et al., 2017). 
 
Figure 1.3. Overview of the main regenerative properties described for cardiac 
stem/progenitor cells (CSCs) in cardiac regeneration and repair. CSCs are described to 
be able to differentiate into the three main cardiac lineages, secrete an array of paracrine 
factors and exosomes, proliferate, migrate to the site of injury, protect the endogenous 
myocardial tissue, promote neovascularization and exert immune-suppressive roles. Adapted 






5. Cardiac Fibroblasts: key players in heart homeostasis and 
disease 
Besides CSCs and CMs, other myocardial cell populations including 
endothelial cells (ECs), SMCs and cardiac fibroblasts (CFs) play key roles in 
I/R pathology.  
Namely, CFs are one of the most numerous non CM cell types in the human 
heart. While most studies account them for representing about 30-60% of 
the total cell number in myocardial tissue (Camelliti, Borg and Kohl, 2005; 
Krenning, Zeisberg and Kalluri, 2010), a more recent study, using a 
combination of genetic tools and  cellular markers, points to percentages 
from 5-10 % (Pinto et al., 2016). Regardless of their percentage in the heart, 
CFs play key roles both in homeostasis and in response to injury. CFs are 
the main cell type involved in synthesis and turnover of extracellular matrix 
(ECM), function as local immune modulators, and are a constituent part of 
the cardiac electrophysiology network (Furtado, Costa and Rosenthal, 
2016). Upon myocardial disease and injury, activated fibroblasts 
(myofibroblasts) become one of the predominant cell types in the healing of 
the infarcted area. Their origin is still debatable, with different authors 
defending different origins of myofibroblasts, including activation of resident 
cardiac fibroblast populations, cardiac pericytes modulation, endothelial to 
mesenchymal transdifferentiation, and recruitment of circulating fibroblasts 
(Saxena, Russo and Frangogiannis, 2016). Myofibroblasts proliferate and 
secrete an excess of ECM proteins (mainly collagen), preserving the 
integrity of the tissue, avoiding major tissue distension and rupture, and 
ensuring that coordinated beating function of the heart is maintained. This 
process is referred as fibrosis and can occur in response to CM death 
(reparative fibrosis) our in response to changes in myocardial load or 
inflammation (responsive fibrosis). Fibrotic tissue is stiffer and less 




tissue workload and arrhythmias (Furtado, Costa and Rosenthal, 2016). 
Fibrosis is a pathological feature present in numerous forms of heart 
disease, including AMI and heart failure. It is estimated that about 45% of all 
deaths in the developed world involve cardiac fibrosis (Wynn, 2007).  
5.1. Cardiac Fibroblasts molecular identity 
Attending to their central role in cardiac fibrosis, a lot of attention has been 
draw to the study of CFs. Although a lot of progress has been made in the 
last years on unveiling CFs mechanisms in homeostasis and pathological 
settings (reviewed in Dostal, Glaser and Baudino, 2015), the lack of a 
proper molecular marker definition has been one of the major impediments 
to the characterization, isolation and study of this cell type both in vivo and 
in vitro. Some of the most commonly used markers for CFs are collagens, 
vimentin, tyrosine kinase discoidin domain receptor (DDR2) and Thy1 cell 
surface antigen (CD90). None of these molecules is neither expressed by all 
CFs neither unique for this cell type (Furtado, Costa and Rosenthal, 2016). 
Recently, a whole human heart proteome analysis revealed a panel of 25 
cell membrane receptors shown to be preferably enriched in CFs, when 
compared to adipose fibroblasts, ECs and SMCs (Doll et al., 2017). 
 
6. Modeling myocardial I/R injury 
Investigation of the molecular mechanisms underlying function and 
response of different heart cell populations requires suitable experimental 
models, both in homeostasis and in disease settings. These models can be 
divided in in vivo (animal models), ex-vivo (isolated whole heart 






Figure 1.4. Main methodologies applied to model ischemia reperfusion (I/R) myocardial 
injury. The most commonly used in vivo models for IR injury include mouse, rat, pigs and 
non-human primates. Ex-vivo heart preparations from mouse and rats are also used to study 
acute myocardial biology. In vitro models rely on the use of primary cultures or cell lines from 
murine origin or on human pluripotent derivatives. Cells can be cultured as monolayers (two 
dimensional, 2D) or in three-dimensional (3D) setups. 
Cardiovascular research has traditionally relied on animals to study AMI and 
I/R injury. In both small and big animal models, the most common 
methodology to recapitulate AMI is the occlusion of the left anterior 
descending coronary (LAD) artery, either by suture ligation (open-chest 
models) or balloon stent inflation (closed-chest models) (Fliegner et al., 
2015). Small animals such as mice and rats are often used since they are 
easy to house, have a short gestation time and many genetically modified 
variants are available. However, despite their widespread use, the small 
size of murine hearts makes them physiologically distant to humans and 
mice hearts have been consistently reported to be more tolerant to drugs. In 
fact, cardiotoxicity is still one of the main causes for therapy withdrawal 
during clinical trials (Han, Zhou and Liu, 2017). Larger animals, such as pigs 




have a higher translational predictive power in terms of drug safety. Ex-vivo 
approaches are also employed, namely the Langendorff and the working 
heart model, that consists on the perfusion of isolated whole hearts (usually 
from mouse or rat) with plasma or blood like medium. Such models have the 
advantage of allowing to impose different degrees of ischemia and flow 
rates, also allowing for studies on drug dose responses, as their 
concentration can be more accurately controlled than in a whole animal 
model (Vidavalur et al., 2008).  
Although preclinical animal models represent a biological complexity level 
closer to humans, and have unquestionable value in AMI cardiovascular 
research, their predictive power is still limited: about 90% of candidate 
therapies that showed efficacy in preclinical studies fail in human trials 
(Olson et al., 2000), generating massive costs in the drug development 
chain. Moreover, the logistical, and financial restraints of ex-vivo and animal 
models, associated with the growing ethical implications represented by the 
concepts of the 3Rs (replacement, reduction and refinement), make them 
not amenable for high-throughput studies in earlier phases of drug 
development. The inherent cell complexity of tissues also makes it difficult 
to interpret single cell or single cell-population mechanisms.  
6.1. In vitro models 
The inherent limitations of animal studies and lack of translational success 
from preclinical to clinical trials illustrates the need for the development of 
additional platforms for filtering therapeutic targets and better understanding 
pathology mechanisms of action. In vitro models provide a complementary 
approach to in vivo and ex vivo models and support earlier stages of 






6.1.1. Cell sources 
When modeling cardiovascular systems in vitro, murine cell populations 
have been extensively used throughout the years. This includes primary 
fetal, neonatal and adult CMs, mouse atrial HL-1 cells and rat ventricular 
H9c2 cell lines (Parameswaran et al., 2013). Fetal and neonatal CMs are 
easier to maintain in culture and are very useful to study adaptive 
mechanisms and cardiac development. However, fetal and neonatal cells 
have a highly glycolytic metabolism, while adult CMs metabolism depends 
more heavily in fatty acids, rendering neonatal cells more resistant to 
hypoxia and I/R injury (Robertson, Tran and George, 2013). In fact, after 
removal of the cardiac apex or coronary artery ligation-induced AMI, the 
neonatal mouse heart has been reported to be almost entirely regenerated, 
a capacity that seems to be limited to the first 7 days after birth, coinciding 
with postnatal maturation of the mouse heart (Soonpaa et al., 1996; Porrello 
et al., 2011).  HL-1 is a cell line that can continuously divide while 
maintaining a cardiac phenotype and spontaneous contractility in vitro. 
However, the metabolism and phenotype of these cells is significantly 
different from primary adult CMs, including key aspects of mitochondrial 
bioenergetics (Kuznetsov et al., 2014). H9c2 are rat myoblasts, with a 
phenotype very distinct from adult differentiated CMs (Hescheler et al., 
1991).   
Murine and human cell physiology greatly differs at the cellular and 
molecular level. For example, repolarization of the cardiac action potential is 
governed by different ionic channels in mice and human. Also, although 
highly conserved at the exons, human and mice only share 50% of similarity 
at the intron level (Yue et al., 2014), which translates into major differences 
in miRNAs, already shown to have an important role at cardiovascular 
homeostasis and pathological processes (Roux, Gonzàlez-Porta and 




advances in hPSCs, including hiPSCs and hESCs has accelerated human 
cell biology research in vitro. Similarly with hPSC-derived CSCs, many 
strategies have been explored in the differentiation of CMs from hPSCs, 
including cultivation as embryoid bodies (EBs, 3D PSCs aggregates formed 
in suspension) (Kehat et al., 2001) and small-molecule based differentiation 
strategies that focus on the modulation of key signaling pathways (e.g., 
BMP, TGF/Activin/Nodal and Wnt) (Talkhabi, Aghdami and Baharvand, 
2016). However, most protocols for cardiac differentiation yield fetal-like 
CMs, presenting immature electrophysiological properties, a highly 
glycolytic metabolism, disorganized sarcomeres and expression of typical 
cardiac fetal genes (Tan and Ye, 2018). Similar to what is described for fetal 
and neonatal murine cells, immature hPSC-CMs are more resistant to 
hypoxia and I/R injury. In fact, by adding a fatty acid-based metabolic 
maturation phase, Hidalgo et al were able to significantly decrease the 
resistance of hESC-CMs and hiPSC-CMs to an I/R injury (in vitro setup) 
(from 5% cell death at day 16 of differentiation to 30% of cell death after an 
extra 8-day maturation phase) (Hidalgo et al., 2018) (table 1.2).Besides 
modulation of metabolism (Correia et al., 2017; Hidalgo et al., 2018), other 
strategies have been applied to improve the maturation state of hPSC-CMs, 
including long term culture (Lundy et al., 2013; Wei et al., 2017), electrical 
and mechanical stimulation (Xia et al., 1997; Ronaldson-Bouchard et al., 
2018), co-culture with other cell types (Kim et al., 2010), culture as 3D 
aggregates (Correia et al., 2018) and hormone supplementation (Yang et 
al., 2014; Ribeiro et al., 2015). Although many advances have been made in 
generating more physiological relevant hPSC-CMs, there are still few 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6.1.2. Mimicking AMI physiology 
Both with murine and human cell populations, different strategies have been 
applied throughout the years to mimic and study AMI physiology in the lab.  
One of the most conventional and employed strategies to reproduce 
ischemia in vitro is by placing the cells at low oxygen (usually ranging from 
1-4% of oxygen), in oxygen depleted hypoxic chambers (P. C. Li et al., 
2014; Wei et al., 2017), analyzing them directly (without reperfusion phase) 
or after re-establishing oxygen levels at atmospheric oxygen (21%) (Pálóczi 
et al., 2016; Chen et al., 2018). In order to mimic the lack of nutrients in the 
ischemia phase, cells can also be incubated in medium with glycolysis 
inhibitors (Canfield et al., 2016), or in serum-free and nutrient depleted 
media (Li, Wang and Tang, 2017; Wang et al., 2017). Other parameters, 
such as osmolarity, pH and lactate concentration have also shown to be 
important to efficiently mimic I/R. For instance, Lu et al identified lactate 
concentration as a critical contributor to cardiac ischemia injury, when using 
rat primary CMs (Lu et al., 2005).   
6.1.3. 3D culture strategies 
Most strategies for in vitro I/R modeling are typically performed using 2D 
planar systems, usually known as monolayers. 2D cell cultures are well 
accepted and have significantly contributed to the advance of our 
understanding on different cardiac cell populations response to I/R injury, 
and on elucidating many associated pathways. However, these strategies 
fail to recapitulate the in vivo cellular organization and microenvironment, 
where cells are embedded in a 3D tissue structure, presenting extensive 
networks of cell-cell and cell-extracellular matrix (ECM) interactions 
(reviewed in Serra et al., 2012).  Although being more difficult to analyze, 
3D in vitro cardiac models allow for enhanced cell-cell and cell-ECM 





shown to better recapitulate physiologic electrical and contractile function 
when comparing to 2D cultures (Zhang et al., 2013; Daily et al., 2015; 
Correia et al., 2018). Currently used in vitro 3D models for cardiovascular 
research include scaffold-free aggregates and culture with biomaterial-
based approaches such as scaffolds, hydrogels and ECM-derived matrices 
(reviewed in Ryan et al. 2016). Culturing cells as aggregates is one of the 
most commonly employed method, since they are relatively easy to 
maintain and handle, allowing cells to self-assemble, the secretion and 
accumulation of endogenous ECM and the generation of molecular 
gradients along the construct. Recently, Correia et al demonstrated that 
culturing iPSC-CMs in 3D aggregates resulted in improved cell metabolic 
maturation and cardiac functionality, when compared to the same 
differentiation and maturation methodology used in 2D monolayers (Correia 
et al., 2018).  
There are few studies that utilize 3D cardiac models to study I/R injury in 
vitro. In 2010, Katare et al embedded neonatal rat CMs in a ring-shapped 
collagen-I scaffold with induced mechanical stretching, and studied the 
construct response to ischemia (Katare et al., 2010). More recently, a 3D 
culture system formed by multiple stacked layers of paper containing 
hydrogel-suspended primary rat neonatal CMs and CFs was developed by 
Mosadegh et al to study CMs and CFs paracrine interaction upon ischemic 
stress (Mosadegh et al., 2014). 
6.1.4. Bioreactors 
Several methodologies have been used to culture 3D models, including the 
hanging-drop method, micro-fluidic supports, non-adhesive substrates and 
stirred culture systems (Fennema et al., 2013). Stirred culture systems such 
as spinner flasks and stirred-tank bioreactors allow cell cultivation in a 




properties over static culture systems. Stirred tank bioreactors can be 
operated in different culture feeding modes (batch, fed-batch, perfusion) and 
also allow for non destructive sampling and precise control and monitoring 
of the culture environment parameters such as oxygen level and pH 
(reviewed in Serra et al., 2012), especially relevant in the context of I/R. 
Bioreactor technology as already been used to modulate ischemia in brain 
(Santos et al., 2005; Amaral et al., 2010), and liver models (Allen and 
Bhatia, 2003), but still no study has been performed to modulate cardiac I/R 
injury. 
There are still some disadvantages associated with cell culture in stirred 
culture bioreactors, namely the “hydrodynamic stress” undertaken by cells 
caused by the agitation to the medium causes the formation of small areas 
of intense turbulence, causing localized shear stress on cells. Animal cells 
lack a cell wall, being therefore sensitive to these forces. Such 
hydrodynamic effects can range from sublytic cell responses, such as 
slower growth, slower protein synthesis, or denaturation of membrane 
proteins, to cell apoptosis and disruption. In the case of stem cells, changes 
in differentiation potential may also occur (Zhiwei, Boyan and Yang, 2012).  
 
7. Proteomics as powerful tool for characterization of cardiac 
populations 
Proteins integrate and control essentially all cellular processes by exerting 
enzymatic catalysis, molecular signaling and structural functions. 
Protein-based knowledge is essential for the understanding of cellular 
pathways that occur under physiological and pathological conditions. In this 
context, the study of protein expression, localization, post-translational 
modifications, and interactions, collectively referred as proteomics, has 





several cardiovascular contexts, including in vivo tissue and in vitro cardiac 
cell models.  
Proteomic studies can be divided into targeted and non-targeted global 
approaches. While target methods involve the examination of hypothesized 
or known targets, global non-targeted methods are discovery-based and 
hypothesis-free, providing an unbiased insight into physiology or pathology, 
often leading to the discovery of novel molecular mechanisms and 
biomarkers. One of the most challenging aspects of non-targeted 
proteomics is the reliable and consistent identification of low abundant 
proteins. Advances in separation techniques (including liquid 
chromatography, LC), mass spectrometry (MS), bioinformatics tools and the 
existence of more robust and complete sequence and annotation 
databases, allow the identification of thousands of proteins per MS run, with 
increased sensitivity and consequently high proteome coverage. For 
example, large proteomic datasets of mouse (8,064 identified proteins, Lau 
et al., 2016)  and human (10,700 identified proteins, Doll et al., 2017) heart 
tissue have been recently reported.  
A typical workflow for non-targeted, label-free proteomics is shown in figure 
1.5. Briefly, after extraction from biological samples, proteins are 
enzymatically digested (usually with trypsin), and the peptide mixture is 
desalted and loaded into a LC column for further separation. Usually, LC 
columns are connected on-line with MS equipments, were peptides are 
ionized, guided by electric fields, isolated and further fragmented (in 
MS/MS) and separated according to their mass over charge (m/z) ratio. MS1 
(intact ion peptides) or MS/MS (peptide ion fragments) m/z spectra are 
generated and compared with aminoacid sequences and theoretical spectra 





Figure 1.5. Typical workflow of non-targeted proteomic approaches. Biological samples 
derived from tissues or cell cultures are processed to extract the proteins which are then 
digested to peptides. The generated peptide mixture is desalted and separated using a high 
performance liquid chromatography (HPLC) column, which is usually directly coupled to a 
mass spectrometer (MS) instrument. In MS, peptides are ionized and mass to charge ratio 
(m/z) spectra are generated. Finally, the peptide sequencing data obtained from the m/z 
spectra are searched against sequence and theoretical spectra databases for protein 
identification.  
 
Although the intensity of a peptide ion in a spectrum does not directly 
correspond to the quantity of the parent protein in the sample (due to 
peptide-inherent variability in accessibility to the protease, solubility and 
ionization efficiency), relative quantifications can be inferred by the peak 
height of the same peptides in different samples (Lam et al., 2016). Also, 
labels (such as stable isotopes) can be added to one of the experimental 
conditions in order to get a more accurate relative quantification (for 
example SILAC, stable isotope labeling in cell culture; ICAT, isotope-coded 
affinity tag techniques; ICPL, non-selective isotope-coded protein labeling; 
iTRAQ, isobaric tags for relative and absolute quantitation and TMT, tandem 
mass tag, reviewed in DeSouza and Siu, 2013; Hsu and Chen, 2016). 





throughput analyses more feasible. One example of a recent label-free and 
high-throughput approach is SWATH-MS (sequential window acquisition of 
all theoretical mass spectra). This method combines data independent 
acquisition (DIA), sequential m/z windows and spectral libraries. Peptide 
ions are fragmented and identified (MS/MS) independently (DIA) of 
precursor peptide ions (prior to fragmentation, MS1 scan) information, 
therefore generating spectra for all generated peptides in defined sequential 
m/z windows. A pre-selected and pre-analyzed peptide library is used to 
compare with the spectral datasets and for quantification.         
Several authors have taken advantage of non-targeted, label-free MS-based 
proteomics approaches to characterize different cardiac populations in 
different settings, including in vitro studies on murine CSCs (Stastna et al., 
2010), hCSC receptome(Gomes-Alves et al., 2016) and secretome (Sharma 
et al., 2017; Torán et al., 2017), in vitro characterization of rat H9C2 
response to I/R injury (X. Li et al., 2014a) and quantitative studies of mouse 
models in response to AMI (Datta et al., 2017) and human heart tissue 
without injury (Doll et al., 2017). 
 
8. Aims and scope of the thesis 
The main goal of this PhD thesis was to develop novel relevant myocardial 
I/R injury in vitro models and to use advanced proteomic tools to advance 
the knowledge on human cardiac cell populations, including endogenous 
hCFs, endogenous hCSCs and hiPSC-CMs. LC-MS proteomic 
methodologies were used to provide a comprehensive description of hCF 
membrane molecular landscape and also to unveil hCSC and hiPSC-CM 
mechanisms of action in a AMI context. The major goals of this thesis and 































































































































































































































The development of an in vitro cell model of myocardial I/R injury using a 
heterotypic co-culture approach of hiPSC-CMs and hCSCs to study hCSC 
response in an AMI context was the aim in Chapter II. A MS-based protocol 
was explored for the characterization of hCSC whole proteome upon injury, 
to provide valuable insights on how an insult situation readjusts cellular 
pathways, directing hCSCs to modulate proteins involved in several 
pathways such as cell cycle regulation, proliferation through EGF signaling 
and reactive oxygen species detoxification.  
Another I/R injury in vitro model is described in Chapter III, we take 
advantage of stirred-tank bioreactor technology to fully monitor and control 
environmental parameters such as pH and dissolved oxygen during an I/R 
setup. In this model, the physiological relevance is addressed by hiPSC-CM 
3D culture strategy. The conditioned medium from these experiments was 
then used in the culture of hCSCs, and their response to hiPSC-CM 
spheroid secreted paracrine factors was analyzed in terms of whole-
proteome quantitative profiling using quantitative SWATH technology 
(Chapter IV). In Chapter V, a different aspect of hCSC biology is studied, 
namely the immunomodulatory capacity of these cells, important in the 
context of hCSC-transplantation strategies upon AMI. Chapter VI focused 
on hCFs. In this chapter, a characterization of hCFs membrane proteins 
was performed, with the aim of creating a dataset that could be the basis for 
the identification of novel hCF specific markers. Finally, in Chapter VII, the 
results obtained along Chapters II-VI were discussed and contextualized 
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Abstract 
Human cardiac stem/progenitor cells (hCSCs) have a recognized role in 
myocardial repair upon ischemia/ reperfusion (I/R) injury, mainly through 
auto/paracrine signaling. However, the mechanisms underlying this 
response are still poorly understood. To further investigate hCSC 
regenerative process, we established the first in vitro human heterotypic 
model of myocardial I/R injury using hCSCs and human induced 
pluripotent cell-derived cardiomyocytes (hiPSC-CMs). This model 
recapitulates hallmarks of I/R, namely hiPSC-CM death upon insult, 
protective effect of hCSCs on hiPSC-CM viability (37.6% higher vs 
hiPSC-CM mono-culture), and hCSC proliferation (approximately 3-fold 
increase vs hCSCs mono-culture), emphasizing the importance of 
paracrine communication between these two populations. In particular, in 
co-culture supernatant upon injury, we report higher angiogenic 
functionality as well as a significant increase in CXCL6 secretion rate, 
suggesting an important role of this chemokine in myocardial 
regeneration. hCSCs response to I/R was further characterized using 
mass-spectrometry tools allowing us to propose new pathways in the 
hCSCs-mediated regenerative process, including cell cycle regulation, 
proliferation through EGF signaling, and reactive oxygen species 
detoxification. 
This work contributes with new insights into hCSC biology in response to 
I/R, and the model established constitutes an important tool to study the 
molecular mechanisms involved in the myocardial regenerative process. 
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Acute Myocardial Infarction (AMI), is still a major cause of death in the 
world (Benjamin et al., 2017). AMI consists on the cessation of blood 
flow, causing oxygen and nutrient supply imbalance, leading to 
myocardial tissue damage, with loss of cardiomyocytes (CMs). For AMI 
patients, the intervention of choice is immediate myocardial reperfusion 
with restauration of blood flow. However, this process can aggravate the 
damage, as the increase of molecular oxygen levels occurs at a toxic 
rate (Ischemia Reperfusion I/R Injury), contributing to up to 50% of the 
final scar tissue size (Hausenloy and Yellon, 2013). Current treatments 
are successful in reducing immediate mortality but do not avoid the 
subsequent scarring and degeneration of myocardium tissue with loss of 
contractile function, often leading to Chronic Heart Failure (CHF), a 
highly fatal condition in which the only available clinic option is heart 
transplant (Lund et al., 2014). 
Regenerative medicine based strategies for infarcted myocardium 
include autologous and allogeneic cell therapies. Several cell types were 
already applied in clinical trials, including bone-marrow derived 
mesenchymal stromal cells (BM-MSCs) (e.g. REPAIR-ACS- 
NCT00711542, BOOST-NCT00224536), adipose tissue derived 
mesenchymal stromal cells (AT-MSCs) (e.g. ADVANCE- NCT01216995, 
and APOLLO- NCT00442806), and cardiac stem/progenitor cells (CSCs) 
(e.g. SCIPIO- NCT00474461, CADUCEUS - NCT00893360, and 
CAREMI- NCT02439398). For all cell types, clinical trials have 
demonstrated some physiological improvements but very low cell 
retention after some weeks, suggesting that the overall beneficial effect 
of transplanted cells is due to paracrine modulation rather than 
differentiation and functional integration in the tissue (Madonna et al., 
2016). In fact, novel strategies focused on the induction of the 




endogenous heart regenerative potential, such as direct growth factor 
administration, have shown to induce tissue regeneration by reduction of 
fibrosis, induction of angiogenesis, inhibition of apoptotic processes and 
recruitment of endogenous  CSCs (Ellison et al., 2011; Koudstaal et al., 
2014). Although in low percentages, with about one stem cell per 8000-
20000 CMs (Anversa et al., 2006), endogenous CSCs seem to play an 
important regenerative role in cardiac homeostasis and in response to  
physiological stress and I/R injury. While the physiological alterations 
undergone by CMs during I/R have been extensively covered, the 
mechanisms by which CSCs exert their protective role are still not well 
defined. Upon injury, there are increased levels of signaling growth 
factors and cytokines released in the myocardium (Torella et al., 2007; Li 
et al., 2014). Such signals have already been proposed to trigger CSCs 
proliferation, differentiation, migration to the site of injury and growth 
factor secretion that together have an effect on cardiomyocyte protection, 
reduction of inflammation and reduction of scar tissue size. Although 
some doubts and controversy still exist regarding the ability of CSCs to 
generate new CMs upon injury (Nadal-Ginard, Ellison and Torella, 2014; 
van Berlo et al., 2014), the regenerative paracrine potential of CSCs has 
already been well documented in several animal studies (Urbanek et al., 
2005; Crisostomo et al., 2015).  
However, mainly due to the lack of relevant human models, the role of 
CSCs in I/R injury has been studied in vitro with murine cells. There are 
relevant gaps between murine and human cardiac physiology both in 
vitro and in vivo, such as different functionality of CMs ion channels, and 
a higher tolerability to drugs in mice and mice cells. Such differences can 
cause misinterpretation of the results and have already been pointed as 





Aiming at filling the gap between murine and human in vitro models, in 
this work we have established the first in vitro human cell based 
myocardial  I/R injury model, using human CSCs (hCSCs) and human 
induced pluripotent stem cell-derived CMs (hiPSC-CMs). The goal of our 
work is to use this co-culture model as a tool to characterize hCSC 
response to I/R injury, and its effect on CM death and survival upon 
injury. Our model was able to recapitulate important features of AMI, 
namely CM death, a paracrine protective effect of CSCs in CMs survival 
and CSC proliferation activation. For the first time, CXCL6, a cytokine 
with documented angiogenic properties, already identified as having an 
important regenerative role in both mesenteric and myocardial infarction 
was found to be highly secreted by hCSCs upon I/R injury in the co-
culture condition. Moreover, we also demonstrated higher angiogenic 
potential of the co-culture supernatant upon ischemia. Human CSC 
whole proteome analysis showed that upon injury, and in the presence of 
hiPSC-CMs, there was an enrichment in proteins involved in pathways 
and functions related with cell proliferation, paracrine signaling, stress 
response and regeneration processes when comparing to control and 
mono-culture conditions.  
 
2. Materials and Methods 
2.1. Cell culture 
CSCs were obtained from human right atria appendage myocardial 
tissue, isolated and characterized as described elsewhere (Lauden et al., 
2013). Cells were cultured at 37°C in humidified incubators (5% CO2, 3% 
O2) in CM001-R medium composed by DMEM:F12: Neurobasal medium 
(1:1), supplemented with 1% penicillin streptomycin, 10% fetal bovine 
serum embryonic stem cell-qualified, N2 supplement (1X), B27 




supplement (1X), 0.9 mM l-glutamine, 50 μM β-mercaptoethanol (Sigma), 
insulin transferrin selenium (0.5X), 10 ng/mL bFGF, 20 ng/mL EGF-I and 
30 ng/mL IGF-II (Prepotech), (all percentages in v/v). Medium was 
replaced by 50% every 3 days. Cells were subcultured when about 80% 
confluent using Tryple™ Select Enzyme for 5 minutes at 37°C. All cell 
culture reagents were purchased from Gibco, Life Technologies unless 
otherwise stated. 
Human iPSC (DF19-9-11T.H, WiCell) were cultured and differentiated to 
CMs (hiPSC-CMs) as previously described (Correia et al., 2016, 2018). 
Using this protocol, monolayer cultures composed of >90% of hiPSC-
CMs were obtained after 15 days. To further improve maturation state of 
this cell population, hiPSC-CMs were cultured for additional 10 days in 
Pluricyte Medium (NCardia), as described elsewhere (Ribeiro et al., 
2015). Cells were maintained at 37°C in humidified incubators (5% CO2, 
95% air). 
2.2. Ischemia/ Reperfusion Injury setup 
I/R experiments were performed with: mono-cultures of hCSCs (plated at 
2x104 hCSCs/cm2); mono-cultures of hiPSC-CMs (plated at 1-1.5x105 
hiPSC-CMs/cm2); and co-cultures of the two cell types (hCSCs:hiPSC-
CMs 1:10 - 1:20) using Transwell® permeable insert supports (0.4 µm 
pore size, Corning). The insert supports are semi permeable polyester 
membranes separating both cell types allowing paracrine interaction. 
hCSCs were seeded in transwell supports (1.2 x104 hCSCs/ insert and 
positioned above hiPSC-CM culture dishes (1.2-2.4x105 hiPSC-CMs/ 
well) at the beginning of the ischemia phase, allowing a paracrine 
interaction between the two cell types during all the sequence of I/R 
injury. All cell populations were cultured in CM001-R at 3% O2 





95% air) at least 15 h before I/R experiments. I/R injury experimental 
setup is illustrated in figure 2.1.  
 
Figure 2.1. Schematic representation of Ischemia/Reperfusion injury experimental 
setup. Ischemia was mimicked by replacing expansion medium by Ischemic Mimetic 
Solution (IMS) and by culturing cells in a N2 gaseous environment. After 5 h of ischemia, 
reperfusion was mimicked by re-establishing normoxic culture conditions (CM001-R at 
3% O2). I/R setup was performed using mono-cultures of hiPSC-CMs, mono-cultures of 
hCSCs and co-cultures of the two cell types using transwell permeable inserts. The 
impact of the I/R was evaluated regarding hCSC proliferation, hiPSC-CM viability, hCSC 
whole proteome and secretion of IGF-1 and CXCL6 factors in different time points: (BI- 
Before injury; Post I – Post Ischemia; Post R – Post Reperfusion). Control cultures were 
done in parallel (using normoxic conditions). 
 
Briefly, ischemia was mimicked by replacing CM001-R medium by 
Ischemic Mimetic Solution (IMS; in mM: NaCl, 135; KCl, 8; MgCl2, 0.5; 
NaH2PO4, 0.33; HEPES, 5.0; CaCl2, 1.8; Na
+-lactate, 20; pH 6.8) (Zhao 
et al., 2013) and by placing cells in a N2 gaseous environment at 37°C. 
After 5 h of ischemia, reperfusion was mimicked by re-establishing 
control culture conditions (CM001-R at 3% O2). Control cultures for all 
culture setups were maintained in parallel (CM001-R at 3% O2). The 
impact of I/R injury was evaluated regarding hCSC proliferation, hiPSC-
CM viability, secretion of growth factors and hCSC whole proteome 
analysis. 




2.3. Total cell number 
hCSC number was accessed by nuclei count with crystal violet solution 
staining. Briefly, cell were resuspended in lysis buffer (0.1% Triton X-100 
in 0.1M citric acid) directly in culture wells /transwells and incubated at 
37°C for at least 48 h. Nuclei were stained with crystal violet dye (0.1% 
v/v in lysis buffer) and the total number of nuclei counted in a Fuchs-
Rosenthal hemocytometer chamber. Fold increase in hCSC number was 
calculated as the ratio between the cell number at the experimental time 
point assayed and cell number before I/R injury.  
2.4. Cell viability 
hiPSC-CM viability was assessed by cell membrane integrity analysis: 
cell monolayers were incubated with 20 µg/mL fluorescein diacetate 
(FDA), that stains viable cells, and 10 µg/mL propidium iodide (PI), a 
membrane impermeable DNA-dye that stains non-viable cells, in DPBS 
for 2-5 minutes. Samples were then observed under a fluorescence 
microscope (DMI 6000, Leica Microsystems GmbH).  
hiPSC-CM viability was further assessed using the metabolic indicator 
PrestoBlue® Cell Viability Reagent (Life Technologies), according to the 
manufacturer’s recommendation. Briefly, cells were incubated with 
CM001-R containing 10% (v/v) PrestoBlue®, for 1 h. Supernatant’s 
fluorescence was measured in 96-well plates using a microwell plate 
fluorescence reader (Infinite 200 PRO NanoQuant TECAN). Values 







2.5. Immunofluorescence microscopy 
Cell monolayers were washed with DPBS and fixed in 4% (w/v) 
paraformaldehyde (PFA) and 4% (w/v) sucrose in DPBS for 20 min. 
Afterwards, cells were permeabilized for 10 min in 0.1% (v/v) Triton X-
100 in DPBS and blocked with 0.2% (v/v) Fish Skin Gelatin (FSG) in 
DPBS for 30 min, at room temperature (RT, 18-20°C). Cells were then 
incubated with primary antibodies diluted in 0.125% (v/v) FSG, 0.1% (v/v) 
Triton X-100 for 2 h at RT. Cells were washed with DPBS and incubated 
with secondary antibodies diluted in 0.125% (v/v) FSG, 0.1% (v/v) Triton 
X-100 for 1 h at RT in the dark. The following primary antibodies were 
used: α-sarcomeric actinin (1:200, Sigma), CD26 (1:80, Thermo Fisher) 
and Ki-67 (1:200, Abcam). 
2.6. Flow cytometry 
After a 5 min dissociation step with TrypLETMSelect at 37°C, cells were 
washed with DPBS by centrifugation and a total of 2-3x105 cells were 
used per analysis. For membrane markers, cells were incubated with the 
primary antibody for 1 h and with the secondary antibody for 30 min at 
4°C in DPBS with 5% (v/v) FBS. For intracellular markers, cells were 
permeabilized using the Inside Stain Kit (Miltenyi Biotec) according with 
manufacturer‘s instructions. The following primary antibodies were used: 
SirPα/β (1:20, CD172a/b-PE, BioLegend), Troponin T (1:200, TnT, 
ThermoScientific), CD105 (1:20,BD Pharmingen), CD166 (1:20,BD 
Pharmingen), CD44 (1:5, eBiosciences), CD11b (1:10, AbDSerotec), 
CD34 (1:5, BD Pharmingen), CD45 (1:5, BD Pharmingen) and isotype 
controls mouse igG1k (1:5, BD Pharmingen), mouse IgG1 (1:2.5,Santa 
Cruz Biotechnologies) and rat IgG2b (1:5, eBiosciences) . Cells were 
analyzed in a CyFlow® space (Partec GmbH) instrument, registering at 
least 10,000 events/sample. 




2.7. Quantification of growth factors 
Quantification of growth factors CXCL6 and IGF-1 in cell’s conditioned 
medium was performed by ELISA Human Quantikine ELISA kit (R&D 
Systems), according to manufacturer’s instructions. Optical density was 
measured in 96-well plates using a microwell plate reader (Infinite 200 
PRO NanoQuant TECAN). The specific rate of growth factor secretion 
was estimated according to the following equation:     
 
Where CGF (g/L) is the variation in growth factor concentration during 
the time period t (h) and Ccell the concentration of cells (cell/L). 
2.8. HUVECS culture and tube-formation assay 
Human Umbilical Vein Endothelial Cells (HUVECs, Lonza ref 2517A) 
were cultured at 37°C in humidified incubators (5% CO2, 3% O2), in 0.1% 
gelatin-coated plates with Endothelial Cell Growth medium 2 (ECGM2, 
PromoCell). Medium was replaced every 3 days. Cells were subcultured 
when about 90% confluent using 0.5% Trypsin-EDTA for 7 minutes at 
37°C.  
Tube formation assay was performed according to Pedroso et al., 2011. 
Briefly, ice-cold undiluted Matrigel (Growth factor Reduced,  BD 
Biosciences) (1.97 mg/cm2)  was used to coat 96-well plates and 
incubated for 40 min at 37°C to allow the Matrigel to solidify. HUVECs 
were seeded at a density of 5.5x104 cells/cm2 and incubated with the 
conditioned mediums from I/R experiments. ECGM2 was used as 
positive control for tube formation. At least four independent images were 





aspects of the tube network were quantified using the ImageJ 
angiogenesis analyzer plugin, including  total branching length (sum of 
length of the trees composed from segments and branches), total 
segment length (sum of length of the segments) and number of nodes 
(Carpentier, 2012). 
All cell culture reagents were purchased from Gibco, Life Technologies 
unless otherwise stated. 
2.9. Whole proteome analysis 
hCSC cells were harvested, and washed twice with DPBS by 
centrifugation. Supernatants were discarded and cell pellets were placed 
at −80°C until further analysis. Proteins were extracted, quantified and 
processed from cell pellets as described elsewhere (Abecasis et al., 
2017). Two biological replicates with 3 technical replicates per time point 
were run. Protein samples were analyzed by NanoLC–MS/MS using 
TripleTOF 6600 (ABSciex). External calibration was performed using 
beta-galactosidase digest (ABSciex). The 40 most intense precursor ions 
from the MS spectra were selected for MS/MS analysis. Data were 
acquired with the Analyst software TF 1.7 (ABSciex). The raw MS and 
MS/MS data were analyzed using Protein Pilot Software v.5.0 (ABSciex) 
for protein identification. The search was performed against Swissprot 
protein database with taxonomic restriction to Homo sapiens. Protein 
identification was considered when unused scores were greater than 1.3 
(95% confidence). Analysis of the protein lists was performed using 
Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/venny/), and Ingenuity 
Pathway Analysis (IPA, Quiagen). Statistically significant representation 
of biological functions and canonical pathways was identified based on 
IPA p-value. This probability score is calculated taking into account the 
total number of proteins known to be associated with a given function or 




pathway, and their representation in the experimental dataset. IPA’s 
calculated p-value is displayed as –log (p-value). All proteomic data have 
been deposited in the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner 
repository with the dataset identifier PXD008156. 
2.10. Statistical analysis 
Statistical analyses were performed with GraphPad Prism6 (GraphPad 
Software Inc.). All data are shown as mean with standard deviation. 
Differences in hCSC fold increases (n=3/5), differences in hiPSC-CM 
viability percentages (n=2/3), differences in specific growth rate secretion 
of CXCL6 and IGF-1 (n=3) and differences in tube formation (n=3/4) 
were analyzed by parametric One Way ANOVA Tukey test. Individual p-
values for each comparison were obtained using the multiplicity adjusted 
p-value test. Differences for ki67 expression percentage were analyzed 
by parametric Student’s T test with Welch’s correction. P-values below 
0.05 were considered significant.  
 
3. Results  
In this study, we developed an in vitro I/R injury co-culture model with 
hCSCs and hiPSC-CMs, using transwell inserts to allow paracrine 
communication between the two cell types. 
Identity of hCSCs was demonstrated by the expression of hCSCs cell-
surface specific markers by flow cytometry. As demonstrated before 
(Gomes-Alves et al., 2016), this cell population is negative for CD34, 
CD45, CD11b, and for CM marker cTnT, and displays a high percentage  





(95.5% ± 1.7) and CD166 (75.1% ± 13.3) (Supporting information  figure 
S2.1A). The expression of CD26 (DPP4), recently found to be selectively 
upregulated in hCSCs when compared to human mesenchymal stem 
cells and human dermal fibroblasts (Torán et al., 2018) was also 
detected by immunostaining (Supporting information figure. S2.1B). 
During the establishment of the I/R injury setup, two different types of 
hiPSC-CMs were tested: i) hiPSC-CMs differentiated as previously 
described (Correia et al., 2016, 2018), and ii) the same cells with an extra 
maturation step (Ribeiro et al., 2015) (please see material and methods 
section for details). With the first hiPSC-CMs tested (without the extra 
maturation step) cell viability was not affected by the injury setup neither 
in mono-culture or in co-culture with hCSCs conditions (Supporting 
Information figure S2.2). These results suggest that these cells were not 
metabolically mature enough, not reflecting the phenotype of adult CMs 
found in the heart. Such results are in accordance with findings that point 
to a relevant role of CMs maturation stage on cell survival upon I/R injury. 
In fact, primary embryonic human CMs are resistant to hypoxia, while 
primary adult human CMs are highly dependent on an adequate oxygen 
supply, which might be related with the different metabolic phenotypes 
between the different developmental stages (Robertson, Tran and 
George, 2013; Hidalgo et al., 2018).  hiPSC-CMs with an extra 
maturation step were therefore used in following studies, since they 
better reflected the typical loss of cell viability during AMI. 
hiPSC-CMs typical cardiac markers were not altered in our assay 
conditions (CM001-R at 3% O2, representing myocardial physiological 
normoxia (Khan et al., 2010)) when compared to the cell’s maturation 
culture conditions (Pluricyte® CM medium, 21% O2), presenting a high 
percentage of cells positive for the cardiac specific proteins SIRPA 
(72.9% ± 5.2) and cTnT (92.6% ± 2.9) (Supporting information Fig. S3A) 




and the characteristic striated pattern of α-sarcomeric actinin (Supporting 
information Fig. S3B). 
The heterotypic model was subjected to I/R injury (figure 1) and analyzed 
in terms of hCSC proliferation, hiPSC-CM viability, secretion of key 
growth factors, angiogenic potential and hCSC whole proteome. Co-
cultures were compared with mono-cultures of the two cell types and 
controls without injury. 
3.1. hCSCs proliferation is activated upon I/R in presence of 
hiPSC-CMs 
hCSC proliferation was evaluated in control (CTL) and injury conditions in 
mono- and co-culture with hiPSC-CMs. hCSCs in co-culture with hiPSC-
CMs showed a significant higher fold increase at 16 h post reperfusion 
when compared to the respective co-culture control (2.7± 0.6 vs 1.8 ± 
0.1, respectively, p=0.0396) and when compared with hCSCs in mono-
culture in injury condition (2.7± 0.6 vs 1.4 ± 0.3, respectively, p=0.0009) 
(figure. 2.2A, B). 
To further confirm the differences observed in proliferation profile 
between hCSCs subjected to injury in both mono- and co-culture 
conditions, hCSCs were labeled with Ki-67, a marker specific for active 
proliferating cells. Although for all conditions tested the percentage of Ki-
67+ hCSCs was between 60-80%, there was a significant decrease of Ki-
67+ hCSCs at 1  h post reperfusion in mono-culture in comparison with 
co-culture conditions (59.3% ± 3.14 vs 68.8% ± 2.3, respectively, 
p=0.0163) (figure 2.2C,D), which might explain the lower cell proliferation 
observed in this condition. These findings suggest that injury diminishes 
hCSC proliferation capacity, especially in early reperfusion period. Such 






Figure 2.2. Impact of I/R injury conditions on hCSCs proliferation. (A) Fold increase 
in hCSC cell number (B) Fold increase in hCSC cell number at 16 h Post Reperfusion; 
(C) Quantification of Ki67
+
 hCSCs by immunostaing; (D) Representative culture imaging 
of Co CSC i and M CSC i labelled with Ki67 at 1h Post R. Black circles: mono-culture 
CTL (M CSC CTL); Grey Diamonds: co-culture CTL (Co CSC CTL); Red squares: mono-
culture hCSCs insult (M CSC i); Green triangles: co-culture hCSCs insult (Co CSC i). 
Post R: Post Reperfusion. *P<0.05; **P<0.01; ***P<0.005.Fold increase was calculated 
as the ratio between the cell number at the experimental time point assayed and cell 
number before injury. 
 
3.2. hCSCs exert a paracrine protective effect on hiPSC-CMs 
upon I/R injury 
The impact of I/R injury conditions in hiPSC-CM viability was evaluated 
for mono- and co-cultures conditions. A decrease in viability was 
observed for hiPSC-CM upon injury when compared to CTL, triggered 
after the first hour of reperfusion (figure 2.3A). hCSCs exerted a 
paracrine protective effect on hiPSC-CMs in the co-culture condition, with 
a higher viability ratio across all reperfusion time points assayed when 
compared with the mono-culture condition, as confirmed by PrestoBlue® 
Cell Viability Reagent results (figure 2.3A,B) and by cell staining with 




live/dead cell dyes (figure 2.3C). At 16 h post reperfusion, hiPSC-CM 
subjected to injury in co-culture conditions presented significantly higher 
viability when compared to hiPSC-CM in mono-culture (68.4% ± 3.0 vs 
30.8% ± 17.9,respectively, p=0.008) (figure 2.3B). When comparing to 
respective controls, at 16 h post reperfusion, hiPSC-CMs in mono-culture 
showed a significant decrease of 62.8% in viability, while in co-culture, 
hiPSC-CMs viability dropped only by 21.9%. 
 
Figure 2.3. Effect of I/R injury on hiPSC-CM viability. hiPS-CM viability  was assessed 
by PrestoBlue® assay (A,B)  and by cell staining with FDA (live cells, green) and PI (dead 
cells, red), scale bars 200 µm (C). Black circles: mono-culture hiPSC-CMs CTL (M CM 
CTL); Grey diamonds: co-culture hiPSC-CMs CTL (Co CM CTL); Red squares: mono-
culture hiPSC-CMs insult (M CM i); Green triangles: co-culture hiPSC-CMs insult (Co CM 
i). Post R: Post Reperfusion. *P<0.05; **P<0.01; ***P<0.005. 
 
3.3. Secretion of key growth factors is up-regulated in I/R 
To further access the paracrine effect observed in the co-culture 
condition, the secretion of two key proteins with documented cardiac 





ligand 6 (CXCL6 or GPC-2) and Insulin-like growth factor 1 (IGF-1) 
(Kawaguchi et al., 2010; Miyamoto et al., 2010; Kim et al., 2012; 
Koudstaal et al., 2014). 
 
Figure 2.4. Specific rates of CXCL6 and IGF-1 secretion during ischemia and 
reperfusion. (A) qIGF-1 measured in conditioned media of mono-culture hCSCs CTL (M 
CSC CTL); mono-culture hCSCs insult (M CSC i) and co-culture hCSCs:hiPSC-CMs 
insult (Co i). (B) qCXCL6 measured in conditioned media of mono-culture hCSCs CTL (M 
CSC CTL); mono-culture hCSCs insult (M CSC i) and co-culture hCSCs:hiPSC-CMs 
insult (Co i). Specific growth factors secretion rates were normalized to the values before 








P<0.0001 vs before insult. 
 
Regarding IGF-1, our data shows that both hCSCs and hiPSC-CMs 
secrete IGF-1 either in mono- and co-culture conditions (data not shown 
for hiPSC-CMs mono-cultures). IGF-1 is secreted and recognized by 
both cell types (Kawaguchi et al., 2010; Ellison et al., 2011; Valiente-
Alandi et al., 2016), therefore it was not possible to isolate and quantify 
how much IGF-1 each cell population secreted in the co-culture 
condition, neither if there was an uptake of IGF-1 by hiPSC-CM or hCSC. 
We could not detect significant changes in IGF-1 secretion upon injury 
neither in hCSCs mono-cultures nor in co-cultures with hiPSC-CMs 
(figure 2.4A). 
CXCL6 seems to be selectively secreted by hCSC, as it was not 
identified in either control or injury conditioned medium of mono-cultures 
of hiPSC-CMs (data not shown). However, in the co-culture condition, 




there is a significant increase in CXCL6 cell specific secretion rate in both 
phases of injury, more pronounced during ischemia (figure 2.4B). In 
hCSCs mono-culture conditions, we observed some alterations in the 
CXCL6 cell specific secretion rates during injury, but such rates do not 
differ between control and injury (figure 2.4B). 
 
Figure 2.5. Angiogenenic functional evaluation of I/R conditioned medium. Ischemic 
Mimetic Solution (IMS), Endothelial Cell Growth medium 2 (ECGM2), conditioned media 
of hCSC mono-culture post ischemia (M CSC i Post I) and of co-culture control post 
ischemia (Coi Post i) conditions were tested for angiogenic potential by HUVECS tube 







P<0.0001 vs IMS. (B) Representative original 
images (left) and quantification by Angiogenesis analyser are shown. In the right image, 
there is an indication of master junctions (pink dots), master segments (yellow), meshes 
(light blue), branches (green) and isolated segments (blue). Scale bars 200 μm. 
 
CXCL6 is described as being an angiogenic chemokine secreted by 
CSCs (Torán et al., 2017). In order to access if the I/R conditioned 
medium has a pro-angiogenic paracrine profile, the in vitro tube formation 
assay was performed. HUVECs were incubated with conditioned media 
from co-cultures and mono-cultures of hCSCs upon ischemic injury. As 





the co-culture condition post ischemia is higher when comparing to the 
mono-culture medium, represented by a significant increase in total 
segment length and total branching length as well as by a higher number 
of nodes (figure 2.5A). 
3.4. Proteomic analysis of hCSCs reveals enrichment in key 
hallmark pathways and functions upon injury 
To further understand the regenerative response of hCSCs to the I/R 
injury, whole proteome analysis of hCSCs was performed in all culture 
conditions. More than 3800 proteins were identified in all samples (figure 
2.6). Biological canonical pathway and functions (terms) enrichment 
analysis was performed using IPA software (full list of scores of canonical 
pathways and functions analysis in Supporting file 2.1). Our analysis was 
focused on terms with relevant described roles in AMI, associated with 
the following categories: cell proliferation, cytoskeleton organization, 
maintenance of cell viability, cell death, oxidative stress, paracrine 
signaling, regeneration, stress response, and metabolism. 
Proteins exclusively identified in hCSCs subjected to I/R injury in mono- 
(M CSC i) and co-culture (Co CSC i), (n=690) were analyzed. Within this 
subset, from the 10 top terms with highest number of proteins, 8 were 
associated with cell death and viability (figure 2.6), suggesting that the 
I/R injury setup elicited an hCSCs a physiological response involving 
activation of mechanisms of cell survival.  
Approximately 9% of the identified proteins (n=354) were exclusively 
identified in hCSCs subjected to injury in co-culture conditions (Co CSC 
i). Within this subset, there was a high enrichment in proteins associated 
with cell proliferation (n=83), cell viability (n=32), organization of 
cytoplasm (n=27), organization of cytoskeleton (n=22), and metabolism 
of protein (n=20), all included in the 10 top terms (Fig. 6). By exploring in 




more detail this subgroup of proteins (Supporting information Fig. S4), we 
can highlight the identification of: APOD and APOH, proteins involved in 
CM viability and opsonization (Tsukamoto et al., 2013), proteins 
associated with CXCR4 signaling (RHOB, PIK3R1, GNAQ, PRKCA, 
RPS6KB2), proteins associated with IGF-1 signalling 
(JAK1,PIK3R1,RPS6KB2, SFN, RASA1, IGFBP2), and SERPINB3, a 
protease inhibitor activated by hypoxia (Cannito et al., 2015) with 
described roles in protection from oxidative damage (Ciscato et al., 
2014), cell proliferation (Quarta et al., 2010), IL-6 signalling, and unfolded 
protein response (Sheshadri et al., 2014). 
 
 
Figure 2.6. hCSC Whole proteome analysis. Venn diagram illustrates the overlap 
between proteins identified in hCSCs in: mono-culture control (M CSC CTL); co-culture 
control (Co CSC CTL); mono-culture insult (M CSC i), and co-culture insult (Co CSC i) 
conditions. Top 10 canonical pathways and functions with -log(p-value)≥ 1.3 and highest 
number of identified proteins  are highlighted for the subsets of proteins exclusively 
identified in hCSCs subjected to I/R injury in both mono- and co-culture conditions (CSC i, 





Moreover, several other pathways and functions relevant in I/R response 
were enriched in Co CSC i proteome when compared to control (Co CSC 
CTL) (Supporting Information table S1) and M CSC i (Supporting 
Information table S2.2), including cell proliferation via EGF-mediated 
pathways, pathways associated with actin filaments, with Reactive 
Oxygen Species (ROS) metabolism, corticotropicoid releasing hormone 
signaling (described has playing a major role in cell adaptation under 
stressful conditions (Hillhouse et al., 2002)), and glycolysis. Paracrine 
signaling terms more enriched in Co CSC i proteome included IGF-1, 
HGF, VEGF, Oncostatin M, Neuregulin, Netrin, PDGF, IL-1, IL-2, IL-3, 
and IL-6 signaling pathways (Supporting information Table S2.1 and 
S2.2), all with documented roles in myocardial I/R (Saini et al., 2005; 
Ellison et al., 2012; Valiente-Alandi et al., 2015; C. Y. Park et al., 2016). 
Following this first comparative analysis, a more exhaustive proteomics 
characterization of hCSCs in the co-culture condition was carried out. 
Terms enrichment was compared between different time points, namely 
in control situations (Co CSC CTL), immediately post ischemia period 
(Co CSC Post i), 1h post reperfusion (Co CSC 1h Post R), and 16h post 











Table 2.1. Canonical pathways and functions differentially enriched in Co CSC CTL and 
Co CSC throughout injury.  
log (p-value)≤1.3 were considered as non significant (n.s.) (less than 95% confidence).  
 Category  
  










Co CSC     
1h Post R 
Co CSC 
16h Post R 
      
      
1. Cell 
Proliferation 
Cell Cycle Progression 11.82 8.58 7.41 9.96 
Cytokinesis n.s. 4.35 n.s. n.s. 
Mitosis 7.39 4.97 n.s. 6.88 
Arrest in Mitosis 4.78 n.s. n.s. 5.38 
Role of CHK Proteins in Cell Cycle Checkpoint 
Control 
2.33 n.s. n.s. 1.74 
Cell Cycle: G1/S Checkpoint Regulation 1.44 n.s. n.s. 1.91 
Cell Cycle Regulation by BTG Family Proteins 1.43 n.s. n.s. 2.16 
ERK5 Signaling n.s. 1.49 2.13 2.67 
EGF Signaling n.s. n.s. 1.48 2.67 
Cholecystokinin/Gastrin-mediated Signaling 1.60 2.01 2.50 3.21 
FLT3 Signaling in Hematopoietic Progenitor Cells n.s. n.s. n.s. 1.46 
      
2. Cytoskeleton 
Organization 
Cell Movement of Embryonic Cell Lines n.s. n.s. 5.83 n.s. 
Cell Movement of Epithelial Cell Lines n.s. n.s. 4.85 n.s. 
Cell Movement of Kidney Cell Lines n.s. n.s. 5.02 n.s. 
Extension of Cells n.s. 3.89 n.s. n.s. 
Invasion of Tumor n.s. 4.59 n.s. n.s. 
Invasion of Tumor Cells n.s. 3.98 n.s. n.s. 
CCR3 Signaling in Eonisophils 2.67 3.53 2.09 2.33 
      
3. Maintenance of 
Cell Integrity / 
Cell Death 
Apoptosis 35.06 26.94 29.56 36.25 
Necrosis 36.61 28.54 33.19 36.68 
Autophagy 5.85 4.04 5.01 5.75 
Cell Survival 18.01 12.04 15.00 18.82 
Cell Viability 17.77 11.82 15.53 18.72 
Death Receptor Signaling 2.79 1.52 3.56 2.48 
Repair of DNA 5.70 n.s. 5.69 7.07 
Nucleotide Excision Repair Pathway 1.43 n.s. n.s. n.s. 
Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation 
1.60 n.s. 1.60 2.20 
Mismatch Repair in Eukaryotes 3.32 n.s. 2.54 3.16 





Table 2.1. (Continued) 
      
4. Oxidative 
Stress 
Hypoxia Signaling in the Cardiovascular System 
2.94 3.14 3.40 3.56 
 
Synthesis of ROS 7.82 7.27 6.09 7.19 
 
Metabolism of ROS 9.06 7.97 7.24 8.34 
Superoxide Radicals Degradation 1.85 2.20 2.78 2.67 
Metabolism of H2O2 n.s. 4.42 n.s. n.s. 
Catabolism of H2O2 n.s. 4.12 n.s. n.s. 
HIF1a Signaling n.s. 1.53 n.s. n.s. 




IGF-1 Signaling 4.00 6.43 5.78 5.73 
GM-CSF Signaling 1.84 2.43 1.53 1.63 
HGF Signaling 3.06 2.72 2.10 3.03 
VEGF Signaling 5.92 7.04 5.92 7.46 
IL-2 Signaling n.s. 1.79 n.s. 1.84 
IL-3 Signaling 2.25 2.61 1.92 3.06 
IL-8 Signaling 5.45 4.76 3.78 3.55 
  IL-15 Signaling n.s. 1.54 1.38 1.77 
IL-22 Signaling n.s. n.s. n.s. 1.37 
Role of JAK family kinases in IL-6-type Cytokine 
Signaling 
n.s. n.s. n.s. 1.75 
JAK/Stat Signaling 1.34 n.s. 1.61 1.99 
PDGF Signaling 2.50 2.58 3.24 4.12 
Neuregulin Signaling 3.99 3.24 2.40 4.50 
  Oncostatin M Signaling 4.25 3.92 3.00 5.39 
  Vasculogenesis n.s. n.s. n.s. 4.94 
  Angiogenesis 7.06 5.55 6.28 7.35 
  Differentiation of Cells n.s. 4.25 4.73 6.45 
      
6. Stress 
Response  
Hypersensitive Reaction 7.83 10.84 7.50 8.03 
Acute Phase Response Signaling 3.47 3.77 4.11 2.73 
Stress Response of Cells n.s. n.s. 4.64 n.s. 
Endoplasmic Reticulum Stress Pathway n.s. 1.72 n.s. 1.68 
Unfolded Protein Response 2.50 3.00 1.70 1.88 
Cardiac ß-adrenergic Signaling 1.66 2.65 n.s. n.s. 
Corticotropin Releasing Hormone Signaling n.s. n.s. n.s. 1.62 
HIPPO signaling 5.54 4.23 5.03 5.08 
 
 




Table 2.1 (Continued) 
      
7. Metabolism Glutathione Redox Reactions I 3.06 3.03 6.52 3.61 
Glutathione-mediated Detoxification 1.99 2.60 3.95 2.42 
 
Cysteine Biosynthesis III (mammalia) 2.20 3.57 2.20 2.74 
Methionine Degradation I (to Homocysteine) 1.86 2.35 1.86 2.41 
Cysteine Biosynthesis/Homocysteine 
Degradation 
n.s. 1.95 n.s. n.s. 
Glutamate Biosynthesis II n.s. n.s. 1.75 1.70 
Glutamate Degradation X n.s. n.s. 1.75 1.70 
Glycolysis I 5.60 7.79 5.60 7.21 
Glycolysis of cells n.s. 4.07 n.s. n.s. 
Consumption of oxygen n.s. 4.30 n.s. n.s. 
 
By analyzing the different time points, terms related with cell proliferation 
via EGF (EGF, Cholecystokinin/Gastrin-mediated and ERK5 Signaling) 
were found as having an increasing representation along injury (table 
2.1, Category 1). FLT3 signaling was also identified as more enriched at 
16h post reperfusion, while cytokinesis (table 2.1, Category 1) and IGF-1 
signaling, also involved in cell proliferation activation (Waring et al., 2014) 
(table 2.1, Category 5), were found as more enriched post ischemia. 
Regarding terms associated with cytoskeleton organization (table 2.1, 
Category 2); cell invasion, extension, and CCR3 signaling (involved in 
eosinophils recruitment to inflammation sites (Bonaros et al., 2008)), 
were enriched after the ischemic period, while terms associated with cell 
movement were enriched at 1h post reperfusion, suggesting an activation 
of hCSC migration and homing to injury in these early injury time points. 
Importantly, although several terms related with cell death and survival 
were found as less enriched in hCSCs upon ischemia, the same returned 
to their control levels during reperfusion period (table 2.1, Category 3). 
It is worth to mention that cell-cycle regulation pathways (table 2.1, 
Category 1) and DNA repair mechanisms, including BER pathway (table 





and recovered to values closer to control at 16h post reperfusion. 
Regarding oxidative stress, terms related with degradation and 
metabolism of H2O2 and HIF-1α signaling were found as more enriched 
in hCSCs post ischemia (table 2.1, Category 4).  
IGF-1 and GM-CSF signaling was also more represented upon ischemia 
(table 2.1, Category 5), while other pathways associated with 
cytokine/growth factors paracrine signaling and cardiac regeneration 
were found as more enriched in hCSCs after 16h of reperfusion, 
including VEGF, Neuregulin, Oncostatin M, Jak/Stat, PDGF, IL-2, IL-3, 
IL-6, IL-15, and IL-22 signaling (table 2.1, Category 5).  
Stress response-associated functions such as hypersensitive reaction, 
endoplasmic reticulum stress (ERS), unfolded protein response (UPR), 
and cardiac β-adrenergic signaling were more enriched upon ischemia 
(table 2.1, Category 6), while acute phase response signaling and stress 
response of cells representation was higher at 1h post reperfusion. 
Importantly, cardiac regeneration associated functions such as cell 
differentiation, vasculogenesis and angiogenesis were also found as 
more enriched after 16 hours of reperfusion (table 2.1, Category 6). 
Cystein Biosynthesis  and gluthatione-mediated detoxification terms, both 
important for protection from oxidative stress (Giordano, 2005),  were 
found as more enriched post ischemia (table 2.1, Category 7). Glycolysis 
and oxygen consumption related pathways was also found to be more 
represented upon ischemia (table 2.1, Category 7), which might point to 
a compensatory mechanism to lack of oxygen availability during this 
phase of injury. 
 
 





In this study, we developed an in vitro human cellular model of 
myocardial I/R injury with hCSCs and hiPSC-CMs that enabled us to 
further decipher the action mechanisms of hCSCs upon injury. The co-
culture model developed recapitulates important hallmarks of I/R injury, 
namely CM death, CSC proliferation activation upon insult and the 
protective role of CSCs on CMs. New players on hCSC regeneration 
response upon I/R including activation of pathways related with cell 
proliferation, cytoskeleton organization, maintenance of cell integrity, 
stress response, paracrine signaling, cardiac regeneration and 
metabolism were identified based on proteome hCSC data (figure 2.7). 
We also showed, for the first time, an increase in CXCL6 secretion rate 
by hCSCs in an I/R setting.  
During the ischemic phase of injury, cells were cultured in conditions 
mimicking the myocardial pathophysiological state of ischemia including 
lack of oxygen availability, nutrient deficiency, acidosis, lactate 
accumulation, and hyperosmosis (Zhao et al., 2013). hCSC proteomic 
analysis results point to a down-regulation of cell-cycle regulation 
pathways, DNA repair mechanisms, and cell repair mechanisms during 
the ischemic phase of injury (figure 2.7A). In fact, down-regulation of cell 
cycle checkpoint control and DNA repair processes has been reported as 
a process involved in activation of several types of quiescent adult stem 
cells (Cheung and Rando, 2013). Proteome analysis also indicates an 
activation of endoplasmic reticulum stress pathways, such as ERS and 
UPR, which have been previously associated with cellular adaptation to 
glucose deprivation and hypoxic stimuli (Groenendyk, Agellon and 
Michalak, 2013). Proteins associated with glycolysis and consumption of 





adaptative response of hCSCs to the lack of O2, via an increase the 
expression of protein machinery associated with energy production. 
The ability of CSCs to differentiate into de novo CMs upon AMI is still 
under active discussion, with different authors defending contrary results 
(Ellison et al., 2013; Nadal-Ginard, Ellison and Torella, 2014; van Berlo et 
al., 2014). In our model, hCSCs did not label for Nkx2.5, an early marker 
of cardiac differentiation (results not shown) neither in CTL nor in injury 
conditions, although an enrichment in proteins related with cell 
differentiation was found in hCSCs upon the ischemic phase of injury. 
Although such controversy still exists regarding cardiac differentiation 
potential of CSCs upon injury, there is a general consensus in the field 
that CSCs exert a protective effect on hCMs under stress mainly due to 
paracrine mechanisms (Kawaguchi et al., 2010; C.-Y. Park et al., 2016), 
supported by extensive pre-clinical and clinical data indicating that 
transplanted CSCs do not survive neither engraft in the myocardium 
while physiological improvement is still registered (Madonna et al., 2016). 
In order to further understand the paracrine cross-talk between hCSCs 
and hiPSC-CMs in our model, we quantified the secretion of two key 
proteins: CXCL6 and IGF-1, both with documented cardiac regenerative 
properties. CXCL6 is an angiogenic chemokine shown to improve heart 
function in mice (Kim et al., 2012; Torán et al., 2017) and identified as 
up-regulated during mesenteric (intestinal) I/R injury (Jawa et al., 2013). 
This chemokine was also recently identified in the secretome of hCSCs, 
where addition of an anti-CXCL6 antibody inhibited the migration and 
angiogenic properties of CSC conditioned medium, proving the 
importance of this chemokine in key paracrine regenerative potential 
features of these cells. We show for the first time an increase in hCSC 
CXCL6 secretion specific rate in a myocardial I/R injury setting, which 
was more pronounced during ischemia, but still significant after 16h of 




reperfusion (figure 2.7A,C). These results support previous findings that 
show that this chemokine is upregulated in ischemic conditions via HIF-
1α signaling (Tian et al., 2014). Cardiac stem cells have been shown to 
home and migrate to the site of injury, a process activated by HIF-1α 
transcription factor and SDF-1 chemokine in response to ischemia 
(Ceradini et al., 2004; Rota et al., 2008). Although CXCL6 was not 
identified by proteome analysis, an enrichment in proteins related to HIF-
1α signaling, and CCR3 signaling, a pathway important for cell homing to 
inflammation and injury sites (Bonaros et al., 2008), was also found in 
hCSCs upon ischemia (figure 2.7A). Moreover, we were able to identify 
proteins associated with CXCR4 signalling, a pathway activated by SDF-
1 with documented roles in cell motility and chemotactic response (Penn 
et al., 2012). Altogether, our data and previous reports regarding CSC 
secretome, namely CXCL6 function, point to an effect of this chemokine 
in hCSC migration and angiogenesis. In fact, we also demonstrate pro-
angiogenic properties of conditioned medium from the ischemic phase of 
injury. 
IGF-1 is one of the key proteins shown to be up-regulated upon injury or 
stress by CSCs (Smith et al., 2010; Valiente-Alandi et al., 2016) and CMs 
(Ellison et al., 2012; Waring et al., 2014) and has also been shown to 
have a role in the activation of hCSC regenerative potential (Kawaguchi 
et al., 2010; C.-Y. Park et al., 2016) and proliferation (Ellison et al., 2012; 
Waring et al., 2014) in vitro and in vivo. Although no significant increase 
in IGF-1 secretion was detected by ELISA, we registered an enrichment 
in IGF-signaling associated proteins in hCSC proteome upon ischemia 
and reperfusion time points (figure 2.7A,C). Several other proteins 
associated with other cytokine/growth factor paracrine signaling 
pathways were also found to be more represented in hCSC proteome 





all with documented paracrine roles acting in CM physiology during I/R 
injury (Saini et al., 2005; Sesti et al., 2005; Turillazzi et al., 2014). 
 
Figure 2.7. Schematic representation of proposed mechanisms involved in hCSCs 
response to the I/R injury model, during (A) ischemia, (B) early (1h Post Reperfusion) 
and (C) late (16h Post Reperfusion) reperfusion phases of I/R injury. 
 
hCSC proteome upon ischemia was also enriched in terms related with 
ROS metabolism, cysteine synthesis, glutamate metabolism and 
gluthatione-mediated detoxification (figure 2.7B). L-cysteine is one of the 
main precursors for gluthathione, a molecule that protects cells  from 




oxidative stress (Giordano, 2005). In fact, glutaminolysis, a pathway that 
leads to the production of gluthatione via L-cysteine and glutamate, was 
found as a key energy source for proliferating mouse CSCs (Salabei et 
al., 2015). ROS formation and oxidative stress has been described as 
caused by the sudden oxygen elevation in the early reperfusion phase of 
injury (Hausenloy and Yellon, 2013), rather than during ischemia. 
However, during the preparation of the samples for proteomic analysis 
upon ischemia, hCSCs were briefly subjected to atmospheric oxygen 
concentrations, which could induce such oxidative stress responses. 
Together, these data point to a mechanistic response of hCSCs to 
ischemia phase of injury focused on a down-regulation of cell cycle 
checkpoint and DNA repair processes in favor of an enrichment in 
proteins associated with stress coping mechanisms, induction of cell 
homing and motility, and activation of pathways associated with 
paracrine communication including CXCL6 secretion (figure 2.7A). Such 
paracrine signaling activation is described as having a beneficial effect 
on CM protection. hCSC paracrine protection on hiPSC-CM was 
recapitulated in our model. Viability of hiPSC-CMs was mainly affected in 
the early reperfusion phase of the injury, which is consistent with the 
described in vivo pathophysiology of CM death during I/R, where the first 
minutes of reperfusion are also the main trigger for CM death and tissue 
damage due to the oxidative stress, calcium overload, mitochondrial 
permeability pore (MPTP) opening and hypercontracture (Hausenloy and 
Yellon, 2013). 
Several authors have reported an increase in the number of resident 
CSC upon AMI in mice (Ellison et al., 2013; Valiente-Alandi et al., 2016) 
and human (Urbanek et al., 2005) hearts. Stastna et al., in 2010, also 
showed that connective tissue growth factor, a pro-fibrosis factor 





atrial natriuretic peptide, a vasodilator molecule also secreted by CMs, 
had an opposite effect, decreasing rat CSC proliferation (Stastna and 
Van Eyk, 2012). These results suggest that CSC proliferation is regulated 
upon injury by paracrine factors secreted by CMs. In fact, in our co-
culture I/R injury model, we were able to observe a significant increase in 
hCSC proliferation upon reperfusion (figure 2.7B,C). Our hCSC whole-
proteome results also showed higher enrichment of pathways related 
with cell proliferation via EGF signaling after reperfusion, which points to 
EGF as one of the key actuator signals in CSC proliferation activation 
upon AMI (figure 2.7B,C). In fact, EGF has been reported as having a 
positive effect on cardiosphere-derived hCSCs proliferation and migration 
(Aghila Rani and Kartha, 2010), as being one of the main factors 
secreted in mice CSC conditioned medium (C.-Y. Park et al., 2016), as 
up-regulated in mice CSCs upon injury (Valiente-Alandi et al., 2016), and 
EGF receptor has also been identified in a hCSCs receptome 
characterization study by our group (Gomes-Alves et al., 2015). Other 
signaling pathways described to be related with cell proliferation were 
also found to be more enriched at 16 hours post reperfusion, such as 
FLT3 signaling (figure 2.7C), a pathway described as important for 
proliferation in hematopoietic progenitor cells (Kim et al., 2015), 
cytokinesis, and IGF-1 pathway. 
Collectively, our data suggests an hCSC response to early reperfusion 
through activation of paracrine signaling mechanisms (including acute 
phase response signaling), cell proliferation, glutathione-mediated ROS 
detoxification, and cell movement, while still inhibiting cell cycle repair 
mechanisms (figure 2.7B). Later in reperfusion, hCSCs proteome also 
demonstrated an enrichment in several pathways associated with 
cytokine/ growth factors paracrine signaling, all with documented 
paracrine roles acting in CM physiology during I/R injury, including 




CXCL6 secretion, a recovery of cell cycle repair mechanisms and 
activation of angiogenesis and vasculogenesis related pathways (figure 
2.7C). These results are in line with the concept that hCSCs regenerative 
capacity is mainly centered on their paracrine potential, being CXCL6 
one of its critical players. 
Our data support the importance of a paracrine cross-talk between CSCs 
and CMs during AMI, and the idea that heterotypic cell models better 
recapitulate in vivo features of I/R when compared to monotypic models.  
 
5. Conclusion 
The I/R injury model developed recapitulates important hallmarks of AMI. 
The use of robust advanced analytical technologies such as LC-MS/MS 
whole cell proteome analysis, combined with more classical and targeted 
methodologies (ELISA growth factor quantification, viability assays) and 
functional assays (tube formation assay) enabled us to further 
understand the response of hCSC to I/R injury, shedding new insights on 
the possible mechanisms involved. We show, for the first time, an 
increase in CXCL6 secretion by hCSCs in a myocardial I/R setting, 
reinforcing the described role of CXCL6 in hCSC regenerative and pro-
angiogenic potential and suggesting the importance of this chemokine in 
the paracrine-mediated protective effect of CSCs in myocardium upon 
AMI. The results reported herein strengthen the importance of studying 
physiological processes using more complex human co-culture in vitro 
models leading to a better recapitulation of the in vivo paracrine signaling 






This work provides new insights and raises new questions related with 
hCSC biology in acute myocardial infarction. We believe that our model 
provides an important tool towards a better understanding of hCSC 
action mechanisms upon AMI, which will enable the development of 
novel therapies focused on activation, recruitment and improvement of 
the endogenous heart regeneration capacity.  
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7. Supporting information 







Figure S2.1. Phenotypic characterization of hCSCs. hCSCs were characterized using 
specific cell markers by flow cytometry (A) and immunostaining (B). Scale bars: 50 µm. 







Figure S2.2. Effect of I/R injury on hiPSCs-hCMs without maturation step. Viability of 
hiPSC-CMs after 15 days of differentiation ( without maturation step) was assessed by 
PrestoBlue® assay (A)  and by cell staining with FDA (live cells, green) and PI (dead 
cells, red), scale bars 200 µm (B). Black circles: mono-culture hiPSC-CMs CTL (M CM 
CTL); Red squares: mono-culture hiPSC-CMs insult (M CM i); Green triangles: co-culture 









Figure S2.3. Phenotypic characterization of hiPSC-CMs. hiPSC-CMs were 
characterized using specific cell markers by flow cytometry (A) and immunostaining (B). 
hiPSC-CMs retain their cardiomyocyte markers expression after 2 days in assay 
conditions (CM001-R at 3% O2: light grey bars) comparing to the hiPSC-CM maturation 
culture conditions (Pluricyte® CM medium at 21% O2: dark grey bars). Scale bars: 50 µm. 






























































































































































































































































































































































































Table S2.1. Canonical pathways and functions enriched in Co CSC I vs Co CSC CTL.      
–log (p-value)≤1.3 were considered as non significant (n.s.) (less than 95% confidence). 
Pathway/ function terms were only selected for analysis when –log (p-value) ratio 
between the two conditions ≥1.2. 
      
                   -log (p-value)  
Category Canonical Pathway/ Function Co CSC 
CTL 
 
Co CSC  
i 
    
Cell Proliferation Cholecystokinin/Gastrin-mediated Signaling 1.60 3.09 
EGF Signaling n.s. 2.82 
Renin-Angiotensin Signaling 1.61 2.52 
ERK5 Signaling n.s. 2.48 
FLT3 Signaling in Hematopoietic Progenitor Cells n.s. 1.80 
    
Cytoskeleton 
Organization 
Quantity of actin stress fibers n.s. 5.32 
Quantity of actin filaments n.s. 5.19 
Quantity of filaments n.s. 5.08 
    
Maintenance of Cell 
Integrity / Cell Death 
DNA Methylation and Transcriptional Repression Signaling 2.55 4.17 
Death Receptor Signaling 2.79 3.54 
Myc Mediated Apoptosis Signaling 2.39 3.04 
Autophagy n.s. 1.53 
    
Oxidative Stress Hypoxia Signaling in the Cardiovascular System 2.94 4.25 
Superoxide Radicals Degradation 1.85 2.43 
    
Paracrine Signaling / 
Regeneration 
VEGF Signaling 5.92 7.14 
Differentiation of Cells n.s. 5.60 
Oncostatin M Signaling 4.25 5.41 
Vasculogenesis n.s. 5.10 
PDGF Signaling 2.50 4.04 
IL-3 Signaling 2.25 3.07 
IL-2 Signaling n.s. 2.03 
JAK/Stat Signaling 1.34 2.70 
PEDF Signaling n.s. 1.42 
Role of JAK family kinases in IL-6-type Cytokine Signaling n.s. 1.46 








Table S2.2. (Continued)  
    
Stress Response Endoplasmic reticulum stress response 10.35 12.49 
 
Tec Kinase Signaling 2.59 4.31 
PDGF Signaling 2.50 4.04 
AMPK Signaling 3.03 3.93 
Acute Myeloid Leukemia Signaling n.s. 1.91 
Corticotropin Releasing Hormone Signaling n.s. 1.32 
    
Metabolism Glutathione Redox Reactions I 3.06 5.63 
 
Glutathione-mediated Detoxification 1.99 3.27 
 
Cysteine Biosynthesis/Homocysteine Degradation n.s. 1.60 
 
Cysteine Biosynthesis III (mammalia) 2.20 3.89 
Methionine Degradation I (to Homocysteine) 1.86 2.80 
 
Table S2.2. Canonical pathways and functions enriched in Co CSC I vs Mono CSC i.       
–log (p-value)≤1.3 were considered as non significant (n.s.) (less than 95% confidence). 
Pathway/ function terms were only selected for analysis when –log (p-value) ratio 
between the two conditions ≥1.2. 
    
-log (p-value)  







   
Cell Proliferation Mitosis 5.34 7.49 
 
Cholecystokinin/Gastrin-mediated Signaling 1.99 3.09 
 
EGF Signaling 1.46 2.82 
 
Renin-Angiotensin Signaling 1.90 2.52 
ERK5 Signaling n.s. 2.48 
Prolactin Signaling n.s. 1.47 
 
   
Cytoskeleton 
Organization 
Morphology of Cells 18.76 23.54 
Cdc42 Signaling 6.64 9.00 
Quantity of Actin Stress Fibers 4.42 5.32 
Quantity of Actin Filaments 3.97 5.19 
PTEN Signaling 2.76 3.48 
 
   
Maintenance of Cell 
Integrity/  Cell Death 
Myc Mediated Apoptosis Signaling 2.32 3.04 
BER pathway n.s. 2.20 
 




Table S2.2. (Continued) 
 
   
Oxidative Stress Metabolism of ROS 5.45 7.63 
 
Synthesis of ROS 4.83 6.65 
Superoxide Radicals Degradation 1.70 2.43 
 
   
Paracrine Signaling / 
Regeneration 
IGF-1 Signaling 4.06 6.87 
Oncostatin M Signaling 4.45 5.41 
vasculogenesis n.s. 5.10 
Chemokine Signaling 3.74 4.63 
Neuregulin Signaling 2.26 4.44 
p70S6K Signaling 3.36 4.04 
PDGF Signaling 2.67 4.04 
IL-3 Signaling 1.81 3.07 
HGF Signaling 1.88 2.84 
JAK/Stat Signaling 1.52 2.70 
IL-2 Signaling 1.38 2.03 
IL-1 Signaling 1.41 1.85 
Netrin Signaling n.s. 1.82 
CNTF Signaling 1.31 1.64 
TNFR1 Signaling n.s. 1.55 
Role of JAK family kinases in IL-6-type Cytokine Signaling n.s. 1.46 
PEDF Signaling n.s. 1.42 
 
   
Stress Response Corticotropin Releasing Hormone Signaling n.s. 1.32 
Acute Phase Response Signaling 2.95 3.99 
 
   
Metabolism Cysteine Biosynthesis/Homocysteine Degradation n.s. 1.60 
Cysteine Biosynthesis III (mammalia) 1.98 3.89 
Methionine Degradation I (to Homocysteine) 1.67 2.80 
Glycolysis I 5.14 7.48 
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Merging bioreactor technology with 3D 
culture approaches: a novel myocardial 
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During acute myocardial infarction (AMI) Ischemia/Reperfusion (I/R) 
injury causes cardiomyocyte (CM) death and loss of heart tissue function, 
making AMI one of the major causes of death worldwide. Cell based in 
vitro models of I/R injury have been increasingly used as a 
complementary approach to in vivo preclinical research. However, most 
in vitro I/R studies use murine cells in two-dimensional (2D) setups, 
which are not able to properly recapitulate human cellular physiology 
cellular interactions as well as nutrient and gas gradients that occur in the 
human heart. In this work we established a novel human in vitro model of 
myocardial I/R injury using CMs derived from human induced pluripotent 
stem cells (hiPSC-CMs). hiPSC-CMs were cultured as three-dimensional 
(3D) aggregates in stirred tank bioreactors. Using this experimental 
setup, we were able to recapitulate important hallmarks of CM response 
to AMI, including loss of viability and disruption of sarcomere and 
mitochondria ultra-structure. We also show higher angiogenic 
functionality and increased secretion of key pro-angiogenic and pro-
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Acute myocardial infarction (AMI) consists on the cessation of blood flow 
to an isolated region of the heart, causing oxygen and nutrient depletion. 
Coronary intervention with restauration of blood flow remains the clinical 
intervention of choice for AMI patients: although necessary for the 
replenishment of blood to the affected area, this process causes 
increased myocardial tissue damage (Ischemia/ Reperfusion, I/R injury) 
with loss of cardiomyocytes (CMs) causing up to 50% of the final 
damaged tissue size (Hausenloy and Yellon, 2013).  
During AMI, CMs in stress have been reported to activate the expression 
and secrete growth factors and cytokines associated with inflammation, 
remodeling of extracellular matrix (ECM), cell adhesion, recruitment of 
endogenous cardiac stem/progenitor cells (CSCs) and angiogenesis, (Li 
et al., 2014; Ong et al., 2015). However, such findings and most research 
associated with CM physiology during myocardial I/R injury is mainly 
based in murine animal models and murine cell populations in vitro, 
including primary neonatal and adult CMs, mouse atrial HL-1 cells and 
rat ventricular H9c2 cell lines. Although central to the study of I/R 
pathophysiology, murine systems hold several disadvantages: murine 
and human cell physiology differ at a tissue and cell level, including 
relevant differences in ion channels (Davis et al., 2011) and microRNAs 
with documented roles in cardiovascular processes (Roux, Gonzàlez-
Porta and Robinson-Rechavi, 2012). Such differences have already been 
pointed as one of the causes of the poor translational success from 
preclinical to clinical trials: about 90% of candidate therapies that showed 
efficacy in preclinical studies fail in human trials (Olson et al., 2000), 
generating massive costs in the drug development chain. 
Therefore, there is an increasing need for novel relevant human in vitro 
cellular models that can effectively recapitulate human CM response to 




I/R injury. These models can be further used as tools for preclinical 
research, contributing to excel the drug developmental process. 
The advent of induced pluripotent stem cell (iPSC) research has 
accelerated human cell biology research in vitro, and several reports 
show that human iPSC-derived CMs (hiPSC-CMs) are effective in 
toxicological safe screenings, being already used for preclinical in vitro 
testing in the pharmaceutical industry (Denning et al., 2016). Moreover, 
several strategies were already developed to improve the maturation 
state and physiological relevance of hiPSC-CMs, including hormone 
supplementation (Yang et al., 2014; Ribeiro et al., 2015) and culture in 
three-dimensional (3D) aggregate configuration (Correia et al., 2018). In 
fact, several studies show that culturing in 3D recapitulates adult CM 
physiological electrical and contractile function when comparing to planar 
culture systems (Zhang et al., 2013; Daily et al., 2015; Correia et al., 
2018). Besides improving the maturation state of cells, 3D in vitro cardiac 
models allow a higher resemblance with in vivo tissue microenvironment 
and architecture, enabling enhanced cell-cell and cell-ECM contacts 
(Serra et al., 2012; Ryan et al., 2016).  
To overcome the drawbacks of the existent in vitro models of I/R and 
aiming at filling the gap between these and in vivo animal research, in 
this work we developed and characterized a novel in vitro I/R system 
using hiPSC-CM 3D spheroids and stirred tank bioreactor technology. 
Bioreactors allow for a fine control and monitoring of critical process 
parameters to mimic the extracellular microenvironment of the ischemia 
and reperfusion phases of AMI, including pO2 and pH. Moreover, 
bioreactors allow for non-destructive sampling for culture characterization 
at different stages of I/R injury. Using this experimental setup, we were 
able to efficiently show several hallmarks of CM response to AMI, 




and mitochondria ultra-structure, and higher secretion of several key pro-
inflammatory and pro-angiogenic molecules during both phases of injury. 
 
2. Materials and Methods 
2.1. Cell culture 
2.1.1. Directed differentiation of hiPSC-CMs 
Human iPSC (DF19-9-11T.H, WiCell) were cultured in Matrigel® 
(Corning) coated plates in mTESR1 medium (STEMCELL Technologies) 
and subcultured when about 80-90% confluent using Versene (Gibco) for 
7 minutes at 37°C. Differentiation to CMs was initiated when cell 
confluence reached about 90%, as described elsewhere (Lian et al., 
2013; Correia et al., 2016). 
At day 7 (when a high proportion of beating zones is observed), cells 
were dissociated by incubation with TrypLE Select (ThermoFisher 
Scientific) for 5 minutes and replated in AggreWell™400Ex plates (Stem 
cell technologies) at density of 1500 cell/microwell, as previously 
described for aggregation of hPSC-CMs (Nguyen et al., 2014): cells were 
centrifuged at 100 g during 3 min, and cultured in RPMI Medium 
supplemented with B27 (without insulin). Medium was exchanged after 
24 hours, and aggregates were transferred to orbital suspension cultures 
(agitation rate of 90 rpm) and maintained for additional 8 days. Using this 
protocol, aggregates composed of >90% of cTnT positive cells 
(confirmed by flow cytometry) were obtained after 15 days (Correia et al., 
2018). To further improve maturation state of this cell population, hiPSC-
CMs were cultured for additional 10 days in a commercial 
triiodothyronine (T3) hormone rich medium (Pluricyte Medium, NCardia) 
as described in Chapter II and elsewhere (Ribeiro et al., 2015). Medium 




was exchanged every two days. Cell cultures were performed in at 37ºC 
an humidified atmosphere (5% CO2, 3% O2). 
2.1.2. Ischemia/Reperfusion injury setup 
After the differentiation and maturation phase (day 25), hiPSC-CMs 
aggregates were inoculated (1.3x105 cell/mL) in small-scale flat-bottom 
stirred-tank bioreactors equipped with trapezoid shaped paddle impellers 
with long arms (DASGIP® cellferm-pre bioreactor system Eppendorf AG) 
in 230 mL of CM001-R media composed by DMEM:F12: Neurobasal 
medium (1:1), supplemented with 1% penicillin streptomycin, 3% fetal 
bovine serum (FBS) embryonic stem cell-qualified, N2 supplement (1X), 
B27 supplement (1X), 0.9 mM l-glutamine, 50 μM β-mercaptoethanol 
(Sigma) (all percentages in v/v). hiPSC-CM aggregates were incubated 
in CM001-R media at least 15 h before I/R experiments. Data acquisition 
and process control were performed using DASGIP® Control Software 
4.0 (Eppendorf AG). Dissolved oxygen, pH and temperature were 
monitored with pH and oxygen electrodes (Mettler-Toledo) and a 
temperature sensor, respectively. Electrodes and temperature sensor 
were calibrated as described by the manufacturer. Cells were cultivated 
under defined and controlled culture conditions: temperature 37°C, 
surface aeration rate 0.1 vols (vvm); 3% O2 (15% pO2 air saturation), 
corresponding to myocardial physiologic normoxia (Khan et al., 2010). 
Stirring rate was set to 70 rpm. 
I/R experimental setup is depicted in figure 3.1. Ischemia was mimicked 
by replacing CM001-R medium with Ischemic Mimetic Solution (IMS; in 
mM: NaCl, 135; KCl, 8; MgCl2, 0.5; NaH2PO4, 0.33; HEPES, 5.0; CaCl2, 
1.8; Na+-lactate, 20; pH 6.8) (Zhao et al., 2013), and by decreasing O2 to 
values below 0.4%. After 5 h of ischemia, reperfusion was mimicked by 




of 3%) for an additional 16 hours. A CTL bioreactor was maintained in 
parallel (CM001-R without FBS at O2 of 3%), respecting the same 
medium exchange intervals. 
 
Figure 3.1. Schematic representation of Ischemia/Reperfusion injury (I/R) 
bioreactor-based experimental setup. Ischemia was mimicked by replacing CM001-R 
medium with 3% FBS by Ischemic Mimetic Solution (IMS) and by culturing cells in a N2 
gaseous environment. After 5 h of ischemia, reperfusion was mimicked by re-establishing 
normoxic culture conditions (CM001-R without FBS at 3% O2). I/R setup was performed 
using aggregates of hiPSC-CMs in stirred tank bioreactors. The effects of the I/R were 
evaluated regarding hiPSC-CMs viability, hiPSC-CMs structure and ultrastructure, hiPSC-
CMs aggregate size, hiPSC-CMs secretory profile and angiogenic potential of conditioned 
(Cond.) media at different time points: (BI- Before injury; Post I – Post Ischemia; Post R – 
Post Reperfusion). Control cultures were done in parallel (using normoxic conditions). 
 
2.2. Culture characterization 
2.2.1. Cell viability 
The impact of I/R injury in hiPSC-CMs viability was evaluated by cell 
membrane integrity analysis: aggregates were incubated with 20 µg/mL 
fluorescein diacetate (FDA), that stains viable cells, and 10 µg/mL 
propidium iodide (PI), a membrane impermeable DNA-dye that stains 




non-viable cells, in DPBS for 2-5 minutes. Samples were then observed 
under a fluorescence microscope (DMI 6000, Leica Microsystems 
GmbH) and representative images were taken. Viability of 3D hiPSC-CM 
cultures was further assessed using NucView® 488 caspase-3 substrate 
(Biotium), according to the manufacturer’s recommendations. Briefly, 
aggregates were incubated for 1 hour with fresh medium containing 
NucView® 488 reagent (1:200). Samples were then observed under a 
fluorescence microscope (DMI 6000, Leica Microsystems GmbH) and 
representative images were taken. 
2.2.2. Aggregate size measurement 
Aggregates were imaged in a fluorescence microscope (DMI6000, Leica 
Microsystems GmbH, Wetzlar, Germany) and Ferret diameter was 
measured using ImageJ open source software (Rasband, WS, ImageJ, 
U.S. National Institutes of Health, Bethesda, MD, USA, 
http://imagej.nih.gov/ij/, 1997–2012).  
2.3. Phenotypic characterization 
2.3.1. Immunofluorescence microscopy 
hiPSC-CMs aggregates were washed with DPBS, fixed in 4% (w/v) 
paraformaldehyde (PFA) and 4% (w/v) sucrose in DPBS for 20 min, and 
dehydrated in 30% (w/v) sucrose overnight. Samples were then 
embedded in Tissue-Tek® O.C.T. (Sakura) and frozen at −80°C for 
cryosectioning. Frozen samples were sliced with a thickness of 10 μm in 
a cryostat (Cryostat CM 3050 S, Leica). Afterwards, sections were 
permeabilized for 10 min in 0.1% (v/v) Triton X-100 in DPBS and blocked 
with 0.2% (v/v) Fish Skin Gelatin (FSG) in DPBS for 30 min, at room 
temperature (RT, 18-20°C). Sections were then incubated with primary 




RT. Cells were washed with DPBS and incubated with secondary 
antibodies diluted in the same solution for 1 h at RT in the dark. The 
following primary antibodies were used: α-sarcomeric actinin (1:200, 
Sigma) and troponin T (1:100, Millipore). Alexa Fluor 488 phalloidin was 
used to stain F-actin (1:100, Invitrogen). 
 
2.3.2. Transmission electron microscopy 
hiPSC-CMs aggregates were washed with DPBS and fixed in 4% (w/v) 
paraformaldehyde (PFA) and 4% (w/v) sucrose in DPBS for 20 minutes. 
Samples were stored in DPBS at 4°C until further processing. 
Aggregates were fixed in a mixture 2% PFA and 2% glutaraldehyde in 
0.1 M Phosphate Buffer for 1 hour on ice. Subsequently, samples were 
washed 3 times with 0.1 M Phosphate Buffer and embedded in 2% low 
melting point agarose. Agarose was allowed to solidify on ice prior to 
post-fixation with osmium tetroxide (1% v/v in 0.1 M Phosphate Buffer, 30 
minutes on ice protected from light). After several washes in distilled 
water, the samples were contrasted in 1% Tannic Acid for 20 minutes on 
ice, washed several times in distilled water, dehydrated in a graded 
series of ethanol and infiltrated in epon resin (epon: ethanol mixtures: 
1:3, 1:1, 3:1, 1 hour and 30 minutes each, pure epon overnight) and 
embedded in flat embedding molds. Ultrathin sections were cut in a 
Reichert Ultramicrotome using a diamond knife.  Samples were 
visualized in a H-7650 Transmission Electron Microscope (Hitachi) and 
representative images were taken. 
2.3.3. Cytokine array 
Conditioned medium from ischemic and reperfusion phases of both CTL 
and injury bioreactors were collected, centrifuged at 1,000 xg for 5 min at 




RT to remove dead cells and debris and stored at -20°C until further use. 
Cytokine detection was performed according to manufacturer's 
instructions (Ab133997, Abcam) and included the screening for the 
following 42 targets: ENA-78, GCSF, GM-CSF, GRO, GRO-α, I-309, IL-
1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p40/p70, IL-
13, IL-15, IFN-γ, MCP-1, MCP-2, MCP-3, MCSF, MDC, CXCL9, MIP-1δ, 
CCL5, SCF, SDF-1, CCL17, TGF-β1, TNF-α, TNF-β, EGF, IGF-I, 
Angiogenin, Oncostatin M, Thrombopoietin, VEGF-A, PDGF BB and 
Leptin. The intensity of chemiluminescent signal is proportional to the 
amount of cytokine bound and was determined using the Image LabTM 
software version 5.0 (Bio-Rad). Spot densities were normalized 
according to the manufacturer instructions. Mean signal density of each 
spot was also subtracted with the mean spot densities of basal medium 
alone (CM001-R medium). IMS-based conditioned medium dismissed 
similar normalization, since IMS is a DPBS-based medium, where no 
proteins were quantified using Microplate BCA Protein Assay Kit (Thermo 
Scientific). 
2.3.4. Quantification of growth factors by ELISA 
Growth factors HGF and IGF-1 were also quantified in hiPSC-CM 
aggregates conditioned medium by ELISA (Human Quantikine ELISA 
kits, R&D Systems), according to manufacturer’s instructions. Optical 
density was measured in 96-well plates using a microwell plate 
fluorescence reader (Infinite 200 PRO NanoQuant, TECAN).  
2.3.5. HUVECS culture and tube-formation assay 
Human Umbilical Vein Endothelial Cells (HUVECs, catalog No. 2517A, 
Lonza) were cultured at 37°C in humidified incubators (5% CO2, 3% O2), 




(ECGM2, PromoCell). Medium was replaced every 3 days. Cells were 
subcultured when about 90% confluent using 0.5% Trypsin-EDTA for 7 
minutes at 37°C.  
Tube formation assay was performed according to Pedroso et al., 2011. 
Briefly, ice-cold undiluted Matrigel (Growth factor Reduced,  BD 
Biosciences) (1.97 mg/cm2)  was used to coat 96-well plates and 
incubated for 40 min at 37°C to allow the Matrigel to solidify. HUVECs 
were seeded at a density of 5.5x104 cell/cm2 and incubated with the 
conditioned media from I/R experiments. ECGM2 and DMEM media 
were used as positive and negative controls for tube formation, 
respectively. At least four independent images were acquired per 
condition after 4h of incubation and the morphological aspects of the tube 
network were quantified using the ImageJ angiogenesis analyzer plugin 
(Carpentier G. Angiogenesis analyzer. Image J News (2012). 
http://image.bio.methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-
ImageJ), including total master segment length (sum of the length of the 
detected master segments in the analyzed area), total segment length 
(sum of length of the segments) total branching length (sum of length of 
the trees composed from segments and branches), number of nodes and 
number of junctions (Carpentier, 2012). All cell culture reagents were 
purchased from Gibco, Life Technologies unless otherwise stated. 
2.4. Statistical analysis 
Statistical analyses were performed with GraphPad Prism6 (GraphPad 
Software Inc.). All data are shown as mean with standard deviation. Data 
were analyzed by One Way ANOVA Tukey test or student t-test (tube 
formation analysis, cytokine and ELISA results). P-values below 0.05 
were considered significant.  





3. Results  
A 5 h period of acidosis, hyperosmosis and oxygen and nutrient 
deprivation was performed to mimic the ischemic period. Reperfusion 
was mimicked by re-establishing control culture conditions, with nutrient-
rich medium (without serum) and 3% O2, corresponding to myocardial 
physiologic normoxia (Khan et al., 2010). Bioreactor time-profiles of pO2 
and pH throughout the experiment are depicted in figure 3.2.  
 
Figure 3.2. Time-profiles of I/R bioreactors. (A) O2 percentage in the culture medium; 
(B) pH in the culture medium. The ischemic phase is represented by a grey rectangle. 
Zero hours correspond to cell inoculation in the bioreactors.  
 
hiPSC-CM aggregates response to the I/R injury was evaluated in terms 
of cell viability, aggregate structure, cell ultra-structure, protein secretion 
profile and angiogenic capacity of the resultant conditioned medium. 
3.1. Effect of I/R injury on hiPSC-CM aggregates viability 
A decrease in viability was observed in hiPSC-CM aggregates upon 
injury when compared to CTL condition. Caspase 3, an early marker of 




burst of apoptotic cells was detected by PI staining after the first hour of 
reperfusion (figure 3.3B). Aggregates maintained in CTL conditions kept 
high viability throughout the experiment (figure 3.3A,B).  
 
Figure 3.3. Effect of I/R injury in hiPSC-CM aggregates viability. hiPSC-CM 
aggregates viability was assessed by NucView Staining (green) (A) and by cell staining 
with FDA (live cells, green) and PI (dead cells, red) (B), before insult, post ischemia, and 
at 1 hour and 16 hours post reperfusion. Scale bars 200 µm. 
 
hiPSC-CM aggregates average diameter was determined before I/R 
injury in the bioreactor (260.8 ± 33.1 μm). Neither CTL nor I/R 
aggregates significantly changed their average diameter during the 
bioreactor culture (262.9 ± 32.6 and 255.0 ± 30.6 μm, respectively) 
(figure 3.4).  
 





Figure 3.4. hiPSC-CM aggregate size. Average aggregate diameters (A) were 
measured before and after I/R bioreactor setup experiments (experimental endpoint, 




3.2. Effect of I/R injury on phenotype and ultra-structure of 
hiPSC-CM  
Aggregates exposed to I/R injury presented hollow lacunae in their core 
(figure 3.5), probably related with the high cell death in this condition 
(figure 3.3). Nevertheless, both CTL and Insult aggregates maintained 
the expression of the typical cardiomyocyte phenotypic markers 
Troponin-T and α-sarcomeric actinin (figure 3.5). 
 
Figure 3.5. hiPSC-CMs aggregates cryosections were characterized using specific 
cell markers at 16 hours post reperfusion (insult) and in control (CTL) conditions. 
Although retaining their cardiomyocyte specific markers (α-sarcomeric actinin and 
Troponin T), hiPSC-CM aggregates upon injury presented hollow lacunae in their 






Figure 3.6. Characterization of hiPSC-CM aggregate ultrastructure. Transmission 
electron microscopy (TEM) images of hiPSC-CMs aggregates in control (CTL) and at 16 
hours Post Reperfusion (Insult) conditions. Z-disks (↓), nuclei (N), mithocondria with 
visible cristae (#) and mithocondria with disorganized cristae structure (*) are highlighted. 
Scale bars: 500 nm.  
TEM analysis was conducted to further characterize the effect of the I/R 
injury bioreactor setup on the hiPSC-CMs. When compared to the CTL 
condition, cells exposed to I/R exhibited: i) disruption of sarcomeres 
myofilament and Z band organization and; ii) higher number of 
mitochondria with disorganized cristae and membrane rupture (figure 
3.6).  
3.3. Impact of I/R injury on the secretion profile of hiPSC-CM 
In order to evaluate the hiPSC-CM aggregate secretory profile in 
response to the I/R injury, we collected the conditioned media after the 
ischemic and reperfusion phases of the injury and analyzed its content 
regarding key cytokines and growth factors by cytokine array. Several 
proteins were identified as differentially expressed between CTL and 
ischemic conditioned media (figure 3.7) and between CTL and 
reperfusion conditioned media (figure 3.8).  




hiPSC-CM aggregate subjected to ischemia showed increased secretion 
of molecules with key roles in inflammation (MCSF, MDC, Oncostatin-M, 
GRO, GRO-α, IL-1β, IL-4, IL-5, IL-8, IL-12 p40/p70, IL-15, CCL5, CCL17, 
CXCL9, TNF-β, VEGF, MCP-1, MCP-2, MCP-3, MIP-1, and ENA-78), 
angiogenesis (Thrombopoietin, PDGF-BB, GM-CSF, and ENA-78) and 
migration (GRO, GRO-α, IL-8, SDF-1, IGF-1, VEGF, MCP-1, MCP-2, 
ENA-78, and SCF) (figure 3.7A). IGF-1 was further validated by ELISA 
assay, confirming the increased secretion of this growth factor by 
ischemic hiPSC-CM aggregates vs CTL (figure 3.7B). 
Upon reperfusion phase of injury, hiPSC-CM aggregates subjected to I/R 
injury  showed increased secretion of pro-inflammatory cytokines (I-309, 
CCL5, TNF-α) as well as two pro-angiogenic proteins (Angiogenin and 
GCSF) (figure 3.8A). Moreover, HGF, a growth factor also previously 
shown to be upregulated in damaged CMs (Ong et al., 2015) was 
quantified by ELISA, also showing an increased secretion in reperfusion 





Figure 3.7. Secretion of cytokines and growth factors in hiPSC-CMs aggregates 
upon ischemia phase of I/R injury. hiPSC-CM aggregates conditioned medium from 
control (CTL) and upon Ischemia was profiled using a cytokine array. Color scale from 0 
(blue) to 4.5 (red) (units in mean normalized spot density) (A). IGF-1 concentration was 
validated by ELISA assay (B). *P≤0.05; **P≤0.01; ***P≤0.001; ****P≤0.0001 (student t-
test, n= 2). 





Figure 3.8. Secretion of cytokines and growth factors in hiPSC-CMs aggregates 
upon reperfusion phase of I/R injury. hiPSC-CM aggregates conditioned medium from 
control (CTL) and upon Ischemia was profiled using a cytokine array. Color scale from 0 
(blue) to 0.32 (red) (units in mean normalized spot density) (A). HGF concentration was 
measured by ELISA assay (B). *P≤0.05; **P≤0.01; ***P≤0.001; ND: not detected (student 





Upon identification of three key angiogenic cytokines in post reperfusion 
injury supernatant (I-309, Angiogenin and GCSF) (Figure 3.8A), the 
increased pro-angiogenic potential of this medium vs CTL was tested by 
in vitro tube formation assay. HUVECs were incubated with conditioned 
media from hiPSC-CM aggregates in CTL condition and after 16h of 
reperfusion. As shown in figure 3.9, the angiogenic potential of the 
conditioned medium from the hiPSC-CM aggregates is increased when 
comparing to CTL conditions, represented by a significant increase in 
total master segment length (figure 3.9A), total segment length (figure 
3.9B) and number of nodes (figure 3.9D). Although not significant, other 
parameters also show higher values in conditioned medium upon injury, 
such as total branching length (figure 3.9C) and number of junctions 
(figure 3.9E). 
 
Figure 3.9. Angiogenic functional evaluation of I/R bioreactors conditioned 
medium. Conditioned media of hiPSC-CMs aggregates in control (CTL, grey bars) and at 
16 hours Post Reperfusion (Insult, black and white dotted bars) conditions were tested for 
angiogenic potential by HUVECS tube formation assay. (A) Total master segment length, 
(B) total segment length, (C) total branching length, (D) number of nodes and (E) number 





P<0.01 (student t-test, n=2). ECGM2 and DMEM were used as positive (black bars) and 
negative (white bars) control, respectively.  





In this work we have developed a novel human I/R injury in vitro model 
using hiPSC-CM 3D cultures and bioreactor technology. In order to 
improve the physiological relevance of the model, several strategies were 
applied, including: i) cells were submitted to a 10-day maturation period 
with T3 hormone-rich commercial media optimized for hiPSC-CM 
myocardial maturation (Ribeiro et al., 2015); ii) hiPSC-CMs were cultured 
in 3D aggregates; iii) and in defined oxygen and pH conditions. 
Besides the addition of a hormone-based maturation process, cells were 
cultivated in 3D, which has also been reported to improve the functional 
maturation level of hCMs (Zhang et al., 2013; Daily et al., 2015; Correia 
et al., 2018), as well as allowing for a higher recapitulation of the native in 
vivo microenvironment, with higher cell-cell and cell-ECM interactions. 
Culture in 3D also results in the creation of oxygen, metabolite and 
nutrient gradients along the spheroid structure, which does not occur in a 
monolayer system. In fact, in the core of spheroids exposed to I/R setup, 
we observed hollow lacunae, probably left behind by dead cells.  
The I/R injury bioreactor setup was successful in mimicking several 
hallmarks of CM response to AMI, including CM death, cellular ultra-
structure modifications and secretion of key cytokines and growth factors 
in the different phases of injury. 
hiPSC-CM spheroids showed a higher concentration of dead cells upon 
the first hour of reperfusion, which is consistent with the described in vivo 
pathophysiology of CM death during AMI, where reactive oxygen species 
(ROS) accumulation, calcium overload and mitochondrial permeability 
pore (MPTP) opening during the first moments after reperfusion cause a 
burst of CM death due to mitochondria swelling (with loss of typical 




cytochrome c and several apoptotic factors, causing activation of 
apoptotic pathways by caspase 3 and 9 activation. (Hausenloy and 
Yellon, 2013). High caspase 3 levels were detected in Post Ischemia 
time-point; however it is important to take into account that caspase 3 
staining was performed for 1 h in reperfusion conditions (3% pO2, in 
CM001-R media). During AMI, upon reperfusion, the intracellular calcium 
overload, pH normalization and ROS accumulation activate calpain 
system mechanisms (Hernando et al., 2010), leading in turn to 
myofibrillar protein degradation and inherent disruption of sarcomere 
structure (Portbury, Willis and Patterson, 2011). In our model we observe 
ultrastructural hallmarks of CM death upon AMI: analysis by TEM 
revealed morphological changes characteristic of I/R injury, including loss 
of organized mitochondria cristae folding structure as well as loss of 
sarcomere organization pattern. 
Using cytokine array and ELISA assays, we were also able to 
characterize hiPSC-CM aggregates secretory profile in both phases of 
injury, comparing CTL with I/R injury conditions. Secretion of 
inflammatory cytokines by CMs is an hallmark of AMI pathophysiology, 
resulting in the recruitment of immune cells to the injury site (reviewed in 
Frangogiannis, 2014). Besides pro-inflammatory, CM signals released 
upon injury have also been reported to be associated with angiogenesis, 
remodeling of ECM as well as recruitment and activation of resident 
CSCs (Li et al., 2014; Ong et al., 2015). hiPSC-CM subjected to ischemia 
showed increased secretion of molecules with key roles in inflammation, 
several of which previously identified as up-regulated in ischemic heart 
tissue such as: MCSF (Frangogiannis et al., 2003), Oncostatin-M 
(Gwechenberger et al., 2004), IL-1β (Saparov et al., 2013), IL-8 (Saini et 
al., 2005; Vandervelde et al., 2005), IL-15 (Turillazzi et al., 2014), CCL5 
(Montecucco et al., 2012), SDF-1, GM-CSF (Vandervelde et al., 2005; 




Ong et al., 2015), VEGF (Vandervelde et al., 2005; Ong et al., 2015), 
PDF-BB, SCF, EGF, MCP-2, MCP-3 (Ong et al., 2015), MCP-1 (Kakio et 
al., 2000), and IL-5 (Saini et al., 2005). Other molecules have also been 
previously associated to angiogenesis (PDGF-BB, GM-CSF, IL1-β) as 
well as migration (GRO, GRO-α, ENA-78 Boucek et al., 2015), (SDF-1, 
Renko et al., 2018) and activation (IGF-1, Waring et al., 2014) of CSCs.  
Conditioned media of hiPSC-CM aggregates exposed to reperfusion 
showed increased levels of pro-inflammatory (CCL5, I-309, TNF-α) as 
well as pro-angiogenic (I-309, Angiogenin and GCSF) proteins. Again, 
most of the proteins identified as differentially expressed have been 
previously identified as increased upon AMI in in vivo and in vitro setups 
including: CCL5 (Montecucco et al., 2012), and TNF-α (Vandervelde et 
al., 2005; Ong et al., 2015; Awada, Hwang and Wang, 2017; Shi et al., 
2017). HGF, a protein associated with activation of resident stem cell 
migration (Aghila Rani and Kartha, 2010; Awada, Hwang and Wang, 
2017) was also identified as more secreted upon reperfusion. The 
increased pro-angiogenic capacity of hiPSC-CM spheroid conditioned 
media was also validated by tube formation assay.  
Interestingly, different sets of cytokines (with the exception of CCL5, 
found in both phases) were found increased in post ischemia and post 
reperfusion phases. Moreover, we detected a more acute response 
regarding number of cytokines and average cytokine signal intensity 
upon ischemia when comparing to post 16h of reperfusion. Such results 
emphasize the distinct pathophysiology of the two phases of injury, and 
the importance to recapitulate both when studying AMI in vitro. To the 
best of our knowledge, most studies focused on cytokine release in AMI 






In summary, we successfully established a novel and relevant human I/R 
injury in vitro model, with recapitulation of important hallmarks of CM 
response to AMI. Culture of hiPSC-CMs as 3D aggregates and the 
application of stirred tank controlled bioreactors allowed us to 
recapitulate key CM hallmark responses to AMI as well as the 
extracellular microenvironment physico-chemical parameters of both 
phases of I/R injury. Moreover, we provide a characterization of hiPSC-
CM cytokine secretion upon the different phases of injury.  
The cell model developed herein represents a step closer to in vivo 
human CM milieu, and can be employed as an alternative to planar (2D), 
human immature and murine cell based I/R models. This model has the 
potential to serve as a platform for further studies aimed at interrogating 
hCM mechanisms of action upon AMI. Moreover, the use of hiPSC-CMs 
allows investigation of hCMs with different genetic backgrounds. Adding 
to mechanistic studies, we also envision our model as relevant for in vitro 
drug screening assays. In future studies, we also plan to increase the 
complexity and representation of in vivo tissue by adding other 
myocardium human cell populations such as endothelial cells, hCFs and 
smooth muscle cells, all with key roles in AMI physiology. 
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Human Cardiac Stem Cells (hCSCs) transplantation is arising as a novel 
therapy option for acute myocardial infarction (AMI) patients. The 
majority of the studies reported point to paracrine signaling as the main 
effector in hCSCs activation and regenerative capacity. However, the 
mechanisms of action of these cells in response to AMI paracrine context 
are still poorly understood. In the present study, a quantitative proteomics 
analysis was employed to investigate hCSC response to paracrine 
factors released by human cardiomyocytes (hCMs) in response to an in 
vitro AMI Ischemia/Reperfusion (I/R) injury. A total of 714 proteins were 
quantified, from which 86 were differentially expressed, including 63 
proteins up-regulated and 23 down-regulated in hCSCs exposed to hCM 
I/R injury conditioned media vs hCSCs exposed to control hCM 
conditioned media. Bioinformatics functional analysis revealed up-
regulation of proteins involved with endocytosis, paracrine signaling, 
proliferation, migration and stress response. This work provides an 
insight into hCSC biology in response to paracrine cues derived from 
hCMs upon I/R injury, and the data generated herein constitutes a rich 
resource for further studies aiming at potentiating the regenerative 
properties of these cells. 
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Acute myocardial infarction (AMI) and the inherent tissue damage 
caused by Ischemia/Reperfusion (I/R) injury is one of the biggest causes 
of death in developed countries (Benjamin et al., 2017). In response to 
the I/R stress, cardiomyocytes (CMs), the main functional cellular unit of 
the myocardium (Pinto et al., 2016; Zhou and Pu, 2016) secrete an array 
of signaling vesicles (Gupta and Knowlton, 2007; Yu et al., 2012; Ribeiro-
Rodrigues et al., 2017; Loyer et al., 2018), cytokines, chemokines and 
growth factors (Torella et al., 2007; Li et al., 2014; Ong et al., 2015) 
which together with the produced reactive oxygen species and I/R injury 
physico-chemical changes recruit immune cells to the site of injury. Such 
molecules have also been proposed to activate resident cardiac stem/ 
progenitor cell (CSC) populations.  
Since their discovery by Beltrami and colleagues (Beltrami et al., 2003), 
CSCs have been increasingly receiving more and more attention due to 
their regenerative properties. CSCs have been reported to proliferate and 
migrate to the site of injury upon I/R, releasing paracrine signals with 
beneficial effects on CM survival and reduction of inflammation. Such 
properties have been demonstrated in several preclinical trials focused 
on endogenous CSC activation with growth factors (Urbanek, Rota, et al., 
2005a; Ellison et al., 2011; Koudstaal et al., 2014; O’Neill et al., 2016; 
Blanco Blazquez et al., 2017) and transplantation of CSCs in animal 
models of AMI (meta-analysis in Zwetsloot et al., 2016). However, so far 
clinical studies have not demonstrated the same level of functional 
results, still lacking a robust benefit over standard-of-care. One of the 
reasons pointed to the lack of success in the translation from animal 
studies to the clinic is the limited understanding of human CSCs (hCSCs) 
regenerative mechanisms of action (Mathur et al., 2017).  




Several studies have been conducted to better understand CSC 
regenerative biology (Stastna et al., 2010; Albulescu et al., 2015; Sharma 
et al., 2015; Park et al., 2016; Torán et al., 2017). However, while 
paracrine communication is considered as the main player in the 
activation and response of this cell population, most studies do not 
evaluate the important contribution of the paracrine milieu resultant from 
injured CMs upon AMI.  
In order to investigate the effect of human CM secretome upon I/R injury  
on hCSCs, we incubated hCSCs with conditioned medium from humsn 
pluripotent stem cell derived CMs (hiPSC-CMs) that were cultured as 
three-dimensional (3D) aggregates in stirred-tank bioreactors and 
subjected to an in vitro I/R injury setup (Chapter III). hCSC proteome 
was characterized by a non-targeted label-free quantitative proteomics 
approach (SWATH-MS, sequential window acquisition of all theoretical 
mass spectra mass spectrometry). In total, 714 proteins were quantified, 
including 86 proteins differentially expressed between hCSCs incubated 
with control and hiPSC-CM I/R injury conditioned medium. Functional 
analysis revealed an upregulation of proteins associated with migration, 
proliferation, paracrine signaling and endocytosis. 
 
2. Material and Methods 
2.1. Generation of hiPSC-CM I/R Conditioned Media 
hiPSCs were differentiated to 3D hiPSC-CM aggregates and subjected to 
I/R injury in a bioreactor setup as previously described (please see 
Chapter III for details). Conditioned medium (serum free) from both insult 
and control bioreactors were collected at the end of reperfusion phase, 
centrifuged (1,000xg, 5 min) to remove dead cells and debris, and stored 





2.2. hCSC cell culture 
CSCs were obtained from human right atria appendage myocardial 
tissue, isolated and characterized as described elsewhere (Lauden et al., 
2013). Cells were cultured at 37 °C in humidified atmosphere (5% CO2, 
3% O2) in CM001-R medium composed by DMEM:F12: Neurobasal 
medium (1:1), supplemented with 1% penicillin streptomycin, 10% fetal 
bovine serum (FBS) embryonic stem cell-qualified, N2 supplement (1X), 
B27 supplement (1X), 0.9 mM l-glutamine, 50 μM β-mercaptoethanol 
(Sigma), insulin transferrin selenium (0.5X), 10 ng/mL bFGF, 20 ng/mL 
EGF-I and 30 ng/mL IGF-II (Prepotech), (all percentages in v/v). Medium 
was replaced by 50% every 3 days. Cells were subcultured when about 
80% confluent using Tryple™ Select Enzyme for 5 minutes at 37 °C. 
Cells were used at passages 7–8. Three different donors were analyzed: 
hCPC1 (57 years old, male), hCPC03 (78 years old, mal) and hCPC04 
(17 years old, female). All cell culture reagents were purchased from 
Gibco, Life Technologies unless otherwise stated. 
2.3. hCSC proliferation 
hCSCs were plated at 1,5x104 cell/cm2 in complete CM001-R medium. 
After 24h, medium was exchanged by CM001-R medium without FBS.  
hCSC number was accessed by nuclei count with crystal violet solution 
staining after 3 days of incubation. Briefly, cells were resuspended in 
lysis buffer (0.1% Triton X-100 in 0.1M citric acid) directly in culture wells 
and incubated at 37°C for at least 48 h. Nuclei were stained with crystal 
violet dye (0.1% v/v in lysis buffer) and the total number of nuclei counted 
in a Fuchs-Rosenthal hemocytometer chamber. Fold increase in hCSC 
number was calculated as the ratio between the cell number at the 
experimental time point assayed and inoculated number of cells. 
 




2.4. Quantification of growth factors 
hCSCs were plated at 1,5x104 cell/cm2 in complete CM001-R medium. 
After 24h, medium was exchanged by CM001-R medium without FBS.  
After 3 days of incubation, quantification of growth factors CXCL6 and 
IGF-1 in hCSCs conditioned medium was performed by ELISA. Human 
Quantikine ELISA kit (R&D Systems) were used according to 
manufacturer’s instructions. Optical density was measured in 96-well 
plates using a microwell plate reader (Infinite 200 PRO NanoQuant 
TECAN). 
2.5. Incubation of hCSCs with I/R Conditioned Media 
hCSCs were plated at 1,5x104 cell/cm2 in complete CM001-R medium. 
After 24h, medium was exchanged by hiPSC-CM conditioned media.  A 
control with non conditioned basal CM001-R (without FBS) was 
maintained in parallel. After 3 days in culture, the impact of hiPSC-CM 
conditioned media was evaluated regarding hCSC whole proteome. Cells 
were cultured at 37°C in humidified incubators (5% CO2, 3% O2). The 
experimental workflow is illustrated in figure 4.1. 
2.6. Quantitative whole proteome analysis 
After 3 days in culture with hiPSC-CM conditioned media, hCSCs were 
harvested (Tryple™ Select Enzyme for 5 minutes at 37°C) and washed 
twice with DPBS by centrifugation. Cell pellets were placed at −80 °C 
until further proteomic analysis. Proteins were extracted, quantified and 
processed from cell pellets as described elsewhere (Abecasis et al., 
2017). Briefly, cell pellets were resuspended in lysis buffer [50 mM Tris 
(pH 7.8); 250 mM Sucrose; 2 mM EDTA] with protease inhibitors and 
incubated on ice for 10 min. Cells were lysed with 30 passes through the 





membrane proteins were pelleted and removed by centrifugation at 1,000 
x g for 10 min at 4 °C and total protein amount in the supernatant was 
quantified using a Microplate BCA Protein Assay Kit (Thermo Scientific).  
Proteins were digested in gel as described elsewhere (Soares et al., 
2016). Briefly, protein bands were distained with 50% (v/V) acetonitrile, 
reduced with 10mM DTT, alkylated ith iodoacetamide 55mM, and 
digested at 37°C with 6.7 μg/mL trypsin.   
2.6.1. Generation of the spectral reference library 
Each sample (2.5 μg) was used for information-dependent acquisition 
(IDA) analysis by NanoLC-MS using TripleTOF 6600 (ABSciex). A 
reversed phase nanoLC with a trap and elution configuration, using a 
Nano cHiPLC Trap column (200 μm × 0.5 mm ChromXP C18-CL 3 μm 
120 Å) and nano column (75 μm × 15 cm ChromXP C18-CL 3 μm 120 Å) 
was performed.  Water with 0.1% (v/v) formic acid (solvent A) and 
acetonitrile with 0.1% (v/v) formic acid (solvent B) were used. Samples 
were loaded in the trap column at a flow rate of 2 μL/min for 10 min using 
100% (v/v) solvent A. Peptide separation was performed in the nano 
column at a flow rate of 300 μL/min applying a 90 min linear gradient of 
5% to 30% (v/v) of solvent B. IDA scanning full spectra (400–2000 m/z) 
for 250 ms. The top 40 ions were selected for subsequent MS/MS scans 
(150–1800 m/z for 50 ms each) using a total cycle time of 2.3 s. The 
selection criteria for parent ions included a charge state between +2 and 
+5, and counts above a minimum threshold of 125 counts per second. 
Ions were excluded from further MS/MS analysis for 12 s. Fragmentation 
was performed using rolling collision energy with a collision energy 
spread of 5. The spectral library was created by combining all IDA raw 
files using ProteinPilot™ software (v5.0 ABSciex) with the Paragon 
algorithm and with the following search parameters: search against 




Homo sapiens from Uniprot/SwissProt database (version 03/2018); 
trypsin digestion; iodoacetamide cysteine alkylation; through identification 
efforts. After a false discovery rate (FDR) analysis, only FDR<1% were 
considered. The output of these searches, in the form of a group file was 
used as the reference spectral library.  
2.6.2. SWATH-MS analysis and targeted data extraction 
For quantitative analysis, 2.5 μg of each sample were subjected to three 
SWATH runs. Similar chromatographic conditions to the previously 
described IDA run were used. The mass spectrometer was operated in a 
cyclic product ion data independent acquisition (DIA). A variable windows 
calculator (SWATH Variable Window Calculator_V1.0, AB SCIEX) and 
SWATH acquisition method editor (AB SCIEX) were used to setup the 
SWATH acquisition. A set of 32 overlapping windows (containing 1 m/z 
for the window overlap) was constructed, covering the precursor mass 
range of 400 – 1200 m/z. A 50 ms survey scan was acquired at the 
beginning of each cycle, and SWATH MS/MS spectra were collected for 
96 ms resulting in a cycle time of 3.172 s. Rolling collision energy with a 
collision energy spread of 15 was used. The spectral alignment and 
targeted data extraction of DIA samples were performed using PeakView 
v.2.1 (AB SCIEX; Framingham, US) with the reference spectral library. 
For data extraction the following parameters were used: six 
peptides/protein, six transitions/peptide, peptide confidence level of 
>99%, FDR threshold of 1%, excluded shared peptides, and extracted 
ion chromatogram (XIC) window of 10 min and width set at 20 ppm, as 
previously described (Cunha et al., 2017; Simão et al., 2018). A total of 
714 proteins were quantified under these conditions. The full list of 






2.6.3. Proteomic data analysis 
To identify differentially expressed proteins, student’s T test analysis was 
performed using GraphPad Prism6 (GraphPad Software Inc., California, 
USA). Resulting p values and fold changes were used to define up- and 
down- regulated proteins. Differentially expressed proteins were defined 
as those which showed a fold change greater than 1.5 (up-regulated) or 
lower than 0.67 (down-regulated) and p values lower or equal to 0.05. 
Hierarchical clustering heat map analysis was performed using Perseus 
software environment (Tyanova et al., 2016). Pathway analysis was 
performed using Ingenuity Pathway Analysis software (IPA, Quiagen, 
Germany) by uploading the entire quantified protein list (only proteins 
with p value≤0.05) and the respective fold change. Statistically significant 
representation of biological functions and canonical pathways was 
identified based on IPA p-value, displayed as –log(p-value). This 
probability score is calculated taking into account the total number of 
proteins known to be associated with a given function or pathway, and 
their representation in the experimental dataset. Prediction of inhibition 
and activation of biological functions and canonical pathways was based 
on IPA z-score, a statistical measure of the match between expected 
relationship direction and observed protein expression resulting in 
activation (z≥2) or inhibition (z≤-2) of the respective pathway. All pathway 
figures were constructed using Servier medical art images, licensed 









3. Results  
 
In this study we characterized the effect of the secretome of injured 
hCMs in hCSCs protein expression profile. hiPSC-CM 3D aggregate 
cultures were exposed to a stirred-tank bioreactor-based in vitro I/R injury 
model, which demonstrated success to recapitulate several hallmarks of 
hCM response to AMI, including loss of hCM viability, disruption of 
sarcomere and mitochondria ultra-structure and the secretion of several 
pro-inflammatory, pro-migratory and pro-angiogenic cytokines (Chapter 
III).  
 
hCSCs were incubated with either basal medium or conditioned medium 
from control hiPSC-CM aggregates (CTL) or from hiPSC-CM aggregates 
I/R injury (Insult) cultures. After 3 days of incubation, hCSCs were 
harvested and analyzed by label-free quantitative unlabeled proteomic 
analysis (SWATH-MS). In total, 714 proteins were quantified in all 
samples (full list of proteins in supporting information file 4.1). Biological 
canonical pathway and functions enrichment analysis was performed 







Figure 4.1. Experimental design and quantitative proteomic workflow. Human 
induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) conditioned media 
(pool of 2 biological replicates) from Ischemia/Reperfusion (I/R) injury and control (CTL) 
bioreactor setups were incubated with cultures of human cardiac stem/progenitor cells.  
 
Upon SWATH, we verified by Principal Component Analysis (PCA) 
(figure 4.2) that protein expression profile of one of the three biological 
replicates analyzed (corresponding to hCSCs isolated from three 
different donors) did not cluster correctly. Therefore, we decided to 
exclude this donor (donor hCPC1) from all the functional proteomic 
analysis done. Moreover, we observed a decreased proliferation rate as 
well as a lower IGF-1 and CXCL6 secretion of this donor (figure 4.3). 





Figure 4.2. Principal Component Analysis (PCA) of all samples, including technical 
and biological replicates (PCA settings: Unsupervised; Weighting – None; Scaling – 
Pareto). Scores for PC1 (39.4%) versus PC2 (18.8%) are displayed. Samples are 
grouped according to the experimental condition (Light Blue: hCSCs incubated with basal 
medium, BasalM; Dark Blue: hCSCs incubated with control hiPSC-CM conditioned 
medium, CondM CTL; Red: hCSCs incubated with I/R injury hiPSC-CM conditioned 
medium, CondM Insult). The effect of CondM CTL vs BasalM (blue arrows) and CondM 
Insult vs CondM CTL (red arrows) are indicated.  
 
 
Figure 4.3. hCSC donors analyzed present different characteristics.  (A) Fold 
increase in hCSC cell number; (B) IGF-1 and (C) CXCL6 concentration measured in 
hCSC conditioned media. *P<0.05; ****P<0.0001, ANOVA Fisher’s LSD test. Error bars 





3.1. Differentially proteome profile in hCSCs exposed to hiPSC-
CM conditioned media (control conditions) 
Firstly, to evaluate the impact of hiPSC-CM secretome (control 
conditions) on hCSC protein expression, we compared the proteome of 
hCSCs incubated in hiPSC-CM CTL conditioned medium vs hCSCs 
incubated in basal medium (figure 4.4). From the 714 proteins quantified, 
31 were classified as down-regulated (fold change≤0.67, p-value≤0.05) 
and 15 were classified as up-regulated (fold change≤1.5, p-value≤0.05) 
in hCSCs exposed to hiPSC-CM CTL conditioned medium (figure 4.4B, 
supporting file 4.2).  
 
Figure 4.4. Quantitative proteomic analysis of hCSC incubated with hiPSC-CM 
control conditioned medium in comparison with hCSCs incubated with basal 
medium. (A) Vulcano plot representing the proteins identified and quantified by SWATH-
MS. This analysis enabled the identification and quantification of 714 proteins, including 
differentially expressed proteins (-log (p-value) ≤1.3): 31 down-regulated (log2(FC)≤-0.58, 
green) and 15 up-regulated (log2(FC)≥0.58, red) in hCSCs incubated with hiPSC-CM CTL 
conditioned medium. (B) list of down- and up-regulated proteins. (C) Canonical pathways 
and functions inhibition (z-score≤-2, green) and activation (z-score≥2, red) scores. Only 
pathways and functions with p-value≤0.05 (-log p -value ≥1.3) were considered. FC: fold 
change. 




Functional analysis (figure 4.4C) showed a significant inhibition of several 
canonical functions and pathways associated with cell movement and 
migration, as well as inhibition of EIF2 signaling, a pathway associated 
with endoplasmic reticulum stress response (Groenendyk, Agellon and 
Michalak, 2013). RhoGDI signaling, a pathway associated with 
suppression of cancer cell migration (Gildea et al., 2002; Xiao et al., 
2014) was also up-regulated. On the other hand, one canonical function 
related with higher cell metabolism was identified as activated by IPA 
analysis (figure 4.4C) (full list of scores and z-scores of canonical 
pathways and disease functions in supporting information file 4.3).  
 
3.2. Differential proteome profile in hCSCs exposed to hiPSC-CM 
I/R injury paracrine factors 
Following this first comparative analysis, a more exhaustive proteomics 
characterization of hCSC incubated with hiPSC-CM Insult and CTL 
conditioned medium was carried out.  
Hierarchical clustering of proteomic data revealed that biological 
replicates clustered together in function of the experimental condition 
(Insult vs CTL conditioned medium), demonstrating experimental 
reproducibility (figure 4.5A) and that culture conditions had more impact 
in hCSC proteome changes than variability between the two donors. 
From the total 714 proteins identified, 63 were classified as up-regulated 
(fold change≥1.5, p-value≥0.05) and 23 as down-regulated (fold 
change≥0.67, p-value≥0.05) in hCSCs incubated with Insult conditioned 







Figure 4.5. Quantitative proteomic analysis between hCSCs incubated with 
Ischemia/Reperfusion injury (insult) conditioned media and hiPSC-CM control 
(CTL) conditioned media. (A) Hierarchical clustering (Pearson correlation) heatmap of 
intensities of proteins (n=714). Perseus z-score values were color coded from green 
(down-regulation) to red (up-regulation).Heat map analysis was performed for the 
biological (hCPC03 and hCPC04) and technical (A, B, C) replicates. (B) Vulcano plot 
representing the proteins identified and quantified by SWATH-MS. This analysis enabled 
the identification and quantification of 714 proteins, including differentially expressed 
proteins (-log(p-value)≤1.3) between control and Insult condition: 23 down-regulated 
(log2(FC)≤-0.58, green) and 63 up-regulated (log2(FC)≥0.58, red). (C) List of down- and 
up-regulated proteins. FC: fold change. 
 
 




Functional analysis revealed that several biological functions and 
canonical pathways were enriched (z-score≥2), including terms 
associated with cell migration and proliferation (table 4.1, figure 4.6), 
paracrine signaling (table 4.1, figure 4.6, 4.7) and stress response (table 
4.1, figure 4.7). On the other hand, RhoGDI signaling, reported to have a 
suppressive role in metastasis of bladder (Gildea et al., 2002) and breast 
cancer (Xiao et al., 2014) was identified with a z-score of -2.71, indicating 
the inhibition of this pathway (table 4.1, figure 4.6), (full list of z-scores of 
canonical pathways and disease functions in supporting information file 
4.5).  
 
Table 4.1. Canonical pathways and functions inhibition (z-score≤-2, green) and activation 
(z-score≥2, red). Only functions and pathways with –log(p-value)≥1.3 are represented. 
 
From the subset of up-regulated proteins, we also identify 2 proteins 
associated with hypoxia induced HIF1-α signaling (HSP90A, and LDHA) 
(figure 4.7, supporting information file 4.4); 6 proteins associated with 
remodeling of cell-cell junctions (ARP2, ARC1B, TBB3, TBB6, and 





endocytosis (ARP2, AP2M1, ARC1B, CLH1, ITB1, RB11B, and RB11B) 
(figure 4.8, supporting information file 4.4). 
 
Figure 4.6. hCSCs activate pro-migratory and proliferation associated pathways. 
Proteomic analysis revealed that Cdc42, Rac, PAK, Rho, CXCR4, and Ephrin Receptor 
pathways are activated in hCSCs exposed to hiPSC-CM I/R injury conditioned media, 
while RhoDGI signaling is inhibited. Proteins are depicted as green (negative fold 
change), red (positive fold change) and grey (not quantified in our analysis). Only proteins 
with p-value≤0.05 were used in the analysis.  
 
 
Figure 4.7. hCSCs activate stress response and proliferation associated pathways. 
Proteomic analysis revealed that HIF1-α, EIF2 and NFR2 pathways are activated in 
hCSCs exposed to hiPSC-CM I/R injury conditioned media. Proteins are depicted as 
green (negative fold change), red (positive fold change) and grey (not quantified in our 
analysis). Only proteins with p-value≤0.05 were used in the analysis.  





Figure 4.8. hCSCs activate clathrin-mediated endocytosis mechanisms. Proteins are 
depicted as red (positive fold change) and grey (not quantified in our analysis).  Only 
proteins with p-value≤0.05 were used in the analysis.  
 
Upstream regulator analysis (figure 4.9) also indicated activation of 
stress response HSP90B protein. 
 
Figure 4.9. Upstream regulator analysis revealed activation of stress response 
regulator HSP90. Proteins are depicted as red (positive fold change) and grey (not 






hCSCs regenerative properties have been extensively described in 
several AMI animal models (meta-analysis in Zwetsloot et al., 2016). 
Such findings have already been used and translated into several clinical 
trials (reviewed in Chapter I). Although with promising results, several 
factors still hamper more robust and beneficial effects of CSC 
transplantation and endogenous CSC activation based strategies, 
including low survival and low tissue engraftment of transplanted cells as 
well as lack of proliferation and migration of endogenous CSCs.  
In this study we applied SWATH-MS technology to characterize and 
quantify proteomic changes in hCSCs upon incubation with hiPSC-CM 
conditioned medium obtained in a context of I/R injury, in order to expand 
the knowledge on how hCSC respond to the milieu of growth factors, 
chemokines and extracellular vesicles released in the heart tissue upon 
AMI. 
Upon SWATH analysis, we verified by PCA that protein expression 
profile of one of the three biological replicates analyzed did not cluster 
correctly. Moreover, we also observed a decreased proliferation rate as 
well as lower IGF-1 and CXCL6 (pro-migratory and pro-angiogenic 
cytokine) (Torán et al., 2017) secretion of this donor. Such event is 
probably related with inherent donor to donor variability. In fact, several 
studies demonstrate that donor dependent factors such as genetic 
background, co-morbidities and age affect hCSCs response as well as 
regenerative potential, including secretory profile, proliferation, and 
migration capacity (Dimmeler and Leri, 2008; Wu et al., 2016; Agarwal et 
al., 2017; Sharma et al., 2017).  
 




Characterization of hiPSC-CM aggregates secretory profile upon I/R 
injury (reperfusion conditioned medium, Chapter III) revealed that 
hiPSC-CMs secreted pro-inflammatory, pro-angiogenic and pro-migratory 
proteins, some previously identified as increased upon AMI in vivo and in 
vitro setups. In fact, by incubating hCSCs in this hiPSC-CM conditioned 
medium resulting from I/R injury setup, we registered the activation of 
several paracrine signaling pathways in hCSCs, including chemokine and 
neuregulin signaling, previously shown to be activated in hCSCs upon 
physiological stress (Torella et al., 2007). Moreover, several proteins 
associated with clathrin-mediated endocytosis were found as 
up-regulated, indicating that hCSCs may use this pathway to increase 
the rate of paracrine signals internalization when exposed to the injury 
derived conditioned medium. Also, stress response has been associated 
with regulation of endocytic pathways (reviewed in Di Fiore and von 
Zastrow, 2014).  
hCSCs response also translated into upregulation of proteins associated 
with activation of proliferation, migration and stress response pathways. 
Proliferation of endogenous CSCs has been previously shown to 
increase upon AMI in adult mice (Ellison et al., 2013; Valiente-Alandi et 
al., 2016) and human (Urbanek, Torella, et al., 2005) hearts. Proteomics 
functional analysis revealed activation of several pro-proliferation 
pathways, including Thrombin (Fabrizi et al., 2011) and receptor tyrosine 
kinases (RTK) associated PAK signaling. Moreover, EIF2 and CXCR4 
signaling, also related with activation of cell proliferation were identified 
as upregulated as well. CXCR4-Rac signaling is also a key pathway 
involved in cell migration and homing to injury of several cell types (Shen 
et al., 2011; Penn et al., 2012) including CSCs (Sanada et al., 2014). 
Other pathways related with cell motility and migration were also found 





be associated with hCSC motility (Goichberg et al., 2013). Moreover, 
several proteins associated with remodeling of cell-cell junctions were 
also quantified as up-regulated. Activation and migration of cardiac stem 
cells in response to AMI has been reported by several authors in 
response to several molecules secreted by CMs, including CTGF 
(Stastna and Van Eyk, 2012), SDF-1 (Ceradini et al., 2004; Rota et al., 
2008), TNF (Al-Lamki et al., 2013), EGF and HGF (Urbanek, Rota, et al., 
2005b; Aghila Rani and Kartha, 2010; Boucek et al., 2015). In fact, we 
identified HGF and TNF-α as significantly upregulated in hiPSC-CM 
insult conditioned media (Chapter III). Moreover, CCL5, a chemokine 
previously associated with migration of adult stem cells (Bonaros et al., 
2008; Phi et al., 2017), and GCSF, known for bone marrow stem cells 
mobilization (Deindl et al., 2006) were also identified as secreted by 
hCMs upon I/R injury (Chapter III), reinforcing the pro-migratory profile of 
the hiPSC-CM conditioned media and its effect on hCSCs.  
Proteins associated with several stress response pathways including 
EIF2, NFR2 signaling and activation of heat shock protein 90 (HSP90, a 
regulator of HIF1-α signaling) were also identified as upregulated in 
hCSCs exposed to I/R injury paracrine factors. HIF-1α signaling has 
been shown to be activated in hCSCs in response to I/R injury (Ceradini 
et al., 2004; Rota et al., 2008). 
While in hCSCs exposed to hiPSC-CM insult conditioned medium we see 
an activation of cell migration, proliferation and stress response 
pathways, when comparing hCSCs exposed to basal medium with 
hCSCs exposed to CTL hiPSC-CMs conditioned medium an opposite 
trend was registered. Namely, we observed inhibition of migration and 
stress-associated EIF2 signaling. Inhibition of migration is associated 
with quiescence and stemness state maintenance (Cheung and Rando, 
2013; Rumman, Dhawan and Kassem, 2015). We also registered 




increase in catabolism of protein pathway that also relates with regulation 
of cellular quiescence. Such results open the hypothesis that CM 
secreted factors in homeostasis conditions also plays a role in the 
regulation of CSC quiescence regulation, besides low oxygen and other 
stem cell niche factors (Leri et al., 2014; Bellio et al., 2016).  
Our results suggest an hCSC response to I/R injury hiPSC-CM-derived 
factors focused on paracrine activation of migration, proliferation and 
stress response mechanisms, which is in line with the findings described 
in the literature. Moreover, this work adds relevant information of 
activation of several pathways, that, to our knowledge, have not been 
previously described in hCSC regenerative action mechanisms, including 
activation of EIF2 signaling. Future studies should include an in-depth 
characterization of hiPSC-CM aggregates secretory profile as well as 
validation of the hCSC pathways described using complementary 
targeted methodologies and functional assays.  
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Abstract 
Transplantation of allogeneic human cardiac/stem progenitor cells 
(hCSC) is currently being tested in several phase I/II clinical trials as a 
novel and promising therapy for restauration of myocardial tissue function 
in acute myocardial infarction (AMI) patients. Previous findings 
demonstrate that these cells have an immune suppressive profile, 
interacting with different populations from the immune system, resulting 
in overall attenuation of myocardium inflammation. However, 
transplanted hCSCs are still recognized and cleared from the injured site 
impairing long retention times in the tissue that could translate into a 
higher clinical benefit.  
In this work, through modeling allogeneic hCSC/T-lymphocyte interaction 
in vitro by direct contact, transwells inserts and hCSC conditioned 
medium, our results demonstrate that hCSCs exert an immune-
suppressive effect on T-lymphocyte proliferation not only through the 
previously described cell-contact dependent PD1/PDL-1 axis but also 
through a paracrine mechanism associated with indoleamine 2,3-
dioxygenase (IDO) enzyme mediated tryptophan metabolism. Such 
findings constitute a step forward in better understanding the 
mechanisms of action of transplanted hCSCs in allogeneic settings. 
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Human cardiac/stem progenitor cells (hCSCs) transplantation is arising 
as a promising therapy for acute myocardial infarction (AMI), one of the 
most prevalent causes of death worldwide (Benjamin et al., 2017). CSCs 
are considered by several authors as the preferred candidate cell source 
for AMI patients, mainly due to their function in the heart, well-
documented paracrine regenerative properties (Chimenti et al., 2010; 
Sharma et al., 2017) and the success of transplantation studies in 
myocardial infarction animal models (Tang et al., 2010; Crisostomo et al., 
2015). 
Such success in preclinical stages has led to a rapid translation to the 
clinic, and several phase I and II clinical trials using hCSCs as an 
autologous therapy emerged (e.g. SCIPIO and CADUCEUS trials). 
Autologous transplantation, although carrying lower immunogenicity 
risks, holds several limitations. Not only might the quality of the cells be 
compromised by patients age and co-morbidities (Dimmeler and Leri, 
2008; Wu et al., 2016; Sharma et al., 2017), but also due to logistic, 
economical and time-constraints issues. To overcome such limitations, in 
the last years the field has been moving towards allogeneic CSC sources 
(e.g. ALLSTAR and CAREMI trials).  
Clinical trials have demonstrated physiological improvements, increase in 
viable tissue and in heart functional outcome (Cahill, Choudhury and 
Riley, 2017). However, an obstacle still preventing CSCs to meet their full 
clinical potential and to provide evident clinical benefit over standard-of-
care is their limited retention and engraftment in the heart (Hong and 
Bolli, 2014; Mathur et al., 2017), a problem aggravated in the allogeneic 
setting (Huang et al., 2010; Malliaras et al., 2012). 




Upon AMI, an immune response is triggered, that although essential for 
proper tissue remodeling and stabilization, carries unwanted 
inflammatory mediated damage (Epelman, Liu and Mann, 2015) and, in 
the case of cell therapy approaches, might be also involved in the 
elimination of injected cells. Effective activation of T-cells, one of the 
main mediators of inflammatory damage upon AMI,requires simultaneous 
engagement of T-cell receptor (TCR) and CD28 receptor. TCR binds to 
antigens presented in major histocompatibility complex (MHC, human 
leukocyte antigens, HLA in humans) and CD28 receptor binds to B7 
(CD80/CD86) costimulatory molecules. hCSCs express HLA class I (that 
attract killer cytotoxic T-cells), but very low levels of HLA class II 
molecules (that stimulate antibody producing B-cells), and do not express 
costimulatory molecules CD80/CD86 (Lauden et al., 2013), presenting 
therefore a weak immunogenic profile. Besides depicting the immune 
phenotype of hCSCs, several studies have shed some light on how 
hCSCs interact with monocytes (Dam et al., 2017), natural killer cells 
(Boukouaci et al., 2014) and T-lymphocytes (Lauden et al., 2013; van 
den Akker et al., 2018). All these studies suggest that the immunologic 
behavior of allogeneic hCSCs might be linked to their therapeutic effects 
rather than eliciting deleterious immune reactions, with an 
immunomodulatory effect resulting in attenuation of myocardium 
inflammation and prevention of adverse scar tissue formation. Also, 
programmed death ligand 1 (PDL-1) mediated cell-cell interaction was 
identified as one of the main mechanisms in hCSC immunomodulatory 
properties, promoting stimulation of regulatory T-cells and subsequent 
inhibition of T-lymphocyte activation and proliferation (Lauden et al., 
2013).  
Besides direct cell-cell interactions, paracrine immunomodulatoy effects 





Akker et al., 2018). Moreover, tryptophan (Trp) metabolism through the 
enzymatic activity of indoleamine 2,3-dioxygenase (IDO) has been 
described as a key immunosuppressive mechanism for human adipose-
derived mesenchymal stem cells (hASCs) (DelaRosa et al., 2009; Menta 
et al., 2014; Mancheño-Corvo et al., 2015), a cell type already used in 
several allogeneic cell transplantation studies (Bajek et al., 2016).  
Aiming at better understanding the immunomodulatory mechanisms of 
hCSCs in an allogeneic setting, we further investigated the capacity of 
hCSCs to inhibit the proliferation of T-lymphocytes in vitro. Taken 
together, our results add to the knowledge on the tolerogenic immune 
behaviour of hCSCs, showing that hCSC mediated immune modulation is 
not dependent exclusively on the PDL-1/ programmed cell death-1 (PD-
1) pathway axis, but also via Trp degradation by IDO enzyme action. 
Such findings open new avenues in designing novel hCSC allogeneic 
transplantation therapies for AMI patients, including strategies to promote 
a higher hCSC engraftment and longer residence time in the tissue. 
 
2. Materials and Methods 
2.1. hASCs isolation and culture 
Human ASCs were isolated from adipose tissue lipoaspirates obtained 
from healthy adult donors as described elsewhere (Mancheño-Corvo et 
al., 2015). hASCs specific surface markers were verified by flow 
cytometry: hASCs were positive for HLA-I, CD90, and CD105, and 
negative for HLA-II, CD40, CD80, CD86, and CD34. The following 
primary antibody dilutions were used: CD105 (1:50), remaining (1:10). A 
total of ten thousand events were acquired using a FACSCalibur (BD 




Biosciences). Percentage of positive cells was calculated using the FSC-
express software. 
Cells were cultured at 37°C in humidified incubators (5% CO2, 3% O2) in 
DMEM medium containing 10% FBS. Medium was replaced every 7 
days. Cells were subcultured when the culture achieved about 90% 
confluency using Trypsin-EDTA 0,05% for 5 minutes at 37°C. Prior to 
immunomodulatory experiments, hASCs were treated with mitomycin-C 
(20 μg/mL) at 37°C for 30 min. All cell culture reagents were purchased 
from Gibco, Life Technologies unless otherwise stated. Cells were used 
at a population doubling level of 14. 
2.2. hCSC isolation and culture 
Human CSCs were obtained from human right atria appendage 
myocardial tissue, isolated and characterized as described elsewhere 
(Lauden et al., 2013). Cells were cultured at 37°C in humidified 
incubators (5% CO2, 3% O2) in Expansion Medium (ExpM, composed by 
DMEM:F12: Neurobasal medium (1:1), supplemented with 1% penicillin 
streptomycin, 10% Fetal Bovine Serum embryonic stem cell-qualified, N2 
Supplement (1X), B27 Supplement (1X), 0.9 mM L-Glutamine, 50 μM β-
Mercaptoethanol (Sigma), Insulin Transferrin Selenium (0.5X), 10 ng/mL 
bFGF, 20 ng/mL EGF-I and 30 ng/mL IGF-II (Prepotech), all percentages 
in (v/v). Medium was replaced by 50% every 3 days. Cells were 
subcultured when the culture achieved about 80% confluency using 
Trypsin-EDTA 0,05% for 5 minutes at 37°C. Prior to immunomodulatory 
experiments, hCSCs were treated with mitomycin-C (20 μg/mL) at 37°C 





hCSCs from 3 different donors were used in this study: hCPC04 
(Female, 17 years), hCSC-40 (Female, 79 years) and hCSC-48 (Female, 
45 years).  Cells were used at passages 4–6. 
2.3. Isolation of hPBMCs 
Blood samples were provided by the National Transfusion Centre of the 
Comunidad Autónoma (Madrid, Spain). Human peripheral blood 
mononuclear cells (hPBMCs) were isolated from the buffy coats by 
density centrifugation gradient using Ficollplaque Plus (GE Healthcare 
Biosciences AB), in accordance with manufacturer instructions. Blood 
samples from 3 different donors were used in the experiments. 
2.4. CFSE labelling 
Proliferation of hPBMCs was accessed with carboxyfluorescein 
succinimidyl ester (CFSE) labeling as previously described (DelaRosa et 
al., 2009). Briefly, cells were washed, resuspended in a 20 µM CFSE 
solution (107 hPBMCs per 200 µL of solution) and incubated under 
constant shaking at 37°C for 10 min. The reaction was stopped by slowly 
adding ice-cold RPMI medium supplemented with 10% FBS (v/v). Cells 
were then cultured overnight, and one aliquot was used to set up and 
control the FL-1 voltage for CFSE. 
2.5. IDO and PDL-1 expression 
hCSCs were seeded in culture well plates and either left unstimulated or 
stimulated with IFN-γ (3 ng/mL). After 24 h and 48 h of culture, cells were 
trypsinized and stained with anti-PDL-1 antibody (2.5:100, ThermoFisher 
Scientific) and anti-IDO antibody (4:100, ThermoFisher Scientific) and 
isotype control IgG (2.5:100, BD Biosciences) using the kit for 




intracellular staining from eBioscience, following the manufacturer’s 
instructions. A total of ten thousand events were acquired using a 
FACSCalibur (BD Biosciences). hASCs were used as a positive control 
IDO expression. 
2.6. Generation of conditioned supernatants 
hASCs (0.2x106) and hCSCs (0.5x106) were seeded per well in 6 well 
plates, treated with mitomycin-C (20 μg/mL, at 37°C for 30 min) and 
cultured in RPMI medium supplemented with 10% FBS (v/v) with or 
without IFN-γ stimulation (3 ng/mL) for 24, 36 and 48 hours. 
Supernatants were collected, centrifuged to remove dead cells and 
debris and stored at -20°C until further use for immunomodulatory 
assays. 
2.7. Immunomodulatory assays 
Immunomodulatory assays experimental design is illustrated in figure 
5.1. Briefly, CFSE-labeled hPBMCs were stimulated with 
phytohemagglutinin (PHA, 1 µg/mL) (Sigma-Aldrich) and cultured in the 
presence of mitomycin C-treated hCSCs at three different ratios 
(hCSC:hPBMC ratios 1:10, 1:17 and 1:25) in RPMI + 10% FBS (v/v).  
Cultures were performed in culture well plates in i) direct contact (DC); ii) 
using transwells (TW) inserts with a 0.4 mm pore size (Corning) to allow 
exchange of soluble factors but separation of both cell types; and iii) 
using hCSCs conditioned medium (Cond.M). Cells were cultured at 37°C 
in RPMI medium supplemented with 10% FBS (v/v), in humidified 
incubators (5% CO2, 3% O2). hASCs were used as a positive control for 
T cell proliferation inhibition via IDO (ratio 1:25 hASCs:hPBMCs). Parallel 





and 96 h (DC and TW experiments) or after 96 h of culture (Cond.M 
experiments), CFSE-labeled hPBMCs were harvested, labeled with 7-
AAD and anti-CD3 antibody, and cell proliferation of the CD3+/ 7-AAD- 
population (viable CD3 T lymphocytes) was evaluated by flow cytometry 
(FACSCalibur, BD Biosciences) according to loss of CFSE signal. A total 
of ten thousand events were acquired using a FACSCalibur (BD 
Biosciences). Division index and percentage of inhibition of proliferation 
were calculated using the FSC-express software. 
 
Figure 5.1. Schematic representation of immunomodulatory assay experiments. 
Carboxyfluorescein succinimidyl ester (CFSE) labeled and phytohemagglutinin (PHA) 
activated human peripheral blood mononuclear cells (hPBMCs) were cultured with 
mitomycin-treated hCSCs/hASCs either in: direct contact (DC); in a transwell support 
(TW); or in contact with mytomicin-C treated hCSCs/hASCs conditioned medium 





 hPBMC population. 
2.8. IDO activity 
IDO enzyme activity was measured by determining both Trp and 
kynurenine (Kyn) concentrations in conditioned medium. About 200 µL of 
conditioned medium was added to 50 mM phosphate buffer and 25 mL of 




2 M trichloroacetic acid. After centrifugation for 10 min at 15,600 g, the 
supernatant was collected and analyzed by high-performance liquid 
chromatography (HPLC), Waters 717plus Autosampler using a Waters 
1515 Isocratic Pump, and a Waters 2487 Dual Absorbance Detector. 
Separation was performed using a C18 4.6 50mm column,(Teknokroma 
Analítica S.A.) in 10 min runs with 40 mM sodium citrate (pH 5.0), 1% 
acetonitrile as mobile phase at a flow rate of 1 mL/min. Trp and Kyn were 
detected at an absorbance of 280 and 360 nm, respectively.  
2.9. Statistical analysis 
Statistical analyses were performed with GraphPad Prism6 (GraphPad 
Software Inc.). All data are shown as mean with standard deviation. Data 
was analyzed by One Way ANOVA Tukey test. P-values below 0.05 
were considered significant. Three different hCSC biological replicates 
(from 3 different donors) were used. 
 
3. Results  
3.1. IDO expression is induced in hCSCs in response to IFN-γ 
We first characterized the hCSC expression of the immune-relevant 
molecules PDL-1 and IDO without and with IFN-γ stimulation 
(representing an inflammatory environment).  
While hASCs only express PDL-1 when activated, hCSCs express PDL-1 
constitutively, and activation with IFN-γ further upregulates its expression 
(figure 5.2). These results are in agreement with the data previously 
reported by Lauden et al., 2013. Neither hCSCs nor hASCs displayed 
any constitutive expression of IDO but both cell types displayed 





PDL-1 upregulation and IDO expression upon IFN-γ activation suggest 
that hCSCs enhance their immunomodulatory profile in an inflammatory 
environment. 
 
Figure 5.2. hCSCs display a favorable immune-suppressive phenotype. 
Representative expression of immune relevant molecules IDO and PDL-1 after 24 and 48 
h in untreated (black line histograms) and IFN-γ activated (red line histograms) cells 
against isotype controls (gray-filled histograms). The percentages (%) of positive cells are 
indicated. hASCs were used as a positive control for IDO expression. hCSC results 
shown for donor hCSC-48. Other donors presented similar results. 
3.2. hCSCs impair activated T lymphocyte proliferation 
Following the characterization of a favorable immune-suppressive 
phenotype of hCSCs, we then examined whether these cells were 
capable of inhibiting T lymphocyte proliferation in an allogeneic setting. 
Stimulated hPBMCs were cultured in direct contact with hCSCs at 
different ratios.  
As previously reported (Lauden et al., 2013), hCSCs do exert an immune 
suppressive role by inhibiting T lymphocyte proliferation. Even though to 
a less extent when comparing with hASCs, hCSCs have a significant 




suppressive effect in T lymphocyte proliferation in a dose-dependent 
manner (figure 5.3). Although no significant difference was registered 
between time points, there is a tendency for higher T lymphocyte 
proliferation inhibition in 96 h vs 72 h of incubation (figure 5.3) in all ratios 
analyzed, suggesting that this effect is also time-dependent. 
 
Figure 5.3. hCSCs inhibit T lymphocyte proliferation in a time and hCSC 
concentration dependent manner. CFSE-labeled hPBMC were stimulated with PHA 
and cultured alone or in direct contact with hCSCs (ratios 1:10; 1:17; 1:25 
hCSC:hPBMC). After 72h (white bars) and 96h (black bars), proliferation of the viable 




) was assayed by loss of CFSE 
staining. Percentage of inhibition of proliferation was determined using FSC Express 
software against proliferation of activated hPBMCs alone. hASCs were used as a positive 
control for T cell proliferation inhibition (ratio 1:25 hASCs:hPBMCs).*P<0.05 **P<0.01 
indicates significant differences between time points. 
3.3. hCSCs immunomodulatory capacity can occur in the 
absence of cell-cell contact 
To evaluate the importance of IDO enzyme and Trp metabolism in the 
immunosuppressive capacity of hCSCs, we carried out T lymphocyte 
proliferation assays in which hCSCs are not in direct contact (DC) with 
hPBMCs, and therefore cannot exert their immunomodulatory activity 
through the PDL-1/PD1 axis.  
We carried out a hCSC:hPBMC co-culture in transwell (TW) setting, 
allowing paracrine interaction between the two cell types. At 72 h of 





exert a significant suppressive effect on T lymphocyte proliferation in TW 
conditions. Moreover, such difference between TW and DC conditions 
was lost after 96 h of incubation (figure 5.4A). 
 
Figure 5.4. hCSCs inhibit T lymphocyte proliferation via a paracrine mechanism. (A) 
CFSE-labeled hPBMC were stimulated with PHA and cultured alone, in direct contact 
(DC) or in a transwell setting (TW) with hCSCs (ratios 1:10 hCSC:hPBMC). (B) 
Concentrations of Trp and Kyn were determined by HPLC in the supernatants. (C) CFSE-
labeled hPBMC were stimulated with PHA and cultured alone or in conditioned medium 
(Cond.M) from hCSCs cultures activated or not with IFN-γ. Conditioned mediums were 
generated for 24 h (white bars), 36 h (grey bars) and 48h (black bars). (D) Concentrations 
of Trp and Kyn were determined by HPLC in the conditioned media. Proliferation of the 




) was assayed by loss of CFSE 
staining after 72 h (white bars) and 96 h (black bars) for TW and DC experiments (A) and 
after 96 h for Cond.M experiments (C). Percentage of cells per generation and % of 
inhibition of proliferation was determined using FSC Express software against 
proliferation of activated hPBMCs alone. hASCs were used as a positive control for T cell 
proliferation inhibition (ratio 1:25 hASCs:hPBMCs).**P<0.01, ***P<0.001, ****P<0.0001 
indicates significant differences between time points; 
¤¤¤
P<0.001, indicates significant 
differences between culture type (CT vs TW); and 
¥¥¥¥
P<0.0001 indicates significant 
differences between -IFN-γ vs + IFNγ. 




Trp metabolism was also accessed by measuring Trp and Kyn (a Trp 
metabolite described as cytotoxic for T lymphocytes, Terness et al., 
2002a)  concentrations in the conditioned mediums. As shown in figure 
5.4.B, Trp is fully depleted already at 72 h in the DC condition, whereas 
in the transwells setting it is also significantly diminished when comparing 
to stimulated hPBMCs alone. Also, the accumulation of Kyn occurred in 
both experimental setups (figure 5.4B). 
Besides TW experiments, hCSC Cond.M was generated for 24 h, 36 h 
and 48 h using control and IFN-γ stimulated hCSCs. Similarly with hASC 
control, hCSCs-derived Cond.M significantly inhibited T lymphocyte 
proliferation, with a significant increase in IFN-γ stimulated cells 
(51.79±11.67 % vs 15.49±8.10 % with 36 h Cond.M; 100±0.00 % vs 
19.01±7.22 % with 48 h Cond.M) (figure 5.4.C). Moreover, Cond.M from 
longer IFN-γ stimulated hCSCs cultures prompted higher inhibition of T 
lymphocyte proliferation (figure 5.4.C). Such findings are also in 
accordance with the Trp and Kyn measurements, in which Trp is 
gradually depleted and Kyn gradually accumulates in the supernatant of 
hCSC cultures (figure 5.3.D). 
 
4. Discussion 
Allogeneic hCSC based therapies continue to be explored as an 
alternative for AMI patients. However, hCSC regenerative medicine 
approaches have yet to prove evident and robust clinical benefit over 
standard-of-care. Although described as having a positive 
immunomodulatory role rather than eliciting further inflammation (Lauden 
et al., 2013; Boukouaci et al., 2014; Dam et al., 2017), one of the main 
challenges to be addressed in hCSC transplantation-based therapies is 





better knowledge of the immunological properties of hCSCs is therefore 
paramount in developing strategies to increase the transplanted cells 
retention time in the myocardium that would consequently increase their 
regenerative benefits. 
hCSCs have been described as having an immune suppressive profile in 
allogeneic settings by directing natural killer cell cytokine secretion 
towards an anti-inflammatory profile and lower cytotoxicity (Boukouaci et 
al., 2014), by modulation of monocytes, macrophages and dendritic cells 
towards an anti-inflammatory phenotype (Dam et al., 2017) and by 
activation of T regulatory lymphocytes with subsequent inhibition of T 
lymphocyte proliferation via PDL-1/PD1 direct cell communication 
(Lauden et al., 2013) as well as via extracellular vesicle-mediated  
paracrine communication (van den Akker et al., 2018). 
In this work, we assayed the immunomodulatory capacity of hCSCs in an 
inflammatory setting by IFN-γ activation and explored the hypothesis of 
paracrine IDO-mediated T lymphocyte proliferation inhibition. 
IFN-γ is highly expressed in inflammation settings (such as after an AMI). 
This pro-inflammatory pleiotropic cytokine is produced primarily by the 
host T lymphocytes in response to antigen recognition and  has also 
shown to induce the expression of immune-relevant molecules in several 
stem cell populations, including neural stem cells (Kulkarni, Ganesan and 
O’Donnell, 2016) and mesenchymal stem cells (Polchert et al., 2008; 
DelaRosa et al., 2009). IFN-γ was shown to cause hCSCs to up-regulate 
expression of both class I and II HLA molecules (Lauden et al., 2013), 
which indicates that their administration into an inflammatory myocardium 
environment might probably increase their recognition and clearance by 
host T lymphocytes. On the other hand, IFN-γ supplementation has also 




previously shown to up-regulate hCSC expression of PDL-1, resulting in 
a hCSC stronger immune-suppressive profile (Lauden et al., 2013). 
IFN-γ activation  has also been correlated with increased IDO expression 
in hMSCs, including hASCs, which in turn has shown to be a key enzyme 
involved in the immunomodulatory capacity of these cells (Li et al., 2014; 
Mancheño-Corvo et al., 2015). IDO exerts its immune effects by 
suppressing T lymphocyte proliferation and promoting T lymphocyte 
death through degradation of Trp, an essential amino acid required for 
cell proliferation and subsequent accumulation of cytotoxic Trp 
metabolites (including Kyn) (Terness et al., 2002; Fallarino et al., 2003). 
IFN-γ also causes the activation of tryptophanyl-transfer RNA synthetase 
(WRS, a aminoacyl synthetase that incorporates Trp into proteins) in 
IDO-expressing cells, which has been postulated to be a compensatory 
mechanisms, allowing IDO expressing cells to better cope with Trp 
depletion (Mellor et al., 2003). 
In our results, we show that IFN-γ activation is correlated with an 
increase in hCSC PDL-1 and IDO expression. Although with an overall 
weaker immune-suppressive profile when comparing to hASCs, we also 
showed that hCSCs are able to inhibit T lymphocyte proliferation in a 
time and hCSC cell concentration dependent manner when in direct co-
culture.  
Moreover, we showed Trp depletion and Kyn accumulation in activated 
hCSC Cond.M. Concordantly, stimulated hCSC Cond.M. showed a 
superior anti-proliferative effect when compared to unstimulated hCSCs 
Cond.M, suggesting a relevant role of IDO-mediated Trp metabolism in 
the immunomodulatory paracrine effect of hCSCs. 
By co-culturing hPBMCs and hCSCs we also show no significant 





proliferation, suggesting that paracrine–mediated are in fact the central 
mechanism of action of hCSCs. 
These findings provide evidence, that although playing a role in the 
process, PDL-1 mediated T regulatory cell modulation is not the 
exclusive neither the central mechanism involved in T lymphocyte 
proliferation inhibition. This finding further supports the prominent 
paracrine-based beneficial CSC activities in the host tissue. 
In this work, we give evidence of Trp metabolism as a novel mechanism 
involved in the hCSC mediated T lymphocyte proliferation suppression 
properties. We also hypothesize that similarly to what is already 
described for hASCs (DelaRosa et al., 2009; Menta et al., 2014; 
Mancheño-Corvo et al., 2015), IDO is the main player in hCSC Trp 
metabolism in inflammation settings. Complementary studies to further 
test this hypothesis should include analysis of WRS expression, Trp 
supplementation and IDO inhibition experiments to further validate IDO 
Trp metabolism as a main player in hCSC immunomodulatory properties 
in the host tissue. 
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Cardiac fibroblasts (CFs) are one of the main cell populations in the heart 
and play important roles in tissue homeostasis and myocardial fibrosis. The 
study of these cells has been hampered by the lack of reliable membrane 
markers: none of the antigens currently used for characterization and 
isolation of CFs is unique for this cell type. This issue has also raised doubts 
regarding a distinct identity of cardiac fibroblasts when compared to other 
myocardium cell populations with similar morphologies. In this work, we 
report a comprehensive description and functional analysis of human CFs 
(hCFs) membrane enriched fraction proteome by advanced mass 
spectrometry-based proteomic tools. A total number of 1478 proteins were 
identified, including 774 membrane proteins (52%). We also report the 
identification of a subset of 30 membrane proteins that in this workflow were 
only identified in hCFs by comparison with the membrane-enriched 
proteome lists of human cardiac stem cells, human mesenchymal stem 
cells, and human dermal fibroblasts. The data reported in this work are a 
valuable source of information for further studies aiming at defining a 
membrane molecular signature of human cardiac fibroblasts (hCFs), and a 
step forward in research regarding membrane proteins with key roles in hCF 
function in homeostasis and disease. 
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Cardiac Fibroblasts (CFs) play key roles in myocardium homeostasis and 
in response to injury. CFs are the main cell type involved in synthesis 
and turnover of extracellular matrix (ECM), function as local immune 
modulators, and are part of the cardiac electrophysiology network 
(Furtado, Costa and Rosenthal, 2016). Upon myocardial injury and other 
cardiac pathologies, CFs undergo activation (differentiation to 
myofibroblasts), proliferate and produce an excess of ECM, a process 
referred as fibrosis. Fibrotic tissue is stiffer and less conductive, which 
leads to impaired normal heart function, with increased tissue workload 
and arrhythmias (Furtado, Costa and Rosenthal, 2016). Fibrosis is a 
pathological feature present in numerous forms of heart diseases: it is 
estimated that about 45% of all deaths in the developed world involve 
cardiac fibrosis (Wynn, 2007). 
Due to their central role in cardiac fibrosis, a lot of attention has been 
drawn to the study of CFs. Although some progress was made recently 
(Furtado, Costa, et al., 2014; Furtado, Nim, et al., 2014; Furtado, Costa 
and Rosenthal, 2016; Ivey and Tallquist, 2016), the lack of a proper 
molecular definition enabling an accurate identification of these cells has 
been one of the major impediments to CF research. Some of the most 
commonly used markers for CFs characterization are collagens, 
vimentin, discoidin domain receptor (DDR2), Thy1 antigen (CD90) and 
smooth muscle actinin (SMA). None of these molecules is neither 
expressed by all CFs neither unique for this cell type (Furtado, Costa and 
Rosenthal, 2016). Recently, a novel antibody, mEF-SK4 (unknown 
antigen) has been identified as a robust fibroblast marker of the adult 
mice heart, but unfortunately, this antibody is not suitable for human cells 
(Pinto et al., 2016). 




Taking into account the lack of reliable membrane CFs markers, and the 
key role that membrane proteins such as integrins (Civitarese et al., 
2017), receptors (Pellman, Zhang and Sheikh, 2016), ion channels (Li et 
al., 2009) and cell junction constituents (Ongstad and Kohl, 2016) have in 
the context of cardiac fibrosis and in CF coupling with cardiomyocytes 
(CMs), a deeper characterization of CF membrane proteins is of outmost 
importance. In the present study, we examined the proteome profile of 
human CFs (hCFs), with a focus on membrane proteins, using an 
optimized membrane protein enrichment protocol previously reported by 
our group (Gomes-Alves et al., 2015). In order to define a protein 
signature distinctive of hCFs, we further compared the membrane-
enriched proteome of these cells with similar membrane-enriched 
fractions from another fibroblast population [human dermal fibroblasts 
(hDFs)] and from two adult stem cells populations [human cardiac stem 
cells (hCSCs) and human mesenchymal stem cells (hMSCs)], shown to 
have high resemblance to hCFs in terms of morphology, cell surface and 
transcriptional markers which has been hampering the establishment of a 
distinct identity (Furtado, Costa and Rosenthal, 2016). 
 
From this specific comparison of membrane-enriched fractions (hCF vs 
hCSC+ hMSC+ hDF), a subset of 72 proteins were identified only on 
hCFs, including 30 membrane proteins. The data herein reported 
constitutes a valuable source of information to further decipher hCFs 
functions and will certainly serve as a building block for a complete 








2. Materials and Methods 
2.1. Cell culture 
hCFs (adult ventricular, cat. 306v-05a) were purchased from Cell 
Applications Inc. (San Diego, USA). The cells were cultured as 
monolayers in humidified incubators at 37 °C at 5% CO2 in complete 
DMEM containing 10% (v/v) fetal bovine serum (FBS), supplemented 
with 1% (v/v) penicillin streptomycin (Pen/Strep). hCFs were used 
between passages 5 and 6.  
hCSCs were isolated as previously described by Lauden et al(Lauden et 
al., 2013). hDFs were obtained from Inbiobank Stem Cell Bank. Both 
hCSCs and hDFs were cultured in DMEM:F12 Neurobasal medium (1:1), 
supplemented with 1% (v/v) Pen/Strep, 10% (v/v) FBS, N2 Supplement 
(1X), B27 Supplement (1X), 0.9 mM L-Glutamine, 50 μM 
β-Mercaptoethanol (Sigma), Insulin Transferrin Selenium (0.5X), 
10 ng/mL bFGF, 20 ng/mL EGF-I and 30 ng/mL IGF-II (Prepotech). 
hMSCs were obtained from Inbiobank Stem Cell Bank (cat. BM#19) and 
cultured with DMEM low glucose medium supplemented with 10% (v/v) 
FBS, 1% (v/v) Pen/Strep and 1% (v/v) L-Glutamine. hCSCs, hDFs and 
hMSCs were cultured as monolayers in humidified incubators at 37°C, 
5% CO2 and 3% O2. Unless otherwise noted, all reagents and chemicals 
are from Thermo Fisher Scientific. 
2.2. Immunofluorescence microscopy 
Cells were washed with Dulbecco's phosphate-buffered saline (DPBS) 
(Thermo Fisher Scientific) and fixed in 4% (w/v) paraformaldehyde (PFA) 
and 4% (w/v) sucrose in DPBS for 20 min. Afterwards, cells were 
permeabilized for 10 min in 0.1% (v/v) Triton X-100 in DPBS and blocked 
with 0.2% (v/v) Fish Skin Gelatin (FSG) in DPBS for 30 min, at room 




temperature (RT, 18-20°C). Cells were then incubated with primary 
antibodies diluted in 0.13% (v/v) FSG, 0.1% (v/v) Triton X-100 for 2 h at 
RT. Cells were washed with DPBS and incubated with secondary 
antibodies diluted in 0.13% (v/v) FSG, 0.1% (v/v) Triton X-100 for 1 h at 
RT in the dark. The following primary antibodies were used: anti-vimentin 
(1:100, Abcam, ref ab16700), anti-DDR2 (1:200, Antibodies Online ref 
ABIN2158508) and anti-SMA (1:100, Agilent ref M085129-2). Unless 
otherwise noted, all reagents and chemicals are from Sigma. 
2.3. Western Blot 
Cell pellets were lysed in Lysis Buffer (50 mM Tris, 5 mM EDTA, 150 mM 
NaCl, 1% (w/v) Triton X-100, and 1X (w/v) complete protease inhibitor 
cocktail (Roche)) for 30 min at 4 ˚C. Total protein was quantified using 
the Micro-BCA Protein Assay Kit (Thermo Scientific). Proteins were 
precipitated with 10% (v/v) Trichloroacetic acid during 10 min at RT. 
Samples were centrifuged again at 15,000 xg for 10 min at 4 °C, 
incubated in cold EtOH 80% for 10 min at -20 ºC. Extracts were clarified 
by centrifugation at 15,000 xg for 10 min at 4 °C and air-dried. 
Proteins were denatured with sample buffer according to manufacturer 
instructions, loaded in an electrophoresis gel (NuPAGE 4-12% Bis-Tris 
Gel) (Thermo Fisher Scientific) under reducing conditions for 40 min (200 
V, 400 mA) and then transferred to a polyvinylidene fluoride (PVDF) 
membrane (Millipore) using iBlot system (Thermo Fisher Scientific), 
according to the manufacturer’s instructions. 
Membranes were blocked by incubation for 1 h with blocking solution 
(0.1% (v/v) Tween 20 and 5% (v/v) dry milk in DPBS), and incubated 
overnight with primary antibody diluted in blocking solution. Blots were 





system after incubation for 1 h at room temperature with horseradish 
peroxidase-labeled anti-mouse IgG or anti-rabbit antibodies (GE 
Healthcare) at 1:5,000 dilution. Chemiluminescence detection was 
performed by incubating the membranes with Amersham ECL Prime 
western blotting detection reagent (GE Healthcare) and analyzed under 
ChemiDoc XRS System (Bio-Rad). The following primary antibodies 
were used: anti-vimentin (1:100, Abcam ref ab16700), anti-DDR2 
(1:1000, Antibodies Online ref 2158508), anti-SMA (1:1000, Agilent ref 
M085129-2), and anti-α Tubulin (1:5000, Sigma ref T6199). Unless 
otherwise noted, all reagents and chemicals are from Sigma. 
2.4. Proteomic Analysis 
hCFs membrane enriched fractions (available at ProteomeXchange with 
the dataset identifier PXD007839) were analyzed and filtered using lists 
of membrane enriched fractions of hCSCs, hMSCs and hDFs previously 
generated by our group and partners (Gomes-Alves et al., 2015) 
(available in ProteomeXchange with the dataset identifiers PXD007839 
and PXD001117 and Peptide Atlas with the dataset identifier 
PASS00827). For all experimental conditions, at least two biological 
replicates with 2/3 technical replicates were run. 
Membrane enriched fractions: 
For all samples analyzed in this work (hCFs, hDFs, hMSCs and hCSCs), 
proteins were extracted, enriched for membrane-associated fractions and 
quantified as described elsewhere (Gomes-Alves et al., 2015). Briefly, 
cell pellets were resuspended in lysis buffer [50 mM Tris (pH 7.8); 250 
mM Sucrose; 2 mM EDTA] with protease inhibitors and incubated on ice 
for 10 min. Cells were lysed with 30 passes through the 301/2 Gauge 
needle at 4 °C. The cell debris, unbroken nuclei, and other membrane 




proteins were removed by centrifugation at 1,000 xg for 10 min at 4 °C. 
The supernatant was layered onto sucrose buffer 1:1 (60% sucrose) and 
centrifuged at 160,000 xg for 70 min at 4 °C. The membrane fraction 
(interface) on top of the sucrose cushion was collected and diluted 1:2 
with 50 mM Tris (pH 7.8) and centrifuged at 100,000 g for 1 h at 4 °C. 
The obtained protein pellet was washed with 100 mM Na2CO3 (pH 11.5) 
for 2 h at 4°C followed by ultracentrifugation at 100,000 xg for 90 min at 4 
°C. Finally, the resultant membrane enriched fraction was rinsed twice 
with cold water. Protein content was measured using BCA™ Protein 
Assay Kit (Pierce). 
Samples solubilized in 0,32% (w/v) Rapigest SF Surfactant (Waters) 
(were subjected to reduction (DTT, 10 mM, 40 min, 56 °C) and alkylation 
(IAA, 20 mM, 30 min in the dark, room temperature 18-20°C), a further 
10 min reduction with DTT (room temperature) was performed to quench 
the excess of IAA). Proteins were digested with trypsin overnightat 37 ºC 
(trypsin:sample = 1:50, in solution). To guarantee a complete digestion a 
second step of in-solution digestion (3h, 37 ºC) was performed using a 
ratio of 1:100 (in 80% acetonitrile). Samples were then dried in the 
speedvac. Resultant tryptic peptides were resolubilized in 5% formic acid 




hCFs tryptic peptides were analyzed by NanoLC–MS/MS using a hybrid 
Quadrupole Time-of-Flight (ABSciex TripleTOF 6600). Separation was 
performed at 300nl/min using an Ekspert 400 nanoLC (Eksigent) with 
CHiPLC (cHiPLC ChromXP C18-CL analytical column, 75 µm x 15 cm, 3 





mm, 3 µm, 120 Å, Sciex). The gradient was as follows: 0-1 min, 5% B 
(0.1% formic acid in acetonitrile, Fisher Chemicals, Geel, Belgium); 1-91 
min, 5-30% B; 91-93 min, 30-80% B; 93-108 min, 80%; 108-110 min, 80-
5% B; 110-127 min, 5% B. The electrospray ionization (Sciex NanoSpray 
III ion source, New Objective PicoTip emitter SilicaTip FS360-20-10-N-
20-C12) was achieved with source gas 1 of 12, gas 2 of 0, curtain gas of 
30, interface heater temperature of 80 and an ion source voltage floating 
of 2300. A top 50 acquisition method was used with a cycle made of one 
full MS1 scan in the TOF, followed by a precursor selection of 50 most 
intense ions applying an exclusion window of 12 seconds and followed 
by the acquisition of 50 product ion scans generated in the Quadrupole 
analyzer, and detected in the TOF.  Collision induced dissociation took 
place in the quadrupole, using nitrogen. Spectra were acquired in 
positive mode. External calibration was performed using beta-
galactosidase digest (ABSciex). The 40 most intense precursor ions from 
the MS spectra were selected for MS/MS analysis. Data were acquired 
with the Analyst software TF 1.7 (ABSciex). The raw MS and MS/MS 
data were analyzed using Protein Pilot Software v.5.0 (ABSciex), with 
ParagonTM and ProGroupTM algorithms for protein identification. The 
search was performed against Swissprot protein database with 
taxonomic restriction to Homo Sapiens. Trypsin was selected as 
digestion type, Iodoacetamide was selected as source of Cys alkylation 
and the TripleTOF 6600 as the Instrument. The ID focus was on 
biological modifications and amino acid substitutions. The search effort 
was set as thorough and a FDR analysis was performed. Protein 
identification was considered when unused scores were greater than 1.3 
(corresponding to 95% confidence and global FDR < 1%).  
The complete list of identified proteins and peptides identified in hCFs is 
presented in Supporting Information file 2. Analysis of the protein lists 




was performed using Venny 2.1 
(http://bioinfogp.cnb.csic.es/tools/venny/), and Ingenuity Pathway 
Analysis v01.7 (IPA, Quiagen). Hits were classified as membrane 
proteins if containing at least 1 predicted transmembrane domain by the 
Hidden Markov Model (HMM)-based method THMM online tool 
(http://www.cbs.dtu.dk/services/TMHMM/). 
Statistically significant representation of biological functions and 
canonical pathways was identified based on IPA p-value. This probability 
score is calculated taking into account the total number of proteins known 
to be associated with a given function or pathway, and their 
representation in the experimental dataset. IPA’s calculated p-value is 
displayed as -log (p-value).  
Proteomic data have been deposited in the ProteomeXchange 
Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE 
partner repository with the dataset identifier PXD007839. 
hCSCs 
Sample tryptic peptides were analyzed by NanoLC–MS/MS using a 
hybrid Quadrupole Time of Flight (ABSciex TripleTOF 6600) similarly to 
hCFs samples. This dataset has also been deposited in the 
ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner 
repository with the dataset identifier PXD007839. 
Protein lists from hCSCs enriched-membrane fractions resulting from a 
previous publication (Gomes-Alves et al., 2015) were also added in order 
to enlarge hCSC membrane-associated proteome coverage  [analysis 





(http://proteomecentral.proteomexchange.org) with the dataset identifier 
PXD001117.  
The complete list of identified proteins in hCSCs is presented in 
Supporting Information file 5. 
hMSCs and hDFs 
MS analysis details and protein lists from the hMSCs and hDFs enriched-
membrane fractions were previously deposited in Peptide atlas 
(http://www.peptideatlas.org/) with the dataset identifier PASS00827. 
The complete list of identified proteins in hMSCs and hDFs is presented 
in Supporting Information file 6 and 7, respectively. 
 
3. Results & Discussion 
As reported in the literature (Furtado, Costa and Rosenthal, 2016; Pinto 
et al., 2016), Vimentin, DDR2 and SMA showed not to be uniquely and 
specifically expressed by hCFs. In our assessment these proteins were 
identified in hCFs as well as in adult stem cells (hMSCs and hCSCs) and 
in other fibroblast population (hDFs) by proteomics, immunofluorescence 
and western blot (figure 6.1 A-C). Moreover, platelet-derived growth 
factor receptor α (PDGFRα), Filaminin A, and collagens Col1α and Col2α 
(proteins which are routinely used as CFs markers) were also identified 
by proteomics in all cell types used as reference (figure.6.1 A).  




Figure 6.1. hCF lack a distinctive molecular marker signature. Vimentin, DDR2 and SMA, 
some of the most commonly used markers for hCFs, were identified in hMSCs, hCSCs, 
hDFs and hCFs through: (A) proteomic analysis- Venn diagram; (B) immunofluorescence 
labelling; and (C) western blot analysis. Scale bars 100µm. 
 
hCF proteome profiling was performed in samples enriched for 
membrane fraction. The analysis rendered the identification of 1478 
proteins, of which 774 (52%) were classified as membrane proteins 
(figure 6.2 A, Full list of identified proteins in Supporting Information file 
6.1; Full List of Identified Membrane Proteins in Supporting Information 
file 6.2). Biological functions and canonical pathways enrichment analysis 
was performed using IPA software (Full list in Supporting Information file 
6.3). We focused the analysis on terms associated with relevant features 





Figure 6.1. Functional analysis of proteins identified in hCFs. (A) A total of 1478 proteins 
were identified in hCFs, including a subset of 774 membrane proteins (52,36%); (B) 
Canonical Pathways and Biological Functions  enrichement analysis  of the 1478 proteins 
identified in hCFs. Cell-Cell junction, ion transport , angiogenesis, vasculogenesis and 
integrin signalling are highlighted; (C) Functional  analysis of the identified subset of 
membrane proteins in hCFs: Ion transport and homeostasis, calcium , integrin and tigh 
junction signalling are highlinhted as highly represented cathegories; (D) Venn diagram 
illustrating the overlaps between membrane-associated proteome profiles of  hCSCs, 
hMSCs, hDFs and hCFs. A total of 72 proteins were exclusively identified in hCFs, 
including 30 membrane proteins, highighted in the blue box.  
Terms associated with cell-cell junctions, ion transport, angiogenesis, 
vasculogenesis and integrin signaling were found as enriched in hCFs 
(figure 6.2 B,C). Also, 113 proteins were identified as associated with 




cardiovascular system and development (Supporting Information file 6.3). 
Such results reinforce not only the important role of hCFs in electrical 
coupling and cell-to-cell adhesion but also the strong cardiac molecular 
signature of these cells, as reported previously (Furtado, Costa, et al., 
2014; Furtado, Nim, et al., 2014). To our knowledge, this work reports for 
the first time a deeper hCFs membrane-associated proteome 
characterization. 
By comparing the proteins identified in hCF, hCSCs, hMSCs and hDFs 
membrane enriched fractions, we were able to report a subset of 72 
proteins exclusively identified in hCFs. From these, 30 were identified as 
membrane proteins, including ACVR1, a protein involved in tight junction 
signaling and five proteins associated with ion transport and homeostasis 
(CD36, SLC31A2, SLC37A3, SLC41A2, SLC46A1) (figure 6.2 C,D). 
Other interesting proteins include HAS3, involved in ECM production, 
vasculogenesis and angiogenesis and CADM1, which is described as 
being involved in cardiac fibrosis remodeling and fibroblast proliferation 
(Cao, Shi and Ge, 2017). From our list of 30 membrane proteins 
exclusively identified in hCFs, 4 proteins (CD14, FAM69A, CADM1 and 
AVCR1) were also identified as specifically enriched in hCFs in a recent 
quantitative whole proteome study of human heart (Doll et al., 2017). 
 
4. Conclusion 
In this work, by comparison of membrane-enriched fractions of hCF vs 
hCSC, hMSC and hDF, we were able to identify a panel of 30 protein 
marker candidates for hCFs. We are aware that these results need 
further validation, as the analysis of enriched-membrane fractions may 
provide potential false positive targets (as only partial proteomes are 





herein for hCFs, constitutes a valuable basis for more exhaustive studies, 
including knockout experiments in order to further unveil proteins with 
key molecular function in hCF physiology. Comparison of hCFs 
membrane proteome with other myocardium populations, such as human 
CMs and human endothelial cells may also be considered to further 
validate these results.  
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The frequency of cardiovascular diseases is expected to rise in 
developed countries as a result of an increase in life expectancy (WHO). 
Within heart disorders, Acute Myocardial Infarction (AMI) is responsible 
for millions of deaths worldwide, still no therapies enable the full recovery 
of the damaged tissue upon Ischemia/Reperfusion (I/R) injury in AMI 
survivors, leading to chronic heart dysfunctions and a significant loss in 
life quality (Benjamin et al., 2017).  
The work developed in this thesis aimed at characterizing human cardiac 
populations, including hCFs, hCSCs and hiPSC-CMs, as well as to 
develop relevant I/R in vitro human cell models. The overview of the main 
aims and achievements is summarized in figure 7.1.  
 
Advanced mass spectrometry (MS) tools were used to provide a 
comprehensive description of human cardiac fibroblast (hCF) membrane 
molecular landscape as well as to unveil human cardiac stem/progenitor 
cells (hCSCs) mechanisms of action in a myocardial I/R injury context. 
Moreover, the study of the immune-suppressive capacities of hCSCs in 



















































































































































































































In Chapter II, an human I/R in vitro model using a heterotypic co-culture 
system with hCSCs and human induced pluripotent stem cell derived 
cardiomyocytes (hiPSC-CMs) was implemented, including a whole 
proteome study of hCSC response to injury. Following this work, an 
alternative I/R in vitro model was developed in Chapter III, taking 
advantage of stirred-tank bioreactor technology and aggregate 3D culture 
of hiPSC-CMs. hCSCs were incubated with the conditioned medium 
resulting from the I/R bioreactor experiments, allowing to study CSC 
response to an AMI-based secretory environment by quantitative whole 
proteomic analysis (Chapter IV). The immunomodulatory capacity of 
hCSCs in an allogeneic transplantation context was also studied in 
Chapter V. Lastly, Chapter VI focused on a different myocardial 
population: hCFs, and in the characterization of their membrane 
proteome landscape. 
1.1. Development of human I/R injury in vitro models 
Different culture strategies were employed in order to recapitulate distinct 
aspects of the human myocardium physiology, having as major aim the 
development of robust human in vitro I/R injury models. Approaches 
applied included the use of human adult/mature cell populations, 
recapitulation of several physico-chemical aspects of myocardium 
environment during ischemia and reperfusion (Chapter II and III) and the 
use of three-dimensional (3D) culture and bioreactor technology systems 
(Chapter III).   
State of the art references have mainly relied on animal models and 
murine cardiac cell cultures to study myocardial I/R molecular 
mechanisms. Murine systems, despite central to cardiovascular 
research, do not fully recapitulate human cellular physiology (Davis et al., 





context, human cell-based models represent an alternative to study I/R 
injury. Taking into account the inherent ethical constraints and lack of 
availability of human biopsies for the isolation of primary adult CMs, as 
well as the technical difficulties in maintaining these cells in culture, CMs 
derived from human pluripotent stem cells (hPSCs) have been 
increasingly used in the last years, accelerating human cardiovascular 
cell biology research in vitro. In fact, CMs derived from human embryonic 
stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) 
have been used in toxicology screening in the pharmaceutical industry 
(Denning et al., 2016), and to modulate a wide range of disorders 
including arrhythmias, metabolic disorders, and cardiomyopathies 
(reviewed in Giacomelli, Mummery, & Bellin, 2017) as well as ischemic 
damage (Ebert et al., 2014; Hidalgo et al., 2018). However, hPSC-CM 
differentiation protocols often yield immature cells, that more closely 
resemble fetal and neonatal rather than adult CM phenotype (Synnergren 
et al., 2012; Birket et al., 2015; Correia et al., 2018). Such issue is 
especially relevant in the context of I/R injury, since immature cardiac 
phenotypes are related with higher metabolic plasticity and higher 
resistance to hypoxia injury (Robertson, Tran and George, 2013; Hidalgo 
et al., 2018), as previously mentioned in the introduction.  
In fact, during the establishment of the monolayer I/R injury in vitro setup 
(Chapter II), hiPSC-CM after 15 days of differentiation showed 
resistance to I/R, with CM viability only being affected after the addition of 
an extra maturation step (Ribeiro et al., 2015) to the differentiation 
protocol. Such findings are in accordance with a recent study from 
Hidalgo et al., in which immature hESC- and hiPSC-CMs displayed 
minimal cell death upon in vitro I/R injury. After an extra 8-day metabolic-
based maturation phase, both CM cell types showed higher cell death 
post injury (Hidalgo et al., 2018). 




Indeed, upon a hormone-based maturation protocol (Ribeiro et al., 2015; 
Correia et al., 2017), both hiPSC-CM monolayer (Chapter II) and hiPSC-
CM aggregate (Chapter III) cultures showed higher concentration of 
apoptotic cells at 1 h post reperfusion, which is consistent with the 
described in vivo pathophysiology of CM death during AMI, where 
reactive oxygen species (ROS) accumulation, calcium overload and 
mitochondrial permeability pore opening cause a burst of CM death in the 
first minutes after reperfusion (Hausenloy and Yellon, 2013). Moreover, a 
deeper cell ultrastructure analysis in hiPSC-CMs aggregates by 
transmission electron microscopy (TEM) (Chapter III) revealed 
morphological changes characteristic of I/R injury, including sarcomere 
disorganization as well as rupture of structure of mitochondria. hiPSC-
CMs subjected to bioreactor I/R injury setup also showed secretion of 
key angiogenic factors, previously shown to be upregulated upon AMI 
(Vandervelde et al., 2005; Torella et al., 2007; Li et al., 2014; Ong et al., 
2015). 
In Chapter II, an heterotypic human I/R injury in vitro model was 
developed, using hCSCs and hiPSC-CMs separated by transwells. 
Heterotypic co-culture models using more than one cell type are more 
representative of in vivo tissue when compared to more traditional mono-
culture, allowing to elucidate how the cross-talk between different cell 
populations influence each cell type phenotype. This is especially 
relevant in the context of CSC mechanisms of action, since several 
studies demonstrate that CSCs are activated, responding to I/R 
molecular cues mainly through recognition and secretion of several 
growth factors and cytokines. CSCs have been shown to secrete 
paracrine factors involved in the modulation of cell proliferation, 
angiogenesis, vasculogenesis and pro-survival of CMs (Torella et al., 





Alandi et al., 2016; Sharma et al., 2017) and to be activated by factors 
highly released in the myocardium upon injury (Aghila Rani and Kartha, 
2010; Stastna and Van Eyk, 2012; Koudstaal et al., 2014; Waring et al., 
2014). Indeed, when comparing with mono-culture controls, our results 
showed that co-culture condition better recapitulated important hallmarks 
of CSC response to injury, including proliferation activation, secretion of 
relevant factors and the enrichment of proteins associated with 
cytoskeleton organization, oxidative stress, stress response and several 
pathways related with cardiac regeneration. In Chapter III, a different 
setup of I/R in vitro model was developed, using bioreactors and 3D 
aggregates of hiPSCs-CMs. Although in this setup the two cell 
populations were not in direct co-culture, the paracrine effect of hiPSC-
CM secretome on hCSCs was also studied, by incubating hCSCs with 
conditioned medium from the hiPSC-CM I/R injury bioreactor 
experiments (Chapter IV). Here, paracrine factors/ extracellular vesicles 
released by hiPSC-CMs upon injury also affected hCSC phenotype, 
including upregulation of proteins associated with migration, proliferation 
and endocytosis.  
Besides using adult/mature cell populations, several physico-chemical 
parameters of ischemia were recapitulated in the developed in vitro 
models (Chapter II and III), including not only oxygen and nutrient 
deprivation, but also acidosis, high lactate accumulation and 
hyperosmosis. In a study comparing all these factors, Lu et al. identified 
lactate and acidosis as critical contributors to adult rat CM death (Lu et 
al., 2005). In our models, reperfusion phase of injury was mimicked by 
the re-establishment of culture conditions, including nutrient rich medium 
and 3% of oxygen, representing myocardial physiological normoxia  
(Khan et al., 2010). Most I/R in vitro injury setups re-establish normoxia 




at atmospheric oxygen (21%), representing hyperoxic conditions that 
might not reflect the in vivo conditions.  
Aiming at further improving our I/R injury in vitro setup, stirred tank 
bioreactor technology and culture of hiPSC-CMs as 3D aggregates was 
combined in Chapter III. 3D culture is increasingly being employed as a 
strategy to modulate cardiac tissue in vitro, since cultivating CMs in 3D 
has shown to better recapitulate contractile function and metabolic 
maturation of cells when comparing to 2D cultures (Zhang et al., 2013; 
Daily et al., 2015; Correia et al., 2018). Although many authors employ 
3D culture strategies in the development of heart tissue constructs 
(reviewed in Ryan et al. 2016), still few studies take advantage of these 
3D systems to model myocardial I/R injury (Katare et al., 2010; 
Mosadegh et al., 2014).  
Stirred tank bioreactors are attractive to cultivate 3D culture systems. 
Bioreactors are commonly employed to generate relevant number of high 
quality cells for cell therapy applications (Hosseinkhani et al., 2010; 
Correia et al., 2014; Kryukov, Ruvinov and Cohen, 2014; Gomes-Alves et 
al., 2016; Kropp et al., 2016; Cunha et al., 2017), for production of 
biomolecules (Sousa et al., 2015; Sequeira et al., 2018), as well as for 
generation of relevant 3D tissue constructs (Tostões et al., 2012; Rebelo 
et al., 2015; Simão et al., 2016; Sgodda et al., 2017). Noteworthy, these 
bioreactors also provide unique advantages when considering in vitro 
disease modeling, especially in the context of I/R injury, in which the tight 
control and monitoring of oxygen and pH levels is important. Adding 
these advantages to the accumulated knowledge in our lab on bioreactor 
culture with neural ischemic setups (Amaral et al., 2010), iPSCs 
aggregates (Abecasis et al., 2017) and cardiac populations (Correia et 
al., 2014; Gomes-Alves et al., 2016), we decided to establish a 





(Chapter III). Using this setup, we were able to successfully mimic both 
phases of I/R injury by readily decreasing the dissolved oxygen in culture 
(pO2 <0.4%) at the start of ischemic phase and re-establishing normoxia 
(pO2=3%) during reperfusion. Moreover, the bioreactor setup enabled 
nondestructive sampling along the experiments without disturbing 
ischemia and reperfusion environmental parameters. 
Overall, in this thesis, multiple strategies were used in order to develop 
robust I/R injury in vitro models, recapitulating several features of in vivo 
human adult myocardial environment. Such strategies included the use 
of adult (hCSCs, hCFs) and mature (hiPSC-CMs) human cell 
populations, the use of heterotypic cultures, the establishment of different 
physico-chemical parameters of I/R, as well as 3D culture configuration 
and stirred tank bioreactor technology. Altogether, the in vitro I/R injury 
models established in this thesis constituted an important step forward in 
I/R injury research, allowing to recapitulate several cellular hallmarks of 
I/R as well as to study the mechanisms of action of hCSCs upon AMI. 
In the future, efforts to further increase the relevance of such models 
should be pursued, including: i) addition of different human cell 
populations with relevant roles in I/R physiology, such as human 
endothelial cells, human cardiac fibroblasts and cells from the immune 
system; and ii) challenging the models using drugs and molecules with 
known effects on cardiac cellular physiology during and upon AMI. 
1.2. Advancing hCSC clinical potential: unveiling hCSC 
mechanisms of action in an AMI context 
hCSCs transplantation emerged as a clinical option for AMI patients. 
However, so far, clinical trials were not able to show a significant 
physiological improvement and benefit over pharmacological standard-of-
care. Several challenges still need to be addressed in order to meet the 




full clinical potential of hCSCs, including the use of advanced human 
based experimental models to further decipher the mechanism of action 
of these cells, as well as novel strategies to improve their retention in the 
target tissue, as recommended by the task force of the European Society 
of Cardiology (Mathur et al., 2017). A better understanding of the 
mechanism of action of hCSCs is relevant not only for the advancement 
of cardiovascular basic biology research by itself, but also to generate 
knowledge on how to direct novel strategies involved in endogenous 
hCSCs activation and enhancement of transplanted hCSCs clinical 
benefits. 
Analytical techniques and software development have substantially 
increased the power of non-targeted global proteomic MS-based 
strategies in the last decade, allowing the identification and/or 
quantification of large sets of proteins in a given sample. Such features 
make proteomics a unique tool for revealing novel molecular 
mechanisms, both in homeostasis and disease settings. Regarding 
CSCs, non targeted global proteomics has been applied for 
characterization of murine (Stastna et al., 2010) and hCSC secretome 
(Sharma et al., 2017; Torán et al., 2017), hCSC receptome (Gomes-
Alves et al., 2015) and whole proteome studies of murine CSCs in 
homeostasis settings (Samal et al., 2012; Torán et al., submitted).  
In this thesis, several strategies were combined in order to further unveil 
the biology of hCSCs in an AMI context, including the use of un-labelled 
global proteomic approaches (Chapter II and IV), as well as the 
development of relevant human in vitro models of injury (Chapter II and 
IV) and inflammation (Chapter V).  
CSCs become activated after injury and transplantation, playing key roles 





lineages, migrating to the site of injury, and secreting important paracrine 
factors involved in the modulation of cell proliferation, angiogenesis, 
vasculogenesis and cytoprotection of CMs. Although CSCs were already 
identified 15 years ago (Beltrami et al., 2003), still several doubts remain 
in the scientific community regarding their ability to efficiently differentiate 
towards cardiac lineages and functionally integrate the tissue upon injury, 
specially concerning c-kit+ CSCs (Ellison et al., 2013; Nadal-Ginard, 
Ellison and Torella, 2014; van Berlo et al., 2014), the cell population used 
throughout this thesis. Although proteomic data analysis revealed an 
enrichment in proteins related with cell differentiation in hCSCs upon 
ischemia (Chapter II), no further evidence for hCSC differentiation was 
found, including change in cell morphology.  
Nevertheless, our results reinforce the idea that CSCs activate 
proliferation and migration in context of I/R, indicated by an enrichment of 
proteins associated with pathways with roles on cell movement and 
proliferation, as well as an increased proliferation upon reperfusion phase 
of injury (Chapter II), and upregulation of proteins associated with 
remodeling of cell-cell junctions and several pro-migratory and 
proliferation pathways (Chapter IV). 
There is a consolidated consensus regarding the importance of 
paracrine-mediated mechanisms in the regenerative response of CSCs, 
supported not only by several studies depicting CSC secretome (Stastna 
et al., 2010; Sharma et al., 2015; Park et al., 2016; Torán et al., 2017), 
but also by the benefic effect of transplanted CSCs even without tissue 
retention and engraftment, reported in several preclinical and clinical 
studies (Madonna et al., 2016). In Chapter II, we show for the first time 
increased CXCL6 secretion by hCSCs upon an I/R injury, suggesting a 
relevant role of this angiogenic chemokine in hCSC mediated myocardial 
regeneration. CXCL6 was also recently identified in the secretome of 




hCSCs, where addition of an anti-CXCL6 antibody inhibited the migration 
and angiogenic properties of CSC conditioned medium, proving the 
importance of this chemokine in key paracrine regenerative potential 
features of these cells (Torán et al., 2017). Moreover, we also show an 
enrichment in several paracrine signaling pathways and angiogenic 
related proteins, as well as an increased angiogenic activity of 
hCSC:hiPSC-CM co-culture conditioned medium upon injury. 
Cytoprotection was also observed in the co-culture model (Chapter II), 
where hCSCs exerted a paracrine protective effect in hiPSC-CMs. 
Interestingly, we can find some parallelisms between activation of hCSC 
paracrine mechanisms in the co-culture system (Chapter II) upon I/R and 
the cytokines detected as secreted in the different phases of injury 
(Chapter III). Concordant with the increased IGF-1, GM-CSF, IL-8, 
PDGF and Oncostatin M secretion during the ischemic phase (Chapter 
III), hCSCs also demonstrated enrichment of proteins associated with 
pathways related with these same molecules upon the ischemic phase of 
injury (Chapter II). Moreover, HGF signaling, detected as one of the 
enriched pathways in hCSCs on late reperfusion (Chapter II) was also 
secreted by hiPSC-CMs upon reperfusion (ELISA results) (Chapter III), 
further strengthening the importance of the paracrine cross-talk between 
the two cell populations. 
As previously mentioned, one of the main challenges to be addressed in 
hCSC transplantation is the rapid elimination of the injected cells by the 
host immune system (Huang et al., 2010; Malliaras et al., 2012), 
aggravated by the highly inflammatory microenvironment of an AMI 
patient heart. A better knowledge on the immunomodulatory properties of 
hCSCs is therefore paramount in developing strategies to increase the 
transplanted cells retention time in the myocardium, that would probably 





immunomodulatory capacity of hCSCs, being able to modulate and 
suppress different responses of the immune system, namely inhibiting 
cell populations, such as T-lymphocytes. Programmed Death Ligand 1 
(PDL-1) mediated direct cell-cell interaction was identified as the main 
mechanisms in hCSC mediated T-lymphocyte proliferation inhibition 
(Lauden et al., 2013). In Chapter V, through modeling hCSC/T-
lymphocyte interaction in an allogeneic context, we were able to 
demonstrate for the first time that hCSCs exert an immune-suppressive 
effect on T lymphocyte proliferation not only through the previously 
described PDL-1 axis but also through a paracrine mechanism 
associated with indoleamine 2,3-dioxygenase (IDO) tryptophan 
metabolism. Such findings not only contribute to a better knowledge of 
hCSCs immunomodulatory mechanisms, but also open new avenues in 
the development of new hCSC transplantation strategies. For instance, 
one can envision IDO high expression as a novel quality attribute for the 
selection of highly immunosuppressive hCSCs donors or genetic 
engineering of hCSCs to express higher levels of this enzyme.   
All findings in this thesis support hCSCs as a cell population with 
significant regenerative properties in AMI context, including paracrine 
signaling promoting hCM protection, angiogenesis and immune-
suppressive properties. Currently, clinical trials and studies in animal 
models including transplantation of CSCs or activation of endogenous 
CSCs show improvements in heart performance. For instance, in a 
recent report of the phase I/II clinical trial CARE-MI (NCT02439398) with 
transplantation of allogeneic c-kit+ hCSCs, safety, low immunogenicity 
and estimated treatment effect of 2.3% of decrease in infarct size area 
were registered (Fernández-Avilés et al., 2018). However, such results 
are still far from the complete regeneration of the infarcted heart to pre-
infarct myocardium functionality level, which constitutes the holy grail of 




modern cardiac regenerative medicine. Improved in vitro studies and 
omics approaches, such as the ones developed in this thesis, contribute 
to further understand the inherent human cellular mechanisms, crucial to 
guide novel biological therapeutic strategies focused on the activation of 
endogenous hCSC populations and on hCSC transplantation. 
1.3. Characterizing hCF membrane proteome 
As introduced in Chapter I, not only CSCs and CMs play important roles 
in AMI physiology. CFs are the main cell type involved in extracellular 
matrix (ECM) kinetics, including collagen deposition upon AMI and other 
heart pathologies, leading to tissue fibrosis. Such central role in cardiac 
fibrosis makes CFs the research focus of several laboratories worldwide. 
However, one of the main challenges pointed out when studying this cell 
population is the lack of a proper molecular identity. Molecular markers 
currently used to isolate and characterize hCFs are not unique nor 
specific. Besides allowing for the identification of a high number of 
proteins per sample, untargeted MS-based approaches allow for an 
unbiased, discovery-oriented and high-throughput profiling of the 
proteome panorama of a given cell population. 
With the aim of filling this gap in hCF research, and by applying an 
optimized membrane protein enrichment protocol previously developed 
by our group (Gomes-Alves et al., 2015), in Chapter VI we provide a 
deep analysis of hCF membrane proteome. By direct comparison with 
other cardiac and stem cell populations, we identified a subset of 72 hCF 
specific proteins including 30 membrane proteins. The characterization of 
the hCF membrane proteome contributes not only to the identification of 
potential novel cell specific molecular markers but also to an increased 
understanding of hCF biology. In order to further filter and strengthen the 





myocardial cell populations, such as smooth muscle cells, endothelial 
cells, CMs, and other hCFs isolated using different methodologies should 
be considered in future experiments. Moreover, the specificity of the 
proteins identified may also be validated with other methodologies, such 
as flow cytometry, western blot and/or immunocytochemistry.  
 
2. Conclusions  
In conclusion, overall the work developed herein contributes: i) with novel 
and robust human cell-based I/R injury in vitro models ii) by unveiling 
hCSCs mechanisms of action in response to AMI in endogenous and 
transplantation contexts and iii) by providing a detailed characterization 
of  membrane proteins of hCFs.  
The knowledge generated in this thesis has the potential to be used in 
the development of novel strategies targeting the enhancement of 
hCSCs regenerative benefits as well as the definition of novel 
hCF-specific molecular markers. 
 
3. Future work  
The increasing incidence of ischemic heart diseases has been directing 
cardiovascular research field towards a better definition and 
understanding of human cardiac cell populations biology in homeostasis 
and under pathological conditions. By using novel human cell-based I/R 
injury in vitro models and advanced proteomic tools, this thesis 
contributed to the field, by providing added knowledge to the 
mechanisms of action of hCSCs upon AMI and with an extensive 
characterization of hCFs membrane proteome. Still, the models and 




findings obtained from this thesis raised new questions that require 
further investigation: 
 I/R injury in vitro models: 
o Challenge I/R models developed with drugs with known effect 
on I/R injury;  
o Increase complexity and representation of in vivo heart tissue by 
adding myocardium human cell populations such as endothelial 
cells, hCFs, smooth muscle cells and cells from the immune 
system; 
o Further characterize conditioned medium content in proteins and 
secretory vesicles by high-throughput untargeted proteomic 
approaches. 
 
 Characterization of hCSC mechanisms of action upon AMI: 
o Validate pathways identified as important for hCSC regenerative 
benefits with knock-out experiments and functional assays; 
o Validate IDO-mediated Triptophan metabolism importance on 
hCSC immunomodulation, including Trp supplementation and 
IDO inhibition experiments; 
 
 Identification of hCF specific molecular markers: 
o Extend membrane fraction proteome comparison to other 
myocardial human cell populations, including hCMs, endothelial 
cells, smooth muscle cells and hCFs isolated using different 
methodologies. 
o Further filter the list of proteins identified as specific for hCFs by 
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